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Infants of diabetic mothers are more prone to develop congenital 
malformations than that of non-diabetic mothers. This project aimed at investigating 
whether genetic and/ or environmental factors could interact with maternal diabetic 
milieu to increase the malformation rate. Two mouse models, with mutations in 
non-diabetogenic and diabetogenic genes, were employed in this study. The 
environmental factor under test was dXX-trans retinoic acid. 
The first mouse model is splotch {Sp^") that carries a non-diabetogenic 
mutation. Homozygous {Sp^^ISp^") embryos develop neural tube defects that include 
exencephaly and/ or spina bifida, whereas heterozygous embryos do not 
exhibit such defects. To allow comparison of development of Sp2Hl+ and wild-type 
(+/+) embryos under the same maternal environment, embryos of these two genotypes 
were obtained by mating of Sp^^!^ male mice with diabetic or non-diabetic +/+ 
female mice. At early gestation, pregnant mice received an injection of dXX-trans 
retinoic acid, a teratogen that is well-known in causing neural tube defects. Results 
showed that upon retinoic acid treatment, the incidence of neural tube defects was 
significantly increased only when the mother was diabetic. Moreover, embryos of 
diabetic mice that carried one Sp^" allele were significantly more susceptible to 
retinoic acid-induced neural tube defects than their wild-type littermates. Sp^^ is 
caused by a mutation of PaxS. To investigate whether maternal diabetes and retinoic 
acid increased the susceptibility of embryos to neural tube defects via the same 
mechanism as the Sp^" mutation, the effect of maternal diabetes and retinoic acid on 
the expression level of PaxS in the embryo was studied by whole mount in situ 
hybridization. Results showed that maternal diabetes caused a down regulation of the 
- X V -
expression level of PaxS in 分:付/+ embryos to a greater extent than +/+ embryos, 
whereas retinoic acid did not induce any changes in PaxS expression levels in 
embryos of either genotype. Further investigation using whole mount in situ 
end-labeling assay to detect apoptotic cells showed that both maternal diabetes and 
retinoic acid increased the amount of apoptosis in the neuropore region. Moreover, 
Sp2Hl+ embryos were more susceptible than +/+ embryos to the apoptosis-inducing 
effect of maternal diabetes or retinoic acid alone, or when they combined together. 
Another mouse model is NOD (non-obese diabetic) mouse in ICR genetic 
background, which spontaneously develops type 1 diabetes due to autoimmunity 
against the pancreatic islet cells. To investigate whether the NOD mutation could 
interact with maternal diabetes to increase the susceptibility of the embryo to neural 
tube defects, embryos were obtained by mating of NOD male mice with diabetic or 
non-diabetic ICR female mice. The NOD allele in the embryo was inherited from the 
father in order to prevent the development of the embryo from being affected by the 
autoimmunity response that might have arisen from the NOD mother. Pregnant mice 
were treated or untreated with retinoic acid. Results showed that a single NOD allele 
could interact with maternal diabetes to significantly increase the susceptibility to 
neural tube defects and the effect was further exacerbated by treatment with retinoic 
acid. However, results from in situ hybridization studies showed that the interaction of 
NOD with maternal diabetes was not mediated via affecting PaxS expression. 
In conclusion, results obtained from the present study have demonstrated that 
genetic and/ or environmental factors could interact with maternal diabetes to increase 








































Chapter 1: General Introduction 
1.1 Diabetes Mellitus 
Diabetes mellitus is a common disease that has a prevalence of 4.5% in adults 
in Hong Kong (Cockram et al., 1993) and more than 8% in Asia-Pacific region and 
estimated to be doubled by 2025 (Cockram, 2000). Moreover, it is estimated that the 
prevalence of diabetes mellitus will be 5.4% of the global population by the year 2025 
and the number of adults with diabetes in the world is expected to rise from 135 
million in 1995 to 300 million by 2025 (King et al., 1998). 
Diabetes mellitus is a group of metabolic disorders of carbohydrate 
metabolism in which glucose is underutilized, producing hyperglycemia. This is 
caused by the inability in producing insulin or improper use of insulin. Insulin, which 
is a hormone produced by the P-cells in the islet of Langerhans in the pancreas, is 
necessary to convert glucose to glycogen for storage in the liver and muscle. Hence, 
insulin is important in controlling blood glucose level. Diabetes has a variety of 
clinical features ranging from an asymptomatic state to acute diabetic ketoacidosis 
and to chronic microvascular (e.g. nephropathy, retinopathy) (Raptis and Viberti, 
2001; Rosenstock et al., 1986) and macrovascular (e.g. atherosclerosis) (Laakso and 
Pyorala, 1988) complications. 
This disease is classified into several categories based on the observed clinical 
phenotypes. Four main types of diabetes are distinguished: type 1, type 2, gestational 
diabetes, and diabetes secondary to other medical conditions (Borg and Sherwin, 2000; 
WHO, 1980). 
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1.1.1 Type 1 diabetes mellitus 
Type 1 diabetes mellitus, formerly known as insulin-dependent diabetes 
mellitus (IDDM) or juvenile-onset diabetes mellitus, is an autoimmune disease， 
caused by autoimmune destruction of the p-cells of the pancreas, rendering the 
pancreas unable to synthesize and secrete insulin (Castano and Eisenbarth, 1990). For 
those affected, there is an absolute requirement of exogenous insulin for survival. 
Among the people affected by diabetes mellitus, only 5-10% are of type 1 and about 
2% of the world population is affected by type 1 diabetes. Although type 1 diabetes 
mellitus presents clinically throughout life, almost all studies limit themselves to cases 
diagnosed in childhood (0-14 years) or before 30 years of age. In the absence of 
insulin, the high glucose level stimulates the TCA cycle in the production of energy, 
which will activate acetyl CoA, and hence, the ketone body level increases. Ketone 
bodies, such as P-hydroxybutyrate, dissolved in the blood will lead to ketoacidosis as 
the pH becomes lower. 
The major risk factor of type 1 diabetes is genetic susceptibility, which 
increases by 10-30% in families where a family member is affected. However, a 
monozygotic twin is less than 50% concordance, which provides evidence that 
environmental factors may be important. Environmental factors may act as initiating 
factors, which begin or continue the pathogenic process that eventually results in type 
1 diabetes, or act as precipitating factors that convert pre-clinical diabetes into overt 
clinical diseases. The environmental insults to pancreatic P-cells can include viruses, 
such as mumps, rubella, coxasackievirus B4, or can be toxic chemical agents like 
Vacor (nitrophenylurea rat poison) and cytotoxins like nitric oxide (Kenny et al., 1981; 
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Kloppel and Clemens, 1997; Krippeit-Drews et al , 1995). These factors can increase 
the susceptibility to diabetes in genetically predisposed individuals. The genetic factor 
finally leads to autoimmune reactions that contribute significantly to progressive 
pancreatic p-cell destruction. Since circulating islet cell autoantibodies are present in 
85% of patients with type 1 diabetes (Dosch et al., 1999), insulin antibodies were used 
for treatment before the invention of insulin therapy. 
The development of diabetes has a strong association with increased frequency 
of certain HLA antigens, which are glycoproteins on the surface of all cells except 
sperms and red blood cells. They allow the immune system to distinguish the body 
cells from microorganisms. A variety of HLA antigens are found in different 
populations. The HLA class II region contains at least 3 genetic loci, namely HLA-
DR, HLA-DQ and HLA-DP, each of which codes for a slightly different glycoprotein. 
The HLA-linked loci are now designated as IDDMl. They are highly polymorphic 
with many alleles being known and type 1 diabetes is associated with HLA-DRB, 
HLA-DQA and HLA-DQB (Baisch and Capra, 1992). In Caucasians, the HLA 
regions contain HLA-B8, B15, CW3, DR3 and DR4. However, in Asians, Africans 
and Latin Americans, the HLA regions contain HLA-DR3 and DR4 only (Brautbar et 
al., 1981;Nishimura et al., 1998). 
Although IDDMl confers strong susceptibility to type 1 diabetes and accounts 
for a major proportion of familial clustering, it is not sufficient to account for the 
complete genetic contribution to the disease. Therefore, attention has started to focus 
on the contribution of non-HLA-linked loci to the pathogenesis of type 1 diabetes, 
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which account for the rest of familial susceptibility. The T cell-mediated 
autoimmunity may target autoantigens in the pancreas. The most common 
autoantigens are insulin (Raffel et al.，1992)，65kDa isoforms of glutamic acid 
decarboxylase (GAD-65) (Kaufman et al.，1992) and insulinoma antigen-2 (IA-2) 
(Lan et al , 1996). The 5' flanking region of INS (insulin gene), which contains the 
variable number of tandem repeats (VNTR), is designated as IDDM2 (Sarugeri et al” 
1998). 
1.1.2 Type 2 diabetes mellitus 
Type 2 diabetes mellitus, formerly known as non-insulin dependent diabetes 
mellitus (NIDDM) or adult-onset diabetes, results from a combination of insulin 
resistance and inadequate insulin secretion (Olefsky, 1988; Reaven, 1997). It is the 
most common form of diabetes, which accounts for 90-95% of diabetes in developed 
countries. It is so called NIDDM because the patient does not depend on insulin 
therapy to sustain life. It is a heterogeneous polygenic disease, with both resistance to 
the action of insulin and defective insulin secretion. Within type 2 diabetes mellitus, 
there is a distinct group called the Maturity Onset Diabetes of the Young (MODY), 
which occurs early in adulthood and in many cases exhibits autosomal dominant 
inheritance. 
Considering the complication of type 2 diabetes mellitus, it is the most 
commonest cause of blindness in the middle-aged elderly people (Prasad et al., 2001), 
an important cause of renal failure (Colhoun et al., 2001) and the most common cause 
leading to lower limb amputation (Ohsawa et al., 2001). Furthermore, people with 
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type 2 diabetes mellitus have a greatly increased risk of coronary heart disease 
(Fonseca, 2000). 
For the pathogenesis of type 2 diabetes mellitus, it is associated with a variety 
of other disorders such as obesity, hypertension and atherosclerosis. Hence, type 2 
diabetes mellitus is not only a disease of carbohydrate metabolism, but also of lipid 
and protein metabolism. Most of the cases of type 2 diabetes are caused by 
environmental factors，but some genetic susceptibility loci have been found, which 
gives evidence that genetic factors may contribute to the onset of type 2 diabetes. 
Unlike type 1 diabetes, in most population groups, type 2 diabetes shows no 
association with genes in HLA regions (Rotter and Rimoin, 1987). Glucokinase gene 
region (GCK-1), with a central role in glucose metabolism, may be important in the 
pathogenesis of type 2 diabetes (Chiu et al., 1993). Furthermore, by linkage analysis, 
D2S125 on chromosome 2 (2q37) shows significant evidence of linkage to type 2 
diabetes mellitus and the locus has been designated as NIDDM 1, which accounts for 
21-30% of familial type 2 diabetes (Hanis et al.，1996). 
1.1.3 Maturity onset diabetes of the young (MODY) 
MODY, a rare subtype of type 2 diabetes mellitus, is autosomal dominant and 
has early onset. It accounts for 2-5% of type 2 diabetes. Up till now, mutations in five 
genes are known to be associated with MODY. More genes are expected to be 
involved since several families with MODY have not been linked to any of the known 
MODY genes (Chevre et al , 1998). All five types of MODY share similar features of 
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early onset of diabetes due to impaired insulin secretion, but with stable form and 
progressive form. MODY 1 is caused by progressive impairment of insulin secretion 
and it is rather rare. The gene involved is hepatocyte nuclear factor-4a {HNF-4a) 
with dominant mode of inheritance (Yamagata et al., 1996). MODY 3 and MODY 5, 
which are caused by the mutation of HNF-1 a md /WF-7/? respectively, share similar 
symptoms as MODY 1 (Kaisaki et al , 1997; Okita et al” 1999). The HNF lesions will 
finally lead to impaired insulin secretion (Hattersley, 1998). Apart from lesions in 
HNF gene family, MODY 2 is caused by the mutation of glucokinase {GCK-1) 
(Velho et al., 1992) and MODY 4 is caused by the mutation of insulin promoter 
factor-1 {IPF-1) (Clocquet et al., 2000). 
1.1.4 Gestational diabetes 
Another type of diabetes mellitus is gestational diabetes. Gestational diabetes 
mellitus (GDM) is carbohydrate intolerance with onset or first recognition during 
pregnancy (Metzger and Coustan, 1998). Gestational diabetes affects up to 14% of the 
pregnant population, approximately 135,000 women per year in the United States 
(Coustan, 1995). Insulin resistance occurs to some degrees in all pregnancies (Xiang 
et al., 1999), but those women who are unable to compensate develop gestational 
diabetes. As pregnancy can be viewed as a physiological stress on the P-cell, glucose 
tolerance depends on the presence of adequate maternal p-cell reserves. In normal 
pregnancy, fasting plasma glucose concentration decreases and postprandial glucose 
concentration rises. The latter effect continues throughout pregnancy. By late 
pregnancy, postprandial insulin release is doubled, whereas insulin sensitivity is 
halved (Kuhl, 1991). Gestational diabetes develops in women whose insulin secretion 
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does not increase sufficiently to counteract this physiological decrease in insulin 
sensitivity. Once glucose intolerance develops, plasma triglyceride concentration 
increases, and there is decreased inhibition of lipolysis after meals, as a result, there is 
increased plasma concentration of glycerol and free fatty acids, which finally leads to 
gestational diabetes. Women at greatest risk of developing such disease are those who 
are obese, older than 25 years of age, have a previous history of abnormal glucose 
metabolism or poor obstetric outcome, have first-degree relatives with diabetes, or are 
members of ethnic groups with high prevalence of diabetes. 
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1.2 Effect of Diabetes on Pregnancy 
As stated above, the onset of type 1 diabetes during childhood is due to 
hereditary factor. Although the onset of type 2 diabetes is in late adulthood, which is 
mainly due to the exposure to environmental factors, such as obesity and lack of 
exercise, there is a tendency of early onset of type 2 diabetes as a result of change in 
lifestyle. Moreover, a subtype of type 2 diabetes, MODY, has onset at maturity. 
Together with gestational diabetes mellitus with onset during pregnancy, there is an 
overall increase in the chance of the pregnant women being diabetic in their child-
bearing age. Hence, it is important to investigate the effect of maternal diabetes on the 
development of the embryo. 
Maternal diabetes is associated with increased risk of spontaneous miscarriage 
(Sutherland and Pritchard, 1987)，and also increases the rate of congenital 
malformations in the offspring in humans (Hod and Meizner, 1997). It increases the 
risk of the fetus to develop caudal regression (Chung and Myrianthopoulos, 1975), 
neural tube defects (Piatt and Golde, 1983), heart anomalies (Rowland et al., 1973) 
and abnormalities associated with somite-derived tissues (Ziereisen et al., 1997). 
Apart from congenital malformations, it also increases the risk of the baby to develop 
neonatal hypoglycemia (Hall et al., 1980), neonatal hypocalcemia (Mimouni et al” 
1990) and neonatal hypomagnesemia (Mimouni et al., 1990), which affect the growth 
of the children, such as enamel development of the teeth (Grahnen and Edlund, 1967), 
decreased bone mineral content (Mimouni et al., 1988) and hypoparathyroidism 
(Tsang et al., 1975). 
- 9 -
Chapter 1: General Introduction 
1.3 Suggested Causes of Diabetic Embryopathy 
Pregnant women with diabetes mellitus are suffering a higher risk for both 
first-trimester spontaneous abortions and major malformations of their fetuses 
(Greene et al., 1989; The Diabetes Control and Complications Trial Research Group, 
1996). The risk is largely dependent on the metabolic control achieved by the women 
during gestation (Tyson and Hock, 1976). It is still under debate whether 
hyperglycemia is responsible for the problem because there are conflicting reports 
which show that glycemic control may or may not decrease the rate of congenital 
malformations (Kitzmiller et al., 1991; Mills et al., 1988). Apart from hyperglycemia, 
raised levels of ketone bodies (Sheehan et al., 1985) and other metabolic 
intermediates, as well as tumor necrosis factor-alpha (TNF-a) have also been 
implicated (Pampfer et al., 1995). The suspected agents that may lead to congenital 
malformations in diabetic pregnancy will be discussed one by one. 
1.3.1 Glucose 
Several hypotheses for the etiology of hyperglycemia-related malformations 
have been suggested. One of them is that excess glucose is channeled into non-
conventional pathways like polyol pathway. It increases the conversion of glucose 
into sorbitol by the enzyme aldose reductase. This increase will destruct cellular 
functions by affecting the tissue's permeability to glucose, thereby, causing 
permanent structural derangements (Shafrir, 1990). The activation of aldose reductase 
may lead to functional deficiency of arachidonic acid (Keogh et al., 1997), which 
serves as specific precursors for eicosanoids that regulate numerous cell and organ 
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functions (Uauy et al., 2000). This deficiency will finally increase the risk of 
retardation in development, such as visual function of the infants, which is related to 
suboptimal blood and tissue levels of these fatty acids (Hoffman et al., 2000). Another 
hypothesis is that hyperglycemia affects visceral yolk sac development and 
differentiation (Pinter et al., 1986). The yolk sac capillaries and vitelline vessels of 
conceptuses become sparse, patchy, non-uniformly located and are unable to mediate 
the selective transfer of macromolecules in the developing embryo. Hence，peroxidase 
uptake is lowered and finally leading to malformations by free radicals (Reece et al., 
1989). 
Apart from the above mentioned teratogenic effects of glucose, it is suggested 
that hyperglycemia may induce programmed cell death (apoptosis) (Chai et al., 2000; 
Fine et al., 1999) by inhibiting GLUTl expression (Chi et al., 2000) and via p53-
mediated apoptotic pathway (Keim et al., 2001). The unusual apoptosis, which will be 
discussed in more details in Chapter 4, may bring about congenital malformations. 
1.3.2 Ketone bodies 
Since the origin of diabetes-induced embryopathy is multifactorial, 
hyperglycemia alone may not be the only factor that causes congenital malformation. 
Ketone bodies, which are found at high levels in type 1 diabetic patients, may be 
another teratogen that act synergistically with glucose to induce growth retardation 
and malformations (Sadler et al., 1989). In uncontrolled type 1 diabetes, where body 
fuel is mainly derived from fat, the level of ketone bodies begins to rise in the blood, 
thus, resulting in hyperketonemia (Champe and Harvey, 1994). Ketone bodies can 
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lead to embryonic growth retardation even in a low dose (Zusman and Omoy, 1987). 
3-hydroxybutarate, the most common ketone bodies, inhibits glucose utilization in the 
brain as shown in the rat (Shambaugh et al.，1977), and finally alters development. 
The elevated level of P-hydroxybutarate will cause disruption of cell shapes in the 
neuroepithelium that is important for the formation of the neural tube (Moore et al., 
1989). 
1.3.3 Somatomedin inhibitors 
Factors other than hyperglycemia and hyperketonemia may contribute to the 
increased incidence of malformations in infants of diabetic mothers. In the diabetic rat 
serum, a low molecular weight (940Da) serum fraction with verified somatomedin 
inhibitory activity was found (Phillips et al., 1983). Upon exposure to such 
somatomedin inhibitors, mouse embryos were growth retarded, and exhibited neural 
tube and craniofacial defects, as well as abnormalities of the forebrain and the face 
(Sadler et al., 1986). It is also suggested that this low molecular weight somatomedin 
inhibitor will alter the visceral yolk sac histiotropic function through decreasing 
pinocytosis and altering protein processing. These effects ultimately result in a 
decreased availability of substrates to the embryo, which finally contributes to 
diabetic embryopathy (Hunter et al., 1991). 
1.3.4 TNF-a 
In type 1 diabetes mellitus, there are considerable evidences to support that 
cytokines may act as mediators of autoimmune diabetes and are involved in diabetic 
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complications (Pankewycz et al., 1995; Rabinovitch, 1994). One of the cytokines, 
TNF-a, is an extremely pleiotropic effector of both immune and nonimmune systems 
(Aggarwal and Natarajan, 1996). The role of TNF-a in type 1 diabetes is to act 
synergistically with other cytokines to inhibit insulin secretion and induce cell death 
in human pancreatic p-cells in vitro (Rabinovitch et al., 1990). Overproduction of 
ovarian steroid will increase TNF-a production in the reproductive tract (De et al., 
1992). As shown in the diabetic pregnant rat, TNF-a expression is up-regulated in the 
uterus (Yelavarthi et al., 1991). The overexpression of TNF-a will inhibit cell 
proliferation and lowers glucose consumption of the rat embryo (Pampfer et al., 1994). 
TNF-a seems to act predominantly like a repressive modulator, whose expression 
must be tightly controlled for pregnancy to proceed successfully. Excessive synthesis 
of TNF-a is likely to affect early development of the embryo and causes abortion 
(Tangri and Rashupathy, 1993). 
1.3.5 Oxidative stress 
Apart from the serum factors, oxidative stress is found to be important in 
diabetic embryopathy (Menegola et al., 1996; Sivan et al., 1997; Wentzel et al., 1999). 
As demonstrated in the rat, when embryos are exposed to high glucose environment, 
the altered structure and function of the embryonic mitochondria will generate 
reactive oxygen species (ROS) by lipid peroxidation (Eriksson and Borg, 1993; Yang 
et al., 1997). The elevated ROS may increase the rate of congenital malformations 
through different mechanisms. Firstly, the free radical-dependent fatty acids oxidation 
will produce products that can induce chromosome breakage (Parman et al., 1999). 
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Secondly, ROS can cause an altered expression of genes, such as protein kinase C, 
cytosolic phospholipase A-2 and cychoxygenase-2, which leads to embryonic 
maldevelopment (Wentzel et al” 1999; Wentzel et a l , 2001; Woo et al., 2000). Lastly, 
ROS is known to control apoptosis during embryonic development in humans and 
mice (Salas-Vidal et al., 1998; Yang et al., 1998). Elevated ROS level may lead to 
abnormal apoptosis that causes congenital malformations. It is therefore conceivable 
that free radical species, through different mechanisms, can lead to embryo 
malformation. 
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1.4 Animal Model of Diabetes 
In studying diabetic embryopahty, animal models are ususally employed 
because there are ethical and technical difficulities in studying human embryos, and 
the restrictions being imposed on human embryo research are stringent. Animals can 
be made diabetic by the administration of diabetogens (Peschke et al., 2000) or using 
mutants that spontaneously develop diabetes (Leiter, 2002). 
1.4.1 Chemically-induced 
Amongst diabetogens that are used to induce diabetes, streptozotocin (STZ) 
and alloxan are the most common ones applied in rats and mice (Lenzen and Panten, 
1988; Szkudelski, 2001). STZ causes damage to the pancreatic p-cells that initiates an 
inflammatory response and finally causes lymphocytic infiltration (Junod et al., 1969). 
The pancreatic p-cells are destroyed and cannot produce insulin. Clinical 
manifestations such as hyperglycemia, hypoinsulinemia, glucosuria, and 
hyperketonemia are resulted. Moreover, weight loss is found, which is due to 
depletion of water, glycogen and triglyceride stored, and reduction of muscle mass as 
amino acids are diverted to form glucose and ketone bodies. The catabolism of muscle 
protein results in weaknesses. Thus, STZ can produce animal models that simulate 
type 1 diabetes in humans and can be used to study the derangement of embryonic 
development as found in human diabetic pregnancy. 
As for alloxan, the underlying diabetogenic mechanisms are still a matter of 
debate. Alloxan is suggested to exert its diabetogenic effect by the production of H2O2 
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in intact islets during its reduction to dialuric acid (Fischer and Hamburger, 1980). 
Three possible mechanisms of alloxan are suggested. Firstly, it is possible that oxygen 
free radicals cause the breakage of DNA strand, leading to the activation of 
poly(ADP-ribose) synthetase, which causes critical depletion of cellular NAD+， 
resulting in P-cell damage and ultimately cell death (Okamoto, 1985). The second 
suggested cause is that ROS causes disruption of plasma membrane through lipid 
peroxidation or through the attack of protein directly (Bromme et al., 2000). Another 
possible mechanism is that alloxan and H2O2 cause an irreversible depolarization of 
3-cells by activating a novel non-selective ion channel, which ultimately results in 
cell death (Herson et al.，1997). 
To date, STZ is more widely used than alloxan because of several advantages. 
Firstly, STZ gives fewer side effects than alloxan (Hoftiezer and Carpenter, 1973). 
Secondly, the half-life of STZ is longer than alloxan (Agarwal, 1980). Lastly and 
most importantly, STZ exerts greater selectivity on the pancreatic P-cells (Junod et al., 
1969). 
Many new diabetogens have been found, such as xanthine oxidase that 
generates ROS, and S-nitroso-N-acetyl-D,L-penicillamine (SNAP) that liberates nitric 
oxide (Peschke et al., 2000). However, most of the new diabetogens are still under 
research. 
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1.4.2 Mutants 
Two rodent models that spontaneously develop diabetes are widely employed 
for many researches on type 1 diabetes. They are the BB (BioBreeding) rat and NOD 
(non-obese diabetic) mouse. In both models, insulitis is succeeded by selective P-cell 
destruction and also resulted in ketoacidosis. These features simulate type 1 diabetes 
in humans (Makino et al., 1980; Nakhooda et al.，1977). 
There are two types of BB rats, namely diabetes-prone BB (BBDP) rats and 
diabetes-resistant BB (BBDR) rats. Inbred BBDP rats develop spontaneous diabetes 
as a consequence of autoantibodies against pancreatic p-cells (Diaz et al., 1991). On 
the other hand, BBDR rats do not develop diabetes in clean environment, but they are 
susceptible to the induction of type 1 diabetes (Schlosser et al., 1994). Genetic 
analysis indicates that the development of diabetes in BB rats requires the presence of 
at least one MHC class II allele. The MHC susceptibility loci found are named iddml, 
iddm2 and iddm4 (Ellerman and Like, 2000; Martin et al.，1999). 
NOD mice were discovered in 1980 (Makino et al., 1980). They begin to 
develop insulitis as early as 4 to 5 weeks old. About 90% of female and 60% of male 
NOD mice become diabetic by 12 months of age. Mild ketoacidosis is observed in the 
NOD mice with overt diabetes and they can survive for weeks without exogenous 
insulin. Similar to the case of human type 1 diabetes, development of diabetes in the 
NOD mouse is also caused by autoantibodies against pancreatic P-cells. It is under 
complex genetic control, requiring both MHC-linked and MHC-unlinked genes 
(Ikegami et al., 1993; Wicker et al., 1994). At present, 18 insulin-dependent diabetes 
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{idd) loci have been mapped on 11 different chromosomes in the NOD mouse 
(Yoshida and Kikutani, 2000). Analogous to the human IDDMl and rat iddm2 loci, 
iddl in the mouse is a major susceptibility locus that has been found in the MHC class 
Il-associated region. 
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1.5 Gene-teratogen Interaction in Diabetic Pregnancy 
Besides maternal diabetes, it is well documented that a large number of gene 
mutations and environmental agents can cause congenital malformations. 
During embryogenesis, the appropriate temporal and spatial expressions of 
suitable developmental genes are absolutely critical to normal development. Hence, 
mutation or mis-regulated expression of a particular developmental gene at critical 
time and place may lead to congenital malformations. 
It is estimated that 5-10% of birth defects is caused by in utero exposure to 
teratogens (Beckman et al., 1984). There is an increasing importance to understand 
the effect of environmental agents on embryonic development since there is growing 
concern that human populations are being exposed to an ever-increasing number of 
potentially harmful agents through the environment. The harmful agents include our 
foodstuffs being contaminated by agricultural chemicals and petrochemicals. It is 
estimated that several thousands of new compounds synthesized each year or 
produced as industrial by-products reach our environment (Wilson, 1977). Over 3300 
chemicals have been tested for their teratogenic potential, and approximately 37% 
exhibits some evidence of teratogenicity (Schardein, 1993). 
The two primary mechanisms whereby environmental agents induce 
congenital malformations are mutagenesis and teratogenesis. These two means of 
inducing birth defects may involve overlapping targets. For example, mutagenesis 
produces heritable changes in the genetic material and ultimately involves alterations 
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in the regulation and/ or expression of a specific target DNA (Bishop et al., 1997). On 
the other hand, teratogen may cause non-inherited changes, inducing congenital 
defects by altering embryological processes, or by alterations of the gene function. 
Regulation of early morphogenesis involves production and recognition of various 
cellular signals. Teratogen-induced disruptions may be mediated via aberrant signal 
production or by altering a cell's recognition and response to a given signal. The 
interference with these processes may directly disrupt or modulate the levels of the 
key molecular components of critical developmental pathways (Rogers et al., 1997). It 
is believed to act in a number of different developmental pathways exploiting multiple 
targets and mechanisms to alter normal embryogenesis (Wilson, 1977). One approach 
successfully applied to investigate complex developmental events and their genetic 
regulation is to disrupt normal morphogenesis using specific teratogenic agents and 
then carefully analyzes the morphological, physiological and molecular consequences. 
Examples of some well-studied agents that are believed to be teratogenic and directly 
influence embryonic gene transcription include thalidomide (Stephens et al, 2000), 
retinoids (Lammer et al., 1985) and valproic acid (Lammcr et al., 1997). 
There are evidences for genc-teratogcn interactions in increasing the 
susceptibility of the embryo to congenital malformations (Cole and Traslcr, 1980). 
Although it is well documented that infants of diabctic mothers arc more prone to 
malformation, little is known with regards to whether this increased risk can be due to 
increased susceptibility to teratogens, such as food or drugs taken during prcgnancy, 
and/ or interaction of the maternal diabctic milieu with gcnclic predisposed factors. 
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1.6 Strategy of the Thesis 
As there is a growing tendency in younger onset of type 1 and type 2 diabetes 
(Bingley and Gale, 1992), it is expected that an increasing number of women will be 
diabetic during childbearing years, hence, there is an urgent need to understand the 
cause and pathogenetic mechanism of diabetic embryopathy in order to derive 
preventative intervention. While most previous studies have been focused on 
determining the teratogenic effects of diabetic serum factors and oxidative stress as 
discussed in Section 1.3, there were few attempts to investigate if genetic and/ or 
environmental factors could interact with the maternal diabetic environment to 
increase the susceptibility of the embryo to malformations. Hence, the aim of my 
project was to use mouse as an animal model to investigate for any possible 
interactions between these factors. Two genetic mutations, one non-diabetogenic 
{splotch - Sp2H�and one diabetogenic (NOD) were employed. The environmental 
factor chosen for testing the hypothesis was aW-tmns retinoic acid (RA). Since 
homozygosity of Sp^^ and NOD mutations, and RA can all increase the susceptibility 
of the embryo to neural tube defects (Alles and Sulik，1990; Emmanouil-Nikoloussi et 
al., 2000; Mancino et al., 1992; Otani et al., 1991), which is one of the most common 
congenital malformations, therefore, the present project focused on studying the 
interactions of the above mentioned factors in altering the rate of neural tube defects. 
The first part of my project, as described in Chapter 3, was to investigate 
whether Sp'^ mutation or RA alone or in combination might increase the 
susceptibility of embryos of diabetic mice to neural tube defects. It was achieved by 
induction of diabetes in female mice before pregnancy, and diabetic or non-diabetic 
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female mice were then mated with heterozygous Sp^^ male mice that carried a 
mutated PaxS allele to obtain heterozygous Sp^^ and wild-type embryos in the same 
litter. Embryos were exposed to RA in utero at a stage when neural tube closure has 
just initiated, which has been demonstrated to be the critical time to induce neural 
tube defects (Alles and Sulik, 1990; Alles and Sulik, 1992; Yasuda et al., 1987). 
Embryos were examined on El3.5 for the incidence of neural tube defects and the 
data were statistically analysed to determine if there were any interactions. 
After establishing that there were indeed interactions among Sp^", RA and 
maternal diabetes in increasing the susceptibility to neural tube defects, the second 
part of my project, as described in Chapter 4，was to determine the cellular and 
yrr 
molecular mechanisms of interaction. In particular, since Sp is due to mutation of 
the gene Pax3 that is indispensable for neural tube closure (Beechey and Searle, 1986; 
Epstein et al., 1991), hence, the expression level of Pax3 under different conditions 
was determined by whole mount in situ hybridization. Moreover, the extent of 
apoptosis in the neuropore and neural tube region of the embryo was examined by 
whole mount in situ end-labeling method to determine whether there was any 
corresponding increases in cell death that might account for the increased incidence of 
neural tube defects. 
In the last part of my project, as described in Chapter 5, the interaction of 
NOD mutation and RA with maternal diabetes was investigated. Embryos 
heterozygous for NOD mutation were obtained by mating of diabetic or non-diabetic 
wild-type female mice with homozygous NOD male mice. Pregnant mice were treated 
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or untreated with RA. Similarly, whole mount in situ hybridization was carried out to 
determine whether any changes in the PaxS expression level could account for the 
interaction. 




General Materials and Methods 
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2.1 Mouse Maintenance and Mating Method 
Mice were kept on a 10:14 hours light-dark cycle, with the dark period starting 
from 9:00 p.m. to 11:00 a.m. One male mouse was housed with up to eight female 
mice for 2 hours from 9:00 a.m. to 11:00 a.m. At 11:00 a.m., male and female mice 
were separated and the female mouse was examined for the presence of a copulation 
plug in the vagina. Fertilization was assumed to occur at 10:00 a.m., which was 
considered as embryonic day (E) 0. 
2.2 Induction of Diabetes 
Female ICR (Institute of Cancer Research) mice, aged 7 to 8 weeks, were 
induced to become diabetic by streptozotocin (STZ) {Sigma). STZ was dissolved in 
O.OIM sodium citrate buffer (pH4.5) just prior to use. STZ, at a dose of 65mg/kg body 
weight, was injected intraperitoneally into female ICR mice on three consecutive days. 
Two weeks after the first dose of STZ, the mice were screened for diabetes by the 
measurement of the glucose level in the whole blood obtained from the tail vein using 
the Glucometer Elite (Bayer). Mice with blood glucose level higher than 16.5mmol/l 
were regarded as diabetic and used in subsequent experiments, whereas mice with 
glucose level lower than 16.5mmol/l were discarded. Age matched untreated mice 
were used as non-diabetic mice. The blood glucose level of each mouse was measured 
again before they were sacrificed for the collection of embryos to ensure that the high 
glucose level was maintained at the time of the experiments. 
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2.3 Preparation of AV\-trans Retinoic Acid 
A\\-trans retinoic acid (RA) (Sigma), at a weight of lOOmg，was dissolved in 
1.5ml of absolute ethanol by shaking vigorously under a vortex for 2 hours. The 
dissolved RA was suspended in peanut oil {Sigma), by vigorous vortexing for 2 hours, 
to a final volume of 15ml or 30ml, in order to obtain RA at a concentration of lOOmg 
per 15ml or 50mg per 15ml respectively. This was to ensure that similar volume of 
suspension was injected into the pregnant mice when they were treated with different 
dosages of RA. The RA suspension was kept at 4°C and used within 2 weeks after 
preparation. To prevent photo-oxidation of RA, all procedures described above were 
carried out with the tube covered with aluminium foil. The RA suspension was 
restored to room temperature before injection. Injection was carried out with a 1ml 
syringe and a 20-gauze needle. 
2.4 Dissection of Embryos 
Pregnant mice were sacrificed by cervical dislocation. The abdomen was cut 
open and the uterus was excised. The uterus was rinsed in ice-cold phosphate buffered 
saline (PBS) to remove the blood. Embryos were then dissected out in ice-cold PBS 
with a pair of fine forceps under a stereomicroscope {Zeiss). Embryos collected were 
freed from the decidual tissue, extra-embryonic membranes, yolk sac and amnion. 
Embryos were processed in different ways depending on the experiment. 
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2.5 DNA Extraction from Yolk Sac for Genotyping 
The whole yolk sac was isolated from the embryo by a pair of forceps. The 
forceps were thoroughly washed before dissection of the next embryo to prevent 
cross-contamination. The yolk sac was washed in ice-cold PBS, and then transferred 
to an eppendorf tube. After a quick spin in a microcentriflige, excess liquid was 
removed and the yolk sac was stored at - 2 0 � C until required for DNA extraction. Two 
methods were employed to extract DNA from the yolk sac depending on the amount 
of tissue obtained. For the yolk sac obtained from embryos at E9.0 or older, they were 
lysed by lO^il of lOmg/ml proteinase K {Sigma) in SOOjLil of prewarmed lysis buffer 
(1% SDS; 0.3M sodium acetate; lOmM Tris, pH 7.9; ImM EDTA, pH 8.0) in a 
thermomixer at 56�C overnight. The digested tissue was frozen at -20°C for at least 2 
hours before centrifuged at 13,000g for 20 minutes at 4°C. The supernatant was 
transferred to another eppendorf tube and precipitated with 4 0 j L i l of 3M sodium 
acetate and 500|li1 of isopropanol. The mixture was centrifiiged at 13,000g at 4°C for 
10 minutes and the DNA pellet was washed with 400)il of 80% ice-cold ethanol in 
water. The pellet was then dried under vacuum. Finally, the DNA was dissolved in 
100|al of autoclaved water. 
For the yolk sac isolated from E8.5 embryos, DNeasy™ Tissue Kit (Qiagen) 
was used to extract DNA in order to obtain a higher yield. The principle to extract 
DNA by this kit was similar to the above method, except cartridge was used to trap 
the DNA. Procedures were carried out according to the manufacturer's instruction. 
The yolk sac was lysed by 180)j1 of lysis buffer (ATL) and 20|il of proteinase K at 
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55®C for 1 hour in a thermomixer. The cells were thoroughly lysed with an additional 
200|al of lysis buffer (AL) at 70°C for 10 minutes. Absolute ethanol at a volume of 
200|il was added to the mixture and the mixture was loaded into the cartridge, which 
was then centrifuged for 1 minute at room temperature. DNA stayed on the membrane 
of the cartridge while the flow through was discarded. The DNA was then washed 
with 500^1 of washing buffer (AWl) under centrifugation for 1 minute at room 
temperature. It was washed thoroughly again with another 500jal of washing buffer 
(AW2) under centrifugation for 3 minutes at room temperature. Finally, the DNA was 
eluted out by 50)al of elution buffer (AE) under centrifugation for 2 minutes at room 
temperature. The dissolved DNA was kept at -20°C before it was used for genotyping. 
2.6 Genotyping of Embryos 
Since Sp^" is a recessive lethal mutation, embryos were obtained by mating 
between mice or by mating between and +/+ mice. The first type of 
mating gave rise to embryos of three genotypes: Sp2Hi+ and +/+, whereas 
the second type of mating generated embryos of two g e n o t y p e s : 分 a n d +/+. To 
distinguish the three genotypes, polymerase chain reaction (PGR) was employed to 
identify the wild-type allele and the Sp^^ allele with a 32 base pair deletion of the 
PaxS gene. A volume of 16.4|al DNA, at a concentration of approximately 0.2|ug/|al 
was placed in a PGR tube with 0.1 |ag of each forward and reverse primers, 200jj.M of 
dNTPs, 2|al of lOX PGR buffer, and 0.2[i\ of Taq DNA polymerase (0.5 unit) (PGR 
Core Kit, Roche) to a total volume of 20\x\. To genotype DNA obtained from the yolk 
sac of E13.5 embryos, PCR was hot-started at 95°C for 5 minutes for initial 
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denaturation, followed by 30 cycles at an annealing temperature of 94®C (30 seconds), 
an extension temperature of 60�C (60 seconds), and a denaturing temperature of 72°C 
(30 seconds). The reaction was ended with a final extension at 72�C (10 minutes). To 
genotype DNA obtained from the yolk sac of E8.5 to E9.5 embryos, 40 PGR cycles 
were performed. 
The sequence of the oligonucleotide primers was as follow: 
Forward primer: 5，-CCT CGG TAA GCT TCG CCC TCT G-3 ’ 
Reverse primer: 5'-CAG CGC AGG AGC AGA ACC ACC TTC-3 ’ 
The PGR products amplified were either 127 base pair (wild-type allele) or 95 
base pair {Sp^^ allele) in length. The amplified PaxS fragments, at a volume of lO^il, 
were analyzed by electrophoresis on a 4% agarose gel in 0.5% TAE buffer (0.04M 
Tris-acetate; ImM EDTA，pH 8.0) and the size of the fragment was determined by 
using a 10 bp DNA Ladder {Gibco) as reference. 
2.7 Preparation of RNA Probes for In Situ Hybridization 
2.7.1 Mini-scale preparation of plasmid DNA 
Transformed bacteria were grown in 5ml of LB Broth (Gibco) with 80jig/ml 
of ampicillin at 37°C overnight with agitation. The bacteria were collected by 
centrifugation at 3000 rpm for 15 minutes at room temperature. The plasmid was 
then separated by using the Concert™ Rapid Plasmid Miniprep Kit {Gibco) according 
to the manufacturer's protocol. In brief, the cells were suspended in 250|il of Cell 
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Suspension Buffer (Gl) and lysed by 250)il of Cell Lysis Solution (G2) at room 
temperature for 5 minutes. The mixture was then neutralized by 350|il of 
Neutralization Buffer (M3). The mixture was loaded into the centrifuging tube with a 
cartridge and centrifuged first at 12,000g for 10 minutes at room temperature, 
followed by 1 minute centrifugation. Plasmid DNA was trapped in the cartridge. It 
was then washed with 700)li1 of Wash Buffer (G4). The plasmid DNA in the cartridge 
was finally eluted with 55|li1 of autoclaved water. DNA at a volume of Ijul was used 
for electrophoresis in a 0.8% agarose gel to confirm the size of the plasmid and 
another l[i\ of DNA was measured by the spectrometer (GeneQuant, Pharmacia 
Biotech) at optical density of 260nm for concentration quantification. The rest of the 
dissolved DNA was stored at -20°C. 
2.7.2 Linearization of plasmid DNA 
The circular plasmid DNA isolated from the bacteria was linearized by cutting 
the appropriate site with restriction enzymes. The reaction mixture was made up as 
follow: 
Plasmid DNA Volume equivalent to 5|Lig 
Restriction enzyme 20 units 
Reaction buffer (lOX) 5|li1 
DEPC-treated water Make up to a final volume of 
5 0 j L i l 
- 3 0 -
Chapter 2: General Materials and Methods 
After mixing, the mixture was incubated at 37^C in a thermomixer for 2 hours. 
To extract the linearized plasmid DNA, equal volume of phenol: chloroform: isoamyl 
alcohol (25:24:1, v:v:v) was added followed by centrifugation at 14,000g for 5 
minutes at 4°C. The upper aqueous layer containing plasmid DNA was collected and 
an equivalent volume of chloroform: isoamyl alcohol (24:1, v:v) was added. The 
reaction mixture was centrifuged again at 14,000g for 5 minutes at room temperature. 
The upper aqueous layer was collected and DNA was precipitated with 0.1 volume of 
3M sodium acetate and 2 volumes of ice-cold absolute ethanol at -20°C overnight. 
The DNA was pelleted by centrifugation at 14,000g for 15 minutes at 4°C. The 
supernatant was discarded and the pellet was washed with 70% ice-cold ethanol. After 
drying thoroughly, the pellet was resuspended in 20|li1 of DEPC-treated water and 
stored at-20°C. 
2.7.3 In vitro transcription 
The linearized plasmid DNA was transcribed into RNA probe by RNA 
polymerase and labeled by DIG RNA labeling nucleotide mix (Roche) that contained 
DIG-labeled UTP but unlabeled ATP, CTP and GTP. The reaction mixture was made 
up as follow: 
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Transcription buffer (1 OX) 2 jul 
DIG RNA labeling nucleotide mix (1 OX) 2 
RNasin ribonuclease inhibitor (40 units/jil) 0.5 |il 
RNA polymerase (20 units/)al) 1.5|il 
Linearized DNA plasmid (approximately 1 jig/|Lil) 4 i^l 
DEPC-treated water 10 |li1 
The reaction mixture was incubated at 37°C for 2 hours for transcription. The 
linearized plasmid DNA template was then digested away by using 2\i\ of DNase I 
(RNase-free) (10 units/|al, Promega) at 37°C for 15 minutes. To precipitate the DIG-
labeled RNA, lO^il of 4M lithium chloride, lOOjil of TE buffer (pH 7.4) and 300|il of 
ice-cold absolute ethanol were added and then kept at - 2 0 � C overnight. On the 
following day, the mixture was spun at 14,000g for 15 minutes at 4°C and the pellet 
was washed with 500pi of 70% ice-cold ethanol. Finally, the pellet was dissolved in 
57|al of cold DEPC-treated water. The size of the RNA probe was confirmed by 
displaying 5|al of the dissolved RNA using gel electrophoresis and the concentration 
was quantified by measuring 2\x\ of the dissolved RNA by spectrometry at optical 
density of 260nm. The remaining RNA solution was aliquoted into volume equivalent 
to l|ag of RNA per tube and stored at —70�C until required. 
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2.8 Whole Mount In Situ Hybridization 
2.8.1 Fixation and dehydration of embryos 
Embryos were dissected out in ice-cold PBS and freed from the yolk sac and 
amnion. Holes were pinched in the brain vesicles of embryos at E9.0 or older with a 
tungsten needle to prevent the trapping of solution that might lead to background 
staining. Embryos were immediately fixed in 4% paraformaldehyde in PBS at 4°C 
overnight. On the following day, embryos were washed twice in PBT (PBS with 1% 
tween-20) for 5 minutes each at 4°C. They were then dehydrated by passing through a 
series of methanol in PBT in increasing concentrations: 25%，50%, 75% methanol 
once and 100% methanol twice for 5 minutes in each step at 4°C. Embryos were 
stored at -20°C. 
2.8.2 Hybridization 
Before hybridization, embryos were first rehydrated by passing through a 
series of decreasing concentrations of methanol in PBT: 75%, 50% and 25% once for 
5 minutes at 4°C and then twice in PBT for 5 minutes each at room temperature. The 
rehydrated embryos were then bleached with 6% hydrogen peroxide in PBT for 1 
hour at room temperature to inactivate the endogenous phosphatase. Embryos were 
then rinsed with PBT three times for 5 minutes each at room temperature. After that, 
embryos were digested with 10 |Lig/ml proteinase K {Sigma) in PBT and the duration 
of digestion was dependent on the embryonic stage. For E8.5, E9.0 and E9.5, embryos 
were digested for 6 minutes, 6.5 minutes and 7 minutes respectively. The proteinase K 
digestion was then stopped by rinsing with 2mg/ml of glycine in PBT for 5 minutes, 
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followed by washing with PBT for 5 minutes at room temperature. Embryos were 
refixed in freshly prepared 0.2% glutaraldehyde in 4% paraformaldehyde in PBT for 
20 minutes at room temperature. After rinsing once with PBT for 5 minutes, embryos 
were pre-hybridized in a pre-warmed pre-hybridization solution (50% deionized 
formamide {BDH)\ 5X SSC, pH 4.5; 50|Lig/ml yeast tRNA (Gibco); 1% SDS (Sigma); 
50|ig/ml heparin (Sigma)) for 2 hours at 70�C with gentle rocking. The pre-
hybridization solution was replaced by the pre-warmed hybridization solution that 
contained l|Lig of DIG-labeled RNA probes in 1ml of pre-hybridization solution. 
Embryos were incubated in the hybridization solution at 70�C overnight with gentle 
rocking. 
2.8.3 Post-hybridization wash 
After overnight hybridization, the unbound probes were removed by washing 
twice with solution I (50% formamide (Sigma); 5X SSC, pH 4.5; 1% SDS {Sigma)) 
for 30 minutes each at 70°C and then once with a solution containing equal volume of 
solution I and solution II (0.5M NaCl; lOmM Tris-HCl, pH 7.5; 0.1% Tween-20) for 
10 minutes at 70°C. Embryos were then washed three times with solution II for 10 
minutes each at room temperature. The non-specifically bound RNA probes were 
digested away by washing twice with lOO i^g/ml of RNase A {Roche) in solution II for 
30 minutes each at 37°C. Embryos were washed once in solution II and once in 
solution III (50% formamide; 2X SSC, pH 4.5) for 5 minutes each at room 
temperature. Embryos were then washed twice with solution III for 30 minutes at 
65°C and then three times with TEST (0.14M NaCl; 2.7mM KCl; 25mM Tris-HCl, 
pH 9.5; 0.5% Tween-20; 0.5 mg/ml levamisole (Sigma)) for 5 minutes each at room 
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temperature. Embryos were pre-blocked with 10% heat-inactivated sheep serum in 
TBST for 90 minutes at room temperature and then incubated overnight at 4°C with 
pre-absorbed alkaline phosphatase-conjugated anti-DIG antibody (refer to Section 
2.8.5 for embryo powder preparation and Section 2.8.6 for pre-absorption procedure). 
2.8.4 Antibody wash and colour development 
The unbound antibody was removed thoroughly by washing three times with 
TBST for 5 minutes each and then 1 hour wash for five times at room temperature, 
followed by an overnight wash at room temperature. Before staining, embryos were 
pre-conditioned in NTMT (lOOmM NaCl; lOOmM Tris-HCl, pH 9.5; 50mM MgCli； 
0.1% Tween-20; 0.5mg/ml levamisole) three times for 10 minutes each at room 
temperature. The signal was then developed by staining the embryos in 4.5|al of nitro 
blue teratzolium (75mg/ml stock in 70% N,N-dimethyl formamide) and 3.5|al of 5-
bromo-4-chloro-3-indolyl phosphate (50mg/ml stock in N,N-dimethyl formamide) per 
ml of NTMT at room temperature in a glass vial wrapped with aluminium foil. The 
signal intensity was monitored occasionally under microscope until optimal level was 
achieved. The reaction of alkaline phosphatase was stopped by washing the embryos 
with PBT for three times. Embryos were post-fixed in freshly-prepared 4% 
paraformaldehyde in PBS overnight at 4°C. Embryos were cleared by washing twice 
with PBT, followed by 50%, 75% glycerol in PBT and 100% glycerol. 
Photomicrographs were taken with a Zeiss bright-field/ dark-field stereomicroscope 
using Fujichrome 64T color slide film. 
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2.8.5 Embryo powder preparation 
E12 mouse embryos were homogenized in PBS with the aid of a polytron 
{Sigma). They were then incubated in cold acetone (-20°C) for 30 minutes twice at 
4°C. After centrifugation at 10,000g for 10 minutes, the pellet was dried and minced 
into fine powder and stored air-tight at until required. 
2.8.6 Pre-absorption of antibody 
Embryo powder at a weight of 3mg was heat-inactivated in 0.5ml of TEST at 
70°C for 30 minutes. After chilling on ice, of heat-inactivated sheep serum and 
l|il of alkaline phosphatase-conjugated anti-DIG antibody (0.75 units/|al, Roche) were 
added and then shaken gently on ice for 1 hour. After centrifugation at 4°C at 12,000g 
for 5 minutes, the supernatant was transferred to a new tube and diluted to 2ml with 
1% heat-inactivated sheep serum in TEST. 
2.9 Whole Mount TUNEL Staining 
For embryos used for whole mount TUNEL staining, they were dissected out 
in ice-cold PBS and freed from the yolk sac and amnion. They were immediately 
fixed in 4% paraformaldehyde in PBS at overnight. On the following day, they 
were dehydrated by passing through a series of methanol in PBSL (2mM levamisole 
in PBS) in increasing concentrations: PBSL, 50%, 70%, 90%, 95%, 100% methanol 
for 5 minutes each at 4°C. Embryos were stored in 100% methanol at -20°C until 
required. When required, embryos were rehydrated by passing through a series of 
methanol in PBSL in decreasing concentrations: 95%, 90%, 70%, 50% and PBSL for 
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10 minutes each and twice with PBSL for 30 minutes each at room temperature. 
Embryos were then soaked in permeabilization solution (0.1% Triton X-100 in 0.1% 
sodium citrate) for 15 minutes at room temperature before washing in autoclaved 
water for 10 minutes at room temperature. Subsequently, embryos were washed three 
times in PBTL (0.1% Triton X-100) in PBSL) for 20 minutes each at room 
temperature. Embryos were then incubated in 50^1 of freshly-prepared TUNEL 
reaction mixtures containing terminal deoxynucleotidyl transferase and nucleotide 
mixture {In Situ Cell Death Detection Kit, AP, Roche) at 37�C in the dark for 3 hours. 
The enzyme and the labeling solution were removed by washing four times with 
PBTL for 30 minutes each at room temperature. Then, 20% sheep serum diluted in 
3% bovine serum albumin in PBTL was added followed by incubation at 4°C in the 
dark overnight. In the next morning, the solution was drained off. Embryos were 
incubated in 60|il of Converter-AP solution (provided in the kit) containing 
peroxidase-labeled anti-fluorescein sheep Fab fragment for 3 hours at room 
temperature in the dark. Embryos were then washed with PBTL four times for 45 
minutes each at room temperature and equilibrated in Tris-buffer (ISOmM, pH 9.2) 
for 5 minutes. Embryos were transferred to a glass vial before staining in 4.5[i\ of 
nitro blue teratzolium (75mg/ml stock in 70% N，N-dimethyl formamide) and 3.5jal of 
5-bromo-4-chloro-3-indolyl phosphate (50mg/ml stock in N,N-dimethyl formamide) 
per ml of Tris-buffer in the dark at room temperature. Embryos were occasionally 
examined under a stereomicroscope. When the signal intensity has reached the 
optimal level, which usually took 30 minutes, enzymatic reaction was stopped by 
washing the embryos three times with PBS for 5 minutes each. Embryos were post-
fixed in freshly-prepared 4% paraformaldehyde in PBS overnight at 4°C. Embryos 
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were washed twice in PBT, and cleared by passing through 50%, 75% glycerol in 
PBT and then 100% glycerol. Photomicrographs were taken with a Zeiss bright-field/ 
dark-field stereomicroscope using Fujichrome 64T color slide film. 
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3.1 Introduction 
As discussed in Chapter 1, maternal diabetes is associated with increased risk 
of congenital malformations. Most of the previous studies have focused on 
determining the teratogenic effects of diabetic serum and oxidative stress, however, 
the aim of this study was to determine whether environmental and/ or genetic factors 
could interact with maternal diabetes to increase the susceptibility to malformations. 
To begin, three factors have to be decided. Firstly, the type of congenital 
malformation to be investigated. Secondly, the environmental factor for testing the 
hypothesis and thirdly, the mutations for testing the effects of genetic factors. 
There is a great diversity in the types of congenital malformations found 
among infants of diabetic mothers. The most common malformations include caudal 
regression syndrome, cardiovascular anomalies, neural tube defects and situ 
abnormalities (Kucera, 1971). Neural tube defects are among the most common birth 
defects and occur at a frequency of 1.5 in 1000 pregnancies in the United States 
(Cragan et al., 1995), with a threefold increase in diabetic pregnancy (Martinez-Frias, 
1994). The cellular and genetic control of neural tube development is comparatively 
well studied, and a number of teratogens and mutants that cause neural tube defects 
have been identified. Hence, neural tube defects were chosen as the congenital 
malformation for investigation. Retinoic acid, which is a well known teratogen that 
causes neural tube defects in humans and in a number of animal species (Diez-Pardo 
et al., 1995; Ehlers et al., 1992; Emmanouil-Nikolouss et al., 2000; Kochhar, 1967; 
Kohga and Obata, 1992; Tom et al., 1991) was chosen to be the environmental factor 
for testing its interaction with maternal diabetes. As for the genetic factor, two mouse 
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mutants, splotch {Sp^^) and NOD (to be discussed in Chapter 5), which are both 
susceptible to neural tube defects, were employed. 
3.1.1 Neural tube defects 
In vertebrates, neural tube development begins by the formation of a flat 
neural plate from the dorsal ectoderm. The two sides of the neural plate then elevate 
and fold towards the midline until eventual fusion. This process is called neurulation. 
Neural tube closure is initiated at the future cervical region and then occurs bi-
directionally in cranial and caudal direction. The formation and closure of the neural 
tube in humans are normally completed within 28 days after conception. Failure in 
closure of the neural tube in the cephalic region results in a clinical condition called 
anencephaly, whereas failure in closure at anywhere along the future spinal cord 
region is called spina bifida. 
3.1.2 Retinoic acid as environmental factor 
AW-trans retinoic acid (RA) is the most active metabolite of vitamin A. 
Vitamin A (retinol) is obtained in the diet either as preformed vitamin A or 
provitamin A (carotenoids). In either case, vitamin A is taken up in the intestine and 
packaged as retinyl ester, and then absorbed into the body through the lymphatics. It 
will be removed from the circulation and stored in the liver. When required, the 
vitamin is mobilized from the liver as retinol and bound to retinol binding protein for 
transportation to target tissues, such as the eye, skin, adipose tissue, kidney, testis, 
lung and bone marrow. Within the cell, dXl-trans retinol is first oxidized to dM-trans 
retinal and then to ^\\-trans RA by the enzymes retinol dehydrogenase and 
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retinaldehyde dehydrogenase respectively. Apart from 2i\\-trans RA, there are eight 
different forms of RA. Among them, only 9-cis RA is as active as 2i\Urans RA. Their 
action is to regulate the retinoid responsive gene. This is achieved by first binding to 
their receptors of which there are two classes: RA receptors (RARs) and retinoid X 
receptors (RXRs). There are three subtypes of RARs, namely RARa, RARp and 
RARy, and also three subtypes of RXRs that include RXRa, RXRp and RXRy 
(Chambon, 1996; Mangelsdorf et al” 1992; Zelent et al., 1989). RARs are activated 
by both dX\-trans and 9-cis RA, whereas RXRs are only activated by 9-cis RA (Levin 
et al” 1992). RAR and RXR can form heterodimers (Giguere, 1994). After binding to 
their receptors, the complex then activates the target gene by binding to a specific 
sequence called the RA responsive element (RARE) (Petkovich, 1992). 
RA is very important for mammals in normal growth, reproduction, vision and 
maintaining normal cellular differentiation and the integrity of the immune system 
(Leid et al., 1992). Moreover, it is important for embryonic and fetal development. 
Both deficiency and excess of RA will result in congenital malformations. Hence, the 
level of RA should be tightly controlled, which can be achieved by regulation of RA 
synthesis and catabolism. As mentioned, the synthesis of RA can be regulated by the 
synthesizing enzymes: retinol dehydrogenase and retinaldehyde dehydrogenase. As 
for catabolism of RA, the key enzyme involved is monooxygenase isozyme 
cytochrome P450 (CYP26) located in the endoplasmic reticulum (Muindi and Young, 
1993). The main functions of cytochrome P450 are to metabolize dXl-trans RA and to 
regulate the feedback loop to control RA levels. The expression of the gene that codes 
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for cytochrome P450 is tightly regulated to protect the embryo from undue exposure 
of sensitive cells and tissues to RA. 
During embryonic development, maternal dietary deficiency of vitamin A will 
result in defects of the central nervous system, the cardiovascular, urogenital and 
respiratory systems, and the development of the skull, skeleton and limbs, as 
demonstrated in chick, rats and mice (Antipatis et al., 2000; Sharma and Misra, 1990; 
Stratford et al” 1996; Verma et al., 1996). Severe deficiency in vitamin A will result 
in alteration of gene expression at the target organ, such as changing the expression of 
elastin and growth arrest-specific gene 6 {gas6) in the fetal lung and heart, causing 
defects in the trachea and bronchi as well as defects in the aortic arch and ventricular 
chambers (Wilson and Warkany, 1949; Zachman, 1995). Deficiency of RA will also 
down regulate Fgf8 and Shh expression, eventually leading to apoptosis and causes 
facial anomalies as well as brain defects (Schneider, 2001). On the other hand, 
excessive exposure to vitamin A or RA during pregnancy have a higher chance of 
having offspring with congenital malformations (Lammer et al., 1985; Rothman et al., 
1995). The type of malformation induced is dependent on both the dose and 
developmental stage of exposure (Shenfelt, 1972a and b). One of the most commonly 
affected systems is the nervous system. Exposure to teratogenic doses of vitamin A or 
RA during early stages of gestation, particularly before neural tube closure, will lead 
to neural tube defects (Alles and Sulik, 1990; Geelen et al., 1980; Tom et al., 1991). 
Since 2i\\-trans RA is a more potent teratogen than 9-cis RA, hence, diW-trans RA was 
chosen for this study. 
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3.1.3 Sp2H as genetic factor 
There are more than 60 mouse mutants and strains that exhibit neural tube 
defects (Juriloff and Harris, 2000). Amongst them, the splotch mutant was chosen for 
the present study because it is a widely accepted model for neural tube defects (Moase 
and Trasler, 1992). Moreover, the mutated gene has been identified (Epstein et al., 
1991), hence, the genotype of the embryo can be distinguished by polymerase chain 
reaction at a stage before the appearance of morphological defects, which will thus 
allow the study of early cellular and molecular changes in the mutated embryos. 
Furthermore, the human homolog of splotch has been identified (Chalepakis et al., 
1994), information obtained from this mutant can therefore provide insight in 
understanding the human cases. 
The original splotch mutation arose spontaneously in the C57BL inbred strain 
(Russell, 1947). Heterozygous splotch mice only show pigmentation defect, with 
white spotting on the belly, and occasionally on the back, feet and tail. On the other 
hand, the homozygotes develop neural tube defects that include either spina bifida or 
exencephaly, or both. Moreover, the homozygotes also show defects in neural crest 
cells migration, causing a severe reduction or even a complete absence of many neural 
crest cell derivatives, such as pigment cells, autonomic ganglia, spinal ganglia and 
cardiac outflow tract (Auerbach, 1954; Beechey and Searle, 1986; Franz, 1989). 
It has been identified that splotch is due to a mutation of the gene PaxS. PaxS 
is one of the eight members of murine Pax gene family containing the paired box 
(Kessel and Gruss, 1990). Pax3 encodes DNA binding transcription factor that 
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expresses along the dorsal half of the neural tube, initially in the entire 
aorticopulmonary somite and later restricted to the dermomyotome and also in some 
neural crest-derived structures (Goulding et al., 1991). Functions of Pax3 include 
establishment of positional identity along the dorsoventral axis of the developing 
neural tube (Erskine et al., 1998), closure of the neural tube (Bennett et al., 1998), 
formation of epithelial somites (Schubert et al., 2001)，migration of cardiac neural 
crest cells to form the aorticopulmonary septum (Conway et al., 1997b) and migration 
of muscle progenitor cells to form the limb (Bober et al.，1994). Different allelic 
mutations in PaxS give rise to six forms of mutants, which include splotch {Sp\ 
splotch-delayed {Sp\ splotch-retarded {Sp"), splotch-Harwell 1 {Sp^"), splotch-
Harwell 2�Sp2H�and splotch-Harwell 4 {Sp^^). Sp and Sp^ arose spontaneously, 
whereas Sp\ Spi", Sp^" and Sp^" were induced by X-irradiation. They are caused by a 
single point mutation {Sp, Sp\ two points mutation intragenic deletion {Sp^") 
or complete deletion {Sp\ Sp^�of PaxS (Epstein et al., 1991，1993; Goulding et al., 
1993; Mancino et al., 1992; Vogan et al., 1993). Different degrees of severity are 
observed in these mutants. Sp^ allele is the least severe form of mutation and 
homozygous embryos can survive to birth (Moase and Trasler, 1992). Homozygous 
Sp, SpiH and Sp^^ embryos die between E13 to E16 as a result of cardiac defects 
(Conway et al , 1997b; Franz et al., 1989; Russell, 1947). S p ^ homozygotes die 
prenatally. Sp” is the most severe allele and causes lethality at early postimplantation 
stage (Beechey and Searle, 1986). 
PAXS gene, mapped in chromosome 2 (2q35) in humans, is homologous to the 
murine PaxS gene that mapped in chromosome 1 (Tassabehji et al., 1992). Mutation 
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in PAXS will cause the Waardenburg syndrome type 1 and type 2 (Tassabenji et al., 
1993) with characteristic pigmentary deficiency in iris, eyelash, white forelock and 
deafness (Fairer et al” 1992; Waardenburg, 1951). Moreover, neural tube defects have 
also been found in patients of Waardenburg syndrome (Lindhout, 1994; Moline and 
Sandlin, 1993). 
3.1.4 Experimental design of this chapter 
The objective of this chapter was to determine whether mutation, RA and 
maternal diabetes would have interaction in increasing the susceptibility of the 
embryo to neural tube defects. To achieve this, ICR female mice were rendered 
diabetes with streptozotocin. Diabetic and non-diabetic ICR female mice were then 
mated with male mice. The Sp^" allele in the embryos was therefore of 
paternal origin, hence, any maternal effects due to the Sp^" mutation could be 
excluded. mice were in a C3H/101/CBA genetic background. In an early 
attempt to induce diabetes in wild-type CBA mice, our laboratory found that they 
were relatively resistant to streptozotocin. Furthermore, they have a comparatively 
small litter size. Hence, ICR female mice, which have a larger litter size and much 
more susceptible to streptozotocin-induced diabetes, were used. The use of male and 
female mice in different strains would not affect the results since and +/+ 
embryos were littermates, and hence they had the same genetic background 
(C3H/101/CBA X ICR). Moreover, they were exposed to the same maternal 
environment. At E8.5, when neural tube closure has just initiated, the pregnant mice 
received an intraperitoneal injection of 50mg/kg of RA. Embryos were examined at 
E13.5 for the presence of neural tube defects. 
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3.2 Material and Methods 
3.2.1 mice 
2H 
Sp arose by x-irradiation at the splotch locus on the C3H/101 genetic 
background at the MRC Radiobiology Unit, Harwell, UK (Beechey and Searle, 1986). 
A heterozygous Sp female was obtained from this unit and then mated with a 
CBA/Ca male and the offspring were mated inter se to found a randomly-bred colony 
at ICRF Developmental Biology Unit, Oxford, UK. The colony was then transferred 
to Institute of Child Health, London, UK. Breading pairs of mice were 
imported from Institute of Child Health to The Chinese University of Hong Kong in 
1997 and a random bred colony was established. 
3.2.2 Mating and RA injection protocol 
分放/+ male 
mice were mated with streptozotocin-induced diabetic (refer to 
Section 2.2 for induction of diabetes) or non-diabetic ICR female mice. At 8day 
lOhours of gestation (refer as E8.5 subsequently), pregnant mice either received an 
intraperitoneal injection of RA at a dose of 50mg/kg body weight (refer to Section 2.3 
for preparation of RA) or were untreated. The suspension vehicle was not injected as 
control because previous studies in our laboratory have shown that there was no 
difference in pregnancy outcome between pregnant mice injected with suspension 
vehicle and those without injection. 
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3.2.3 Dissection of fetuses and analysis of neural tube development 
The pregnant mice were sacrificed on El3.5，and the blood glucose level of 
diabetic mice was measured by a glucometer {Bayer). The conceptus was excised. 
The number of resorptions and the number of live fetuses were recorded. The fetuses 
were dissected out in ice-cold PBS. The yolk sac of the fetus was separately collected 
in an eppendorf tube and kept at -20°C until required for DNA extraction and 
genotyping according to the method as described in Sections 2.5 and 2.6 respectively. 
The number of fetuses with exencephaly and/ or spina bifida was recorded (Fig. 3.1). 
-48 -
Chapter 3: Maternal Diabetes，Sp and RA Interaction •2// 
3.3 Results 
Altogether eight groups of fetuses were obtained from mating between 
diabetic or non-diabetic ICR female and heterozygous Sp^" male mice, with or 
without RA treatment on E8.5. The genotype of the fetus was either wild-type (+/+) 
or heterozygous depending on whether the wild-type (+) or the mutated 
(Sp ) allele was inherited paternally. The number and the percentage of live fetuses 
of the same genotype with exencephaly (with or without spina bifida; EX), spina 
bifida (with or without exencephaly; SB) and neural tube defects (including 
exencephaly and/ or spina bifida; NTD) in each group was shown in Table 3.1 to 
Table 3.12. The mean percentage of fetuses of the same genotype per litter with NTD, 
EX and SB was shown in Graph 3.1 A-C. The data were analyzed by Chi-square 
Fisher's exact test with the P value shown in Table 3.1 to Table 3.12. The mean 
percentage of resorption per litter was shown in Graph 3.2. The data were analyzed by 
Paired Student's t test. The data were regarded as statistically significant '\fP< 0.05. 
In this study, three factors: maternal diabetes, S p � " mutation and RA, were 
tested. To facilitate the comparison of results, the effect of each individual factor on 
neural tube development was first discussed (Section 3.3.1 to 3.3.3), followed by the 
interaction of two of these factors (Section 3.3.4 to 3.3.6), before the interaction of all 
three factors (Section 3.3.7) was analyzed. 
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3.3.1 Maternal diabetes alone 
Table 3.1 
Effect of maternal diabetes on wild-type fetuses without RA treatment 
Maternal diabetic state : Diabetic V ! , Non-diabetic 
Genotype +/+ ； ^ 
Dose of RA (mg/kg) 0 0 
No. of litters U 12 
No. of live fetuses ^ ^  
No. of fetuses with NTD (%) 0 (0%) 0 (0%) 
P value No measures of association were computed 
No. of fetuses with EX (%) Q (0%) | 0 (0%) 
P value No measures of association were computed 
No. of fetuses with SB (%) 0 (0%) | 0 (0%) 
P value No measures of association were computed 
The percentage of fetuses that had developed NTD, EX and SB under non-
diabetic or diabetic maternal environment was summarized in Table 3.1 and Graph 
3.1. To determine the effect of maternal diabetes alone, fetuses used for comparison 
were all wild-type and without RA treatment. Under both diabetic and non-diabetic 
maternal environment, none of the fetuses had developed neural tube defects. The 
resorption rate of the non-diabetic group was only 3.0% (Graph 3.2). However, the 
resorption rate was elevated to 19.6% in the diabetic group, with the difference 
compared with non-diabetic group close to, but not yet statistically significant. 
Although these results showed that neural tube defects were not formed in 
wild-type fetuses under maternal diabetes alone, the possibility that the resorbed 
embryos might have developed neural tube defects could not be ruled out. 
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3.3.2 Sp mutation alone 
Table 3.2 
Effect of mutation on fetuses of non-diabetic mothers without RA treatment 
Maternal diabetic state Non-diabetic Non-diabetic 
Dose of RA (mg/kg) 0 0 
No. of litters 12 
No. of live fetuses ^ 63 
No. of fetuses with NTD (%) 0 (0%) Q {Q%) 
P value No measures of association were computed 
No. of fetuses with EX (%) 0 (0%) | Q (QQ/q) 
P value No measures of association were computed 
No. of fetuses with SB (%) 0 (0%) | Q (0%) 
P value No measures of association were computed 
The percentage of wild-type and fetuses that had developed NTD, EX 
and SB was summarized in Table 3.2 and Graph 3.1. To determine the effect of Sp^" 
mutation alone, only fetuses under non-diabetic maternal environment and without 
RA treatment were considered. Both wild-type and fetuses did not show any 
neural tube defects. The rate of resorption could not be compared because the 
genotype of the fetus at the resorbed site was not determined. 
These results show that a single Sp^" allele is not sufficient to cause neural 
tube defects. 
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3.3.3 RA alone 
Table 3.3 
Effect of RA treatment on wild-type fetuses of non-diabetic mothers 
Maternal diabetic state Non-diabetic Non-diabetic 
Genotype +/+ +/+ 
^os^ofRA(mg/kg) , L - ^ 0 丫 二 ： 《 5 0 子 
No. of litters 12 15 
No. of live fetuses 63 63 
No. of fetuses with NTD (%) Q (Q%) 4 (6.3%) 
P value 0.060 
No. of fetuses with EX (%) Q (0%) | 4 (6.3%) 
P value 0.060 
No. of fetuses with SB (%) 0 (0%) | l (1.6%) 
P value 0.500 
The percentage of fetuses that had developed NTD, EX and SB after RA 
treatment or no treatment was summarized in Table 3.3 and Graph 3.1. To determine 
the effect of RA alone, only wild-type fetuses of non-diabetic mice were considered. 
Without RA treatment, none of the fetuses developed neural tube defects. However 
when the mothers received 50mg/kg of RA on E8.5, 4 out of 63 fetuses (6.3%) had 
developed exencephaly. Among these 4 fetuses, one of them exhibited spina bifida as 
well. Although the incidence rate was not high enough to be statistically significant 
(P=0.06), it might be underscored as RA caused a significant increase in the 
resorption rate (Graph 3.2). 
These results show that RA, at the dose of 50mg/kg, can induce neural tube 
defects, including both exencephaly and spina bifida, in a small percentage of fetuses, 
though the incidence rate was not yet statistically significant. 
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3.3.4 Maternal diabetes and RA interaction 
Table 3.4 
Effect of RA treatment on wild-type fetuses of diabetic mothers 
Maternal diabetic state Diabetic Diabetic 
Genotype +/+ — 
Dose of RA ( m g / k g ’ : ，： : / . /〜 0 : : : 50 一 
No. of litters 13 16 
No. of live fetuses 59 55 
No. of fetuses with NTD (%) Q (Q%) 8 (14.3%) 
P value 0.002* 
No. of fetuses with EX (%) Q (Q%) | 1 (1.80/0) 
P value 0.487 
No. of fetuses with SB (%) 0 (0%) | 7 (12.5%) 
P value 0.005* 
* Statistically significant 
Table 3.5 
Effect of maternal diabetes on wild-type fetuses treated with RA 
Maternal diabetic state : Diabetic , " Non-diabetic 
Genotype +/+ +/+ 
Dose of RA (mg/kg) 50 50 
No. of litters 16 15 
No. of live fetuses 56 ^  
No. of fetuses with NTD (%) 8 (14.3%) 4 (6.3%) 
P value 0.129 
No. of fetuses with EX (%) 1(1.8%) | 4(6.3%) 
P value 0.221 
No. of fetuses with SB (%) 7 (12.5%) | 1 (1.6%) 
P value 0.020* 
* Statistically significant 
- 5 3 -
Chapter 3: Maternal Diabetes，Sp and RA Interaction •2// 
Under the effect of maternal diabetes and RA treatment, the percentage of 
fetuses that had developed NTD, EX and SB was summarized in Table 3.4, Table 3.5 
and Graph 3.1. To exclude the effect of Sp^^ mutation, all fetuses considered were 
wild-type. As shown in Table 3.4, without RA treatment, none of the fetuses of 
diabetic mice exhibited neural tube defects. However, when fetuses of diabetic mice 
were treated with 50mg/kg of RA on E8.5, the incidence rate of NTD, which was 
mainly caused by SB, increased significantly from 0% to 14.3% (Table 3.4, Graph 
3.1). Comparison of results in Table 3.4 with Table 3.3 showed that RA only exerted 
a statistically significant effect in inducing SB, and hence an overall increase in the 
incidence rate of NTD when under maternal diabetic condition. In other words， 
maternal diabetes showed significant difference from non-diabetic pregnancy in 
inducing SB in the fetuses only when under RA treatment (Table 3.5, Graph 3.1). 
However, this difference between maternal diabetic and non-diabetic condition was 
not due to their differences in resorption rate after RA treatment (Graph 3.2). Despite 
a significant difference in the incidence rate of SB, the incidence rate of NTD did not 
increase significantly (Table 3.5, Graph 3.1). This was probably due to the 
insignificant difference in the incidence rate of EX, which diluted out the overall 
effect. 
Hence, taken into account the results in Table 3.3, Table 3.4 and Table 3.5, it 
is concluded that maternal diabetes can exacerbate the incidence of RA-induced SB. 
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3.3.5 Sp mutation and RA interaction 
Table 3.6 
Effect of RA treatment on fetuses of non-diabetic mothers 
Maternal diabetic state Non-diabetic Non-diabetic 
Genotype 分放/+ 
Dose of RA (mg/kg) ’二 / ” 0 �H 50 , 
No. of litters 12 15 
No. of live fetuses 92 73 
No. of fetuses with NTD (%) Q (Q%) 11 (15.1%) 
P value < 0.0005* 
No. of fetuses with EX (%) Q (0%) | 3 (4.1 q/q) 
P value 0.085 
No. of fetuses with SB (%) 0 (0%) | 8(11.0%) 
P value 0.001* 
* Statistically significant 
Table 3.7 
Effect of Sp2H mutation on fetuses of non-diabetic mothers treated with RA 
Maternal diabetic state Non-diabetic Non-diabetic 
genotype, , • 身，+ � . .. +/+ 
Dose of RA (mg/kg) 50 50 ~ ~ ~ 
No. of litters 15 
No. of live fetuses 73 63 
No. of fetuses with NTD (%) 11 (15.1%) 4 (6.3%) 
P value 0.088 
No. of fetuses with EX (%) 3 (4.1 %) | 4 (6.3%) 
P value 0.418 
No. of fetuses with SB (%) 8 (11.0%) | 1 (1.6%) 
P value 0.028* 
* Statistically significant 
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The percentage of and wild-type fetuses that had developed NTD, EX 
and SB under RA treatment or no treatment was summarized in Table 3.6 and Table 
3.7 and Graph 3.1. To exclude maternal effect, only fetuses of non-diabetic mice were 
considered. As shown in Table 3.6, fetuses did not exhibit neural tube defects 
without RA treatment. However, when treated with 50mg/kg of RA on E8.5, the 
incidence rate of NTD increased significantly from 0% to 15.1%, which was mainly 
attributed by a significant increase in the incidence rate of SB from 0% to 11.0% 
(Table 3.6, Graph 3.1). Comparison of results in Table 3.6 with Table 3.3 showed that 
RA only caused a statistically significant effect on fetuses, but its effect on 
wild-type fetuses was not big enough to be statistically significant. Hence, as shown 
in Table 3.7 and Graph 3.1, in response to RA treatment, fetuses had a 
significantly higher incidence rate of SB (11.0%) than wild-type fetuses (1.6%). 
However, the overall incidence rate of NTD did not show significant difference 
between these two genotypes, which was probably due to the balancing effect caused 
by the non-significant difference in the incidence rate of EX. 
Hence, taken into account the results in Table 3.3, Table 3.6 and Table 3.7, it 
is concluded that a single Sp^" allele can enhance the fetus's susceptibility to RA-
induced SB. 
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3.3.6 Sp mutation and maternal diabetes interaction 
Table 3.8 
Effect ofSj?2H mutation on fetuses of diabetic mothers without RA treatment 
Maternal diabetic state Diabetic Diabetic 
.:G?notype ；: ‘ Sp^�’ ：K‘ +/+  
Dose of RA (mg/kg) 0 0 
No. of litters U  
No. of live fetuses ^ 59 
No. of fetuses with NTD (%) 0 (0%) Q (QQ/q) 
P value No measures of association were computed 
No. of fetuses with EX (%) 0 (0%) | Q (QQ/q) 
P value No measures of association were computed 
No. of fetuses with SB (%) 0 (0%) | Q (Q%) 
P value No measures of association were computed 
Table 3.9 
Effect of maternal diabetes on Sp2H/+ fetuses without RA treatment 
；%]^atemal diabetic, state z Diabetic Non^diabetic 
Genotype 
Dose of RA (mg/kg) 0 0 
No. of litters \3 12 
No. of live fetuses 59 ^  
No. of fetuses with NTD (%) 0 (0%) 0 (0%) 
P value No measures of association were computed 
No. of fetuses with EX (%) 0 (0%) | 0 (0%) 
P value No measures of association were computed 
No. of fetuses with SB (%) 0 (0%) | 0 (0%) 
P value No measures of association were computed 
The percentage of and wild-type fetuses that had developed NTD, EX 
and SB under diabetic and non-diabetic environment was summarized in Table 3.8, 
Table 3.9 and Graph 3.1. To exclude the effect of RA, all fetuses were untreated. As 
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shown in Table 3.8 and Graph 3.1, none of the and wild-type fetuses 
developed neural tube defects under maternal diabetes. In other words, fetuses 
did not develop neural tube defects no matter whether they were in a diabetic or non-
diabetic maternal environment (Table 3.9, Graph 3.1). 
Hence, taken into account the results in Table 3.8 and Table 3.9, it is 
concluded that the combined effect of maternal diabetes and a single S p � " allele is not 
sufficient to induce neural tube defects. 
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3.3.7 Maternal diabetes, Sp^" mutation and RA interaction 
Table 3.10 
Effect of RA treatment on fetuses of diabetic mothers 
:;M^emal diabetic,state ‘ ^ Diabetic' Diabetic 
Genotype 分放/+ 
Dose of RA (mg/kg) 0 50 
No. of litters 13 \6  
No. of live fetuses ^ ^  
No. of fetuses with NTD (%) 0 (0%) 37(61.7%) 
P value < 0.0QQ5*  
No. of fetuses with EX (%) 0 (0%) | 13 (21.7%) 
P value < 0.0005* 
No. of fetuses with SB (%) 0 (0%) | 33 (55.0%) 
P value < 0.0005* 
* Statistically significant 
Table 3.11 
Effect of maternal diabetes on 
Sp2H/+ fetuses treated with RA 
Maternal diabetic state Diabetic Non-diabetic 
Genotype 
Dose of RA (mg/kg) 50 50 
No. of litters \6 15 
No. of live fetuses ^ 73 
No. of fetuses with NTD (%) 37(61.7%) 11 (15.1%) 
P value <0.0005* 
No. of fetuses with EX (%) 13 (21.7%) | 3 (4.1 %) 
P value <0.0005* 
No. of fetuses with SB (%) 33 (55.0%) | 8(11.0%) 
value <0.0005* 
* Statistically significant 
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Table 3.12 
Effect ofSj}2H mutation on fetuses of diabetic mothers treated with RA 
Maternal diabetic state Diabetic Diabetic 
G e n o _ _ � � �… … S p 2 H l — � - 瑜 , 
Dose of RA (mg/kg) ^ 50 
No. of litters 16 
No. of live fetuses ^ 56 
No. of fetuses with NTD (%) 37 (61.7%) 8 (14.3%) 
P value < 0.0005* 
No. of fetuses with EX (%) 13 (21.7%) | 1 (1.8%) 
P value 0.001* 
No. of fetuses with SB (%) 33 (55.0%) | 7 (I2.50/0) 
P value J < 0.0005* 
* Statistically significant 
Under the effect of maternal diabetes and RA treatment, the percentage of 
and wild-type fetuses that had developed NTD, EX or SB was summarized in 
Table 3.10, Table 3.11，Table 3.12 and Graph 3.1. As shown in Section 3.3.6，the 
combined effect of maternal diabetes and a single Sp^" allele is not sufficient to 
induce neural tube defects without RA treatment. However, when treated with 
50mg/kg of RA on E8.5, over 61% of fetuses developed NTD; among them 22% 
developed EX and 55% developed SB (Table 3.10, Graph 3.1). This significant effect 
in inducing neural tube defects was not attributed by RA alone, it was the result of 
interaction among RA, maternal diabetes and the Sp^^ allele. This could be shown by 
the fact that the percentage of fetuses that developed NTD after RA treatment 
was significantly reduced to 15.1% when the mother was non-diabetic (Table 3.11, 
Graph 3.1). This difference in the incidence rate of NTD between fetuses of 
non-diabetic and diabetic mice was attributed by highly significant difference in both 
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the incidence rates of EX and SB. Moreover, although it has been shown in Section 
3.3.4 that maternal diabetes could exacerbate the incidence rate of RA-induced SB in 
wild-type fetuses, the effect of maternal diabetes and RA was significantly much 
greater on fetuses than wild-type fetuses, and the significant difference was not 
limited to the incidence rate of SB, but also in the incidence rate of EX, and hence in 
the overall incidence rate of NTD (Table 3.12, Graph 3.1). 
To summarize, maternal diabetes, Sp^" mutation and RA can interact together 
to significantly increase the susceptibility of the fetus to neural tube defects, including 
both exencephaly and spina bifida. 
-61 -
Chapter 3: Maternal Diabetes, S p ^ ^ and RA Interaction 
3.4 Discussion 
The objective of this chapter was to investigate whether there were any 
interactions among maternal diabetes, Sp^^ mutation and RA in affecting the 
susceptibility of the fetus to neural tube defects. 
3.4.1 Maternal diabetes alone does not cause neural tube defects 
Results of the present study showed that maternal diabetes alone did not cause 
neural tube defects. However, this result is not in agreement with previous in vitro and 
in vivo studies carried out by other groups. It has been found that when mouse and rat 
embryos were cultured in serum made hyperglycemic by the addition of D-glucose 
(Reece et al., 1985; Sadler, 1980b), or cultured in serum obtained from diabetic rats 
(Sadler, 1989), neural tube defects were induced in a high percentage of embryos. 
However, it would be difficult to directly compare the result obtained from in vitro 
culture studies and the result of the present study because in those in vitro studies, 
embryos had been developed in a normal maternal environment before they were 
explanted and they were then suddenly exposed to a hyperglycemic/ diabetic 
environment, and the hyperglycemic/ diabetic level was maintained relatively 
constant throughout the culture period. In contrast, embryos in this study had been 
exposed to a diabetic milieu since conception. There might be maternal or embryonic 
changes to protect the embryo from the deleterious effect of the diabetic environment. 
Moreover, the level of hyperglycemia would be affected by multiple factors, such as 
maternal metabolism, and hence was subjected to fluctuation. Moreover, some weaker 
embryos, which were more sensitive to the teratogenic effect of the diabetic 
- 6 2 -
Chapter 3: Maternal Diabetes，Sp and RA Interaction •2// 
environment, might have been eliminated before implantation or early during 
gestation. Indeed, it was found in the present sUidy that the resorption rate was about 
20% in diabetic pregnancy, whereas the resorption rate was only 3% in the case of 
non-diabetic pregnancy. In an in vivo study by Loeken's group (Phelan et a l , 1997) 
where female mice were rendered diabetic by streptozotocin before pregnancy, it was 
found that about 75% of fetuses exhibited neural tube defects. However, the mice had 
been maintained normoglycemic by insulin pellet implants and only became 
hyperglycemic around the time of implantation, as the level of insulin released from 
the implant was insufficient to maintain normal blood glucose level because of 
hormonal changes accompanied with pregnancy. However, insulin has been suggested 
to be teratogenic and could increase the susceptibility of the embryo to neural tube 
defects (Cole and Trasler, 1980; Landauer, 1972). Furthermore, in that study, even in 
the control embryos of non-diabetic mothers, about 25% of them developed neural 
tube defects, showing that the strain of mice or the environment they were housed 
could contribute to the increased susceptibility of the embryo to develop neural tube 
defects. 
3.4.2 RA induces neural tube defects 
As discussed in Section 3.1.2, excessive vitamin A or RA is teratogenic. The 
effective dose to bring about a teratogenic response in the embryo is specie- and 
strain-dependent (Kalter and Warkany, 1961; Nolen, 1969). Moreover, the 
susceptibility of different tissues/ organs to RA is dependent on the developmental 
stage of exposure and the dose of RA (Shenefelt, 1972b). For example, as low as 
2.5mg/kg can induce neural tube defects when given to mouse embryos at presomite 
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stage (Sulik et al” 1995). However, a much higher dose is required if given at later 
time, and embryos are no longer susceptible to RA-induced neural tube defects once 
the neuropores have closed (Tibbies and Wiley, 1988; Yasuda et al.，1987). In this 
study, at the time of RA treatment (E8.5), the embryos were in early somite stage, at 
which the anterior and posterior neuropores were still widely open. Results showed 
that RA, at the dose of 50mg/kg, could induce a low percentage of neural tube defects 
in the wild-type fetuses. However, the result was statistically insignificant, and 
appeared to be lower than other studies (Kapron-Bras et al., 1984). One of the 
possibilities that could account for the different susceptibility to RA might be strain 
difference. In fact, it has been shown that mice with different genetic background 
could show great variations in susceptibility to teratogens (Austin et al., 1982; Finnell 
et al., 1986, Tom et al., 1991). Furthermore, in this study, it was found that there was 
a significantly higher resorption rate in RA-treated litters. It could not be ruled out 
that some of these resorbed embryos might have developed neural tube defects. 
3.4.3 Interaction of maternal diabetes with RA in increasing the 
susceptibility to neural tube defects 
In this study, it was found that maternal diabetes alone did not cause neural 
tube defects, and 50mg/kg of RA injected on E8.5 only induced a small percentage of 
spina bifida in the wild-type fetuses of non-diabetic mothers. However, when 
embryos were treated with the same dose of RA under a maternal diabetic 
environment, there was a significant increase in the incidence rate of SB, showing that 
maternal diabetes could exacerbate the spina bifida-inducing effect of RA. 
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As mentioned, the susceptibility to RA is both dose and stage-dependent 
(Shenefelt, 1972b). It has been shown that maternal diabetes would increase the blood 
flow of the uterine and decidual tissues, that led to an increase in supply of nutrients 
to the developing embryo through the implantation site (Wentzel et a l , 1995). Hence, 
although diabetic and non-diabetic mice were treated with the same dose of RA, it 
was possible that embryos of diabetic mice might actually receive a higher dose of 
RA than embryos of non-diabetic mice, resulting in increased susceptibility to spina 
bifida. 
On the other hand, although macrosomic infant is associated with diabetic 
pregnancy (Pederson, 1954), maternal diabetes has also been suggested to cause early 
growth delay in humans (Pedersen and Molsted-Pedersen, 1981). As shown in rats, 
maternal diabetes can alter the function of the placenta (Padmanabhan and Shafmllan, 
2001), which affects the development of the fetal pancreas and fetal metabolism, 
resulting in growth retardation (Holemans et al., 1998). Hence, if embryos of diabetic 
mice were developmentally delayed, this might increase their susceptibility to RA. 
However, our laboratory has recently shown that embryos of diabetic and non-
diabetic mice were at similar somite stage at E9.5 (Chan et al., 2002). Furthermore, if 
there was a developmental delay in embryos of diabetic mice at E8.5, anterior 
neuropore should be affected to a greater extent in developmentally younger embryo 
and therefore, an increase in exencephaly, rather than spina bifida, should be resulted. 
Hence, the increased incidence of spina bifida found in embryos of diabetic mice in 
the present study was unlikely due to developmental delay. 
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Another possible explanation for the increased susceptibility might be due to 
some common mechanistic features shared by maternal diabetes and RA. In fact，a 
number of malformations associated with diabetic pregnancy (Kucera, 1971; Mills, 
1982) were also found in cases of excessive intake of RA or vitamin A (Lammer et al., 
1985; Rothman et al” 1995). For example, caudal regression syndrome (Passarge and 
Lenz, 1966; Shum et al , 1999), cleft palate (Spilson et al., 2001; Sulik et al., 1988), 
heart defects (Ferencz, 1990; Sinning, 1998) and neural tube defects (Alles and Sulik, 
1990; Sadler, 1980b). RA is suggested to induce malformation in a number of tissues, 
including the neuroepithelium, via inducing cell death (Alles and Sulik, 1992), and 
increase in cell death has also been found in embryos exposed to diabetic or 
hyperglycemic condition (Phelan et al., 1997; Sadler, 1980a). Hence, elevation of cell 
death in target tissues may be a common pathogenetic mechanism of RA and maternal 
diabetes, which when combined together, may account for the increased incidence of 
malformations. 
In this study, it was found that maternal diabetes only exacerbated the effect of 
RA in inducing spina bifida, but not exencephaly. The most likely explanation was 
related with the time of RA treatment. The anterior and posterior neuropores have 
different susceptible period to the teratogenic effect of RA, with the critical period for 
induction of exencephaly being earlier (Tom et al., 1991). Once the critical period is 
passed, it is no longer susceptible to RA. In fact, in separate studies carried out in our 
laboratories, it is found that there is no interaction of maternal diabetes with RA in 
inducing spina bifida when RA is administered at E9.5，although at that stage, the 
posterior neuropore is still open (Chan et al., 2002). On the other hand, if RA is 
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administered at an earlier stage (E8.25), it increases the susceptibility of embryos of 
diabetic mice to exencephaly rather than spina bifida (Tang C.Y. and Shum A.S.W., 
unpublished data). 
3.4.4 Embryos with Sp^" allele show increased susceptibility to 
neural tube defects when triggered by maternal diabetes and 
RA 
The splotch {Sp^") mutation is semi-dominant. Homozygous Sp^^ embryos 
develop neural tube defects, whereas the possession of one functional PaxS allele in 
heterozygous Sp^" embryos is already sufficient to undergo complete neural tube 
development under normal condition (Beechey and Searle, 1986). However, results of 
the present study showed that upon exposure to RA, fetuses had a significantly 
higher incidence rate of SB than their wild-type littermates. This result is similar to 
the finding on Sp mutants that the presence of a single Sp allele can increase the 
susceptibility of the embryo to the spina-bifida inducing effect of RA (Dempsey and 
Trasler, 1983; Kapron-Bras and Trasler, 1984). In comparing the size of the posterior 
neuropore in *Sp/+ and wild-type embryos at different stages, it is found that Sp/-^ 
embryos exhibit a transient delay in posterior neuropore closure (Kapron-Bras and 
Trasler, 1988a). Since closure of the neuropore has to be completed within a defined 
developmental time window to ensure normal development (Copp，1985)，therefore, 
although this delay is not sufficient to cause defects in the Sp/+ embryos, it will 
predispose the embryo to the teratogenic effect of RA that also delays posterior 
neuropore closure. Hence, these two predisposed factors {Sp and RA), when add 
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together, will greatly increase the risk of failure in closure of the posterior neuropore, 
leading to spina bifida. However, although both splotch mutation and RA can cause 
delay in posterior neuropore closure, the underlying mechanism is suggested to be 
different. Decreased number of mesoderm cells and extracellular matrix around the 
neural fold is associated with abnormality in neural fold elevation and fusion in the Sp 
mutants, whereas RA induces abnormal shape of the neural groove that may inhibit 
neural folds fusion (Kapron-Bras and Trasler, 1988b). 
In this study, it was found that fetuses only showed increased 
susceptibility to RA-induced spina bifida, but not exencephaly. Similar findings were 
also obtained with Sp mutants being exposed to RA on E8.5 (Dempsey and Trasler, 
1983; Kapron-Bras and Trasler, 1984). Although Sp mutants also show delay in 
anterior neuropore closure (Dempsey and Trasler, 1983), yet, as mentioned in Section 
3.4.3, the anterior neuropore has a susceptible period to RA earlier than that of the 
posterior neuropore (Tom et al., 1991). Hence, this might explain the lack of 
significant interactive effect between the Sp^ H allele and RA in increasing 
exencephaly. 
JTT 
Sp is caused by a mutated Pax3 allele (Epstein et al., 1991), which causes 
neural tube defects in embryos homozygous for the mutation (Beechey and Searle, 
1986). Down regulation of Pax3 has also been observed in embryos of diabetic mice 
and was suggested to be the basis of increased neural tube defects associated with 
diabetic pregnancy (Phelan et al., 1997). Since PaxS is affected in both mutation 
and maternal diabetes, it is expected that these two factors, when add together, may 
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increase the susceptibility to neural tube defects. However, in this study, neural tube 
defect was not found in any fetuses even under maternal diabetic environment. 
This result was in contrast to the finding by Machado et al. (2001), which found that 
fetuses carrying an Sp allele had a higher incidence of spina bifida, but not 
exencephaly, than wild-type fetuses in a maternal diabetic environment. There are 
several possibilities to account for the differences in results between the present study 
and those by Machado et al. (2001). Firstly, the genetic background of the embryos 
employed in the two studies was different. In the present study, the paternal strain was 
in mixed genetic background of C3H/101/CBA, while the maternal strain was ICR. In 
Machado et al. (2001)'s study, the embryos were in C57BL/6J genetic background. It 
is known that genetic background will affect the penetrance of the defects. For 
example, Sp/Sp mice in C57BL/6J background exhibit 100% spina bifida and 56% 
exencephaly (Auerbach, 1954)，whereas outcrossing to In(l)lRk mice results in only 
25% spina bifida , but 100% exencephaly (Moase and Trasler, 1987). Moreover, 
different genetic background can also affect the susceptibility to the teratogenic effect 
of the diabetic environment. It was reported that about 15% of embryos in C57BL/6J 
background developed exencephaly under maternal diabetes (Machado et al., 2001), 
whereas a much higher incidence of neural tube defects was observed in ICR embryos 
of diabetic mice (Phelan et al., 1997). Secondly, the splotch locus examined was 
different in the two studies. In the present study, the Sp^^ allele was studied, whereas 
Machado et al. (2001) examined the interaction of maternal diabetes with the Sp allele. 
Although neural tube defects were not found in any fetuses of diabetic 
mice, there was indeed interaction between the Sp^" allele and maternal diabetes. This 
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was shown by the fact that when exposed to RA, the incidence rates of neural tube 
defects，including both EX and SB, were significantly much higher in fetuses 
of diabetic mice (NTD: 61.7%; EX: 21.7%; SB: 55%) in comparison to wild-type 
fetuses of diabetic mice (NTD: 14.3%; EX: 1.8%; SB: 12.5%) or fetuses under 
non-diabetic environment (NTD: 15.1%; EX: 4.1%; SB: 11%). Hence, showing that 
the interaction of maternal diabetes, RA and S p � " mutation in increasing the incidence 
of neural tube defects is not simply an additive effect, but it is rather through some 
synergistic mechanisms. The cellular and molecular mechanisms of their interactions 
were addressed in Chapter 4. 
In conclusion, results of this study suggest that although maternal diabetes 
alone does not cause neural tube defects, it will enhance the teratogenic effects of 
environmental agents, such as RA, especially in embryos that are genetically 
predisposed to the defect. In other words, the increased susceptibility to congenital 
malformations in diabetic pregnancy may not be attributed solely by the maternal 
diabetic milieu, but can also be influenced by the genetic make-up of the embryo and 
exposure to teratogens during pregnancy. 
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4.1 Introduction 
In Chapter 3，it has been established that maternal diabetes, RA and Sp^" 
mutation could interact together to increase the susceptibility to neural tube defects. 
The aim of this chapter was to determine the underlying mechanisms of interaction. 
4.1.1 Mechanism of diabetic embryopathy 
Maternal diabetes is associated with increased incidences of congenital 
malformations (The Diabetes Control and Complications Trial Research Group, 1996). 
It is believed that maternal diabetic environment can affect embryonic gene 
expression, which causes birth defects in various ways. For example, it is suggested 
that maternal diabetes can cause skeletal malformations via inhibition of the 
cartilage-specific chondroitin sulfate core protein gene expression (Leonard et al., 
1989). Diabetic environment as well as elevated levels of ketone bodies，such as 
butyrate, alter Hox genes expression and are suggested to be the cause of delayed lung 
development (Jacobs et a l , 1998). Moreover, maternal diabetes up regulates the 
expression of insulin-like growth factor binding protein-1, which is associated with 
growth retardation and developmental delay (Rajaratnam et al., 1997). 
Regarding the pathogenetic mechanism of neural tube defects associated with 
maternal diabetes, it has been demonstrated in rats that during diabetic pregnancy or 
under hyperglycemic condition, there was an increase in embryonic ROS levels in the 
neural tissue that might be caused by a reduction in the free radical scavenging 
enzymes, such as superoxide dismutase, catalase and glutathione peroxidase 
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(Forsberg et al., 1996; Sivan et al., 1997; Yang et al.，1997). The ROS generated 
down regulated the expression of cyclooxygenase-2 (Wentzel et a l , 1999), which 
subsequently led to a lowering of embryonic prostaglandin E2 levels during 
neurulation that might inhibit neural tube fusion (Baker et al., 1990; Piddington et al , 
1996). Reduced prostaglandin E2 levels were also found in human yolk sacs from 
diabetic pregnancies (Schoenfeld et al., 1995). Furthermore, maternal diabetic 
environment and elevated glucose level are found to down regulate PaxS, which is 
suggested to be associated with development of neural tube defects (Phelan et al” 
1997; Fine et al., 1999). Moreover, a number of genes regulated by PaxS have been 
identified. For example, Diabetic Embryopathy-1 (Dep-l) is found to be a 
transcriptional target of PaxS and is down regulated in embryos of diabetic mice (Cai 
et al., 1998). 
Besides affecting gene expression, maternal diabetes can also induce 
congenital malformations via apoptosis (Moley, 2001). Apoptosis, also known as 
programmed cell death, indicates an endogenous cell suicide program by which 
unwanted or damaged cells are eliminated. It plays an essential role in many processes 
during normal embryogenesis, for example, in canalization of ducts and tubes, 
formation of digits, fusion of palatal shelves and closure of the neural tube (Cho et al., 
1995; Lee et al., 1993; Naruse and Keino, 1995; Taniguchi et al., 1995). 
During embryonic development, apoptosis occurs in specific location and at 
specific time. Focal apoptosis involved in morphogenesis is precisely controlled by 
genetic, hormonal and/ or local factors (Wyllie et al., 1980). Similar to other 
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pathophysiological processes, excessive or defective apoptosis can be deleterious for 
normal embryogenesis (Su, 2000), and causes developmental abnormalities, such as 
cleft palate and neural tube defects (Chen and Huang, 1999; Park et al., 1998). It is 
found in mouse embryos that there is an elevated level of apoptosis in the 
neuroepithelium under maternal diabetes or hyperglycemic conditions and is 
suggested to play a role in the etiology of neural tube defects (Fine et al., 1999; 
Phelan et al., 1997). Furthermore, hyperglycemia is found to induce apoptosis in pre-
implantation embryos through modulation of cell death regulating genes, such as Box 
(Moley et al., 1998). 
4.1.2 Mechanism of Sp^^ mutation in development of neural tube 
defects 
As discussed in Chapter 3, the Sp^" allele is caused by mutation of PaxS that 
leads to neural tube defects when in homozygous state (Beechey and Searle, 1986; 
Epstein et al.，1991.). Expression of Pax3 is initiated in the neuroepithelium before 
neural tube closure. In the neural tube, its expression domain is restricted to the dorsal 
half, extending from the prosencephalon to the anterior margin of the posterior 
neuropore (Goulding et al., 1991). It encodes a transcription factor that is important 
for neural tube closure. In S p � " mutation, there is a 32 base pair deletion in the paired 
homeodomain of Pax3, which creates a termination codon at the deletion breakpoint, 
resulting in the production of a truncated non-fiinctional protein that lacks a complete 
paired homeodomain and its entire C-terminal half potentially involved in 
transactivation (Epstein et al, 1991). Studies of the heterozygous and homozygous Sp 
bryos show that the expression levels of N-cam, N-cad, bcl-2, p53 and Wee-1 are 
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altered at E8.5 to ElO.O in comparison to wild-type embryos (Bennett et al., 1998). 
Together with the known function of these genes in governing cell cycle or 
extracellular matrices of the developing neural tube, it is proposed that they may have 
interaction with PaxS in controlling neural tube closure. 
Recently, it is known that PaxS regulates neural tube closure by inhibiting 
p53-dependent apoptosis (Pani et al., 2002). In other words, mutation of PaxS 
increases p53 protein levels that results in uncontrolled apoptosis in the 
neuroepithelium, which finally leads to failure in neural tube closure. Crossing of Sp 
mutants with p53 null mutants results in rescuing of homozygous Sp embryos from 
developing neural tube defects. 
4.1.3 Mechanism of RA teratogenicity 
As discussed in Chapter 3, it is well documented that excessive exposure to 
retinoid during early pregnancy will increase the risk of the embryos to congenital 
malformations, including craniofacial defects, central nervous system defects, thymic 
defects, heart defects, musculoskeletal defects, urogenital defects and defects of the 
digestive tract (Lammer et al, 1985; Rothman et al., 1995). The teratogenicity of RA 
can be mediated via different mechanisms. Firstly, RA can affect the expression of 
genes that are important for normal embryonic development. For example, it has been 
shown that RA induced heart malformation in rat embryos by down regulation of both 
Mash-1 and c-Ret (Shoba et al., 2002). RA can induce caudal truncation by down 
regulating Bmchyury, Wnt-3a and Cdx-4 in the caudal region of the embryo 
(lulianella et al.，1999; Shum et al, 1999). Teratogenic dose of RA can also induce 
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bilateral clefting of the lip and palate via inhibition of the expression of Sonic 
hedghog (Shh) in the craniofacial primordial tissues (Helms et al., 1997). Secondly, 
excessive RA can affect embryonic development by inhibition of cell proliferation 
and cell migration. For example, it has been shown in chick embryos that RA blocked 
DNA synthesis and decreased the proliferative activity of neural crest cells that 
eventually led to failure in neural crest cell migration, resulting in craniofacial defects 
(Salvarezza and Rovasio，1997). Thirdly, it has been demonstrated in a number of 
tissues that excessive doses of RA induced apoptosis, especially in the areas of 
physiological cell death. For example, RA induces apoptosis in the apical ectodermal 
ridge of the limb bud and leads to limb reduction defects (Jiang and Kochhar, 1992). 
Regarding the pathogenetic mechanism of RA in inducing neural tube defects, 
high doses of RA can affect the expression of genes that is important for normal 
neural tube development. For example, RA can down regulate AP2, which leads to a 
number of malformations, including exencephaly (Zhang et al.，1996). Apart from 
affecting gene expression, RA has been reported to exert its action on neurulation 
through its ability to change the shape of neuroepithelial cells and to induce excessive 
cell death (Alles and Sulik, 1990; Geelen et al., 1980), resulting in failure in neural 
tube closure. 
4.1.4 Possible common pathways shared by maternal diabetes, RA 
and Sp2H mutation 
In Chapter 3, it was found that maternal diabetes, RA and S p � " mutation 
interacted together to increase the susceptibility of the fetuses to neural tube defects. It 
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is possible that some common mechanistic features are shared by these factors. Based 
on the potential pathogenetic mechanisms of these factors as discussed in Sections 
4.1.1, 4.1.2 and 4.1.3, it is speculated that the mechanism of interaction at the 
molecular level may be mediated via affecting the expression of a common gene, and/ 
or induction of apoptosis at the cellular level. 
One of the candidate genes that may be commonly affected by the three 
factors is PaxS. Since Sp^" is a loss of function allele of PaxS and Sp^" is semi-
dominant, therefore, the functional PAXS protein levels in heterozygous Sp^" 
embryos should be reduced in comparison to that of wild-type embryos. If there is a 
threshold level ofPAX3 that directs proper neural tube development, below which the 
neural tube will fail to close, it is possible that maternal diabetes and RA may increase 
the susceptibility to neural tube defects by lowering PAXS to sub-threshold level via 
down regulation of PaxS. Since the antibody against the PAXS protein was not 
commercially available, to test this hypothesis, the expression level of PaxS mRNA in 
embryos under different conditions were compared in this study. 
Maternal diabetes can induce apoptosis (Phelan et al., 1997). In the Sp 
homozygous mutants, absence of PaxS alleviates its inhibition on p53-dependent 
apoptotic pathways and leads to excessive cell death in the neuroepithelium (Pani et 
al., 2002; Phelan et al., 1997). It is also well documented that RA can cause 
malformations via inducing excessive cell death (Shum et al, 1999). Hence, apoptosis 
appears to be a common cellular event and therefore, it is proposed that the three 
factors may interact together to increase the susceptibility to neural tube defects via 
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elevating the level of apoptosis along the neuroepithelium. To test this hypothesis, the 
level of apoptosis in the neuroepithelium of embryos under different conditions were 
compared. 
4.1.5 Experimental design of this chapter 
The objective of this chapter was to determine whether there were any changes 
in the levels of PaxS and apoptosis that could account for the interaction of Sp^" 
mutation, maternal diabetes and RA in increasing the susceptibility to neural tube 
defects. 
Since antibodies against PAX3 protein are not available, hence the expression 
of was determined by its mRNA level. There are several methods that can detect 
mRNA, for example, in situ hybridization, Northern blotting and RT-PCR. Since 
PaxS expression is not limited to the neural tube, but also in the somite, and it is 
technically difficult to isolate the neural tube or neuroepithelium in the neuropore 
region with enzymatic treatment, therefore, Northern bloting and RT-PCR, though 
more quantitative, are not suitable to restrict the detection of PaxS in the neural tube 
or neuropore region. Hence, in this study, whole mount in situ hybridization was 
employed to examine the expression levels of PaxS in different regions of the embryo 
under various conditions. 
Considering the experimental methods to detect apoptosis, many of them are 
based on detection of the characteristic DNA fragments produced. In apoptosis, a 
series of biochemical pathways activate endonucleases to generate intemucleosomally 
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fragmented DNA with 3'-OH ends. These 3'-OH ends can be detected by in situ 
terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling 
(TUNEL) assay (Gavrieli et al., 1992). Furthermore, as caspases play a central role in 
apoptosis (Henkart, 1996), this has led to the development of assay based on the 
measurement of these important enzymes in situ. In this study, whole mount TUNEL 
staining was employed, which enabled the analysis of the level of apoptosis in 
different regions of the neural tube and neuropore. 
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4.2 Materials and Methods 
4.2.1 Sample collection for studying Pax3 expression in and 
+/+ embryos in response to maternal diabetes or RA by whole 
mount in situ hybridization 
Heterozygous (分�付/+) and wild-type (+/+) embryos were obtained by mating 
between male and ICR (+/+) female mice. To determine the effect of maternal 
diabetes on Pax3 expression, diabetic ICR female mice were used, whereas non-
diabetic ICR female mice served as control. Embryos were collected at E8.5, E8.75 
and E9.0. These time points were selected because the expression level of Pax3 
within this period is critical in affecting neural tube closure. The number of embryos 
studied was shown in Table 4.1. 
Table 4.1 
No. of embryos used for in situ hybridization to study Pax3 expression levels at 
different embryonic stages under maternal diabetic or non-diabetic environment 
！' J Diabetic P Non-diabetic ~ 
Embryonic stage —— ： • 
“ � �V /+ . +/+ V /+ +/+ 
� … � V - -. I - � ‘ � ， I • . • I . 
^ 12 15 Yx ^ 2 9 “ “ 
E8.75 10 12 16 14 
^ 16 ^ ^ 
To determine the effect of RA on PaxS expression, non-diabetic ICR female 
mice were treated with RA at a dose of 50mg/kg or lOOmg/kg body weight at E8.5 or 
untreated with RA. Embryos were collected at 6 hour (E8.75) and 12 hour (E9.0) after 
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RA treatment. These time points were selected because it has been demonstrated that 
RA could affect gene expression in the embryo within a couple of hours after 
intraperitoneal injection (Shum et al.，1999) and RA would be metabolized within 24 
hours (Kraft et al., 1995). Other than 50mg/kg, embryos were also treated with a high 
dose of RA (lOOmg/kg) because at this dosage, most embryos would develop neural 
tube defects, hence, it would be easy to distinguish whether RA caused neural tube 
defects via affecting PaxS expression. The number of embryos studied was shown in 
Table 4.2. 
Table 4.2 
No. of embryos used for in situ hybridization to study PaxS expression levels at 6 
and 12 hour after treatment with various dosages of RA 
^ • ^ h ^ u r ^ f t e r l ' 0 mg/kg ^ ^ I 50 mg/kg RA I 100 mg/kg RA ； 
RA treatment | +/+ :处巧+ 广 i 处 、 : 
> ：； z ‘ , ‘ 
6 hours (E8.75) 1 6 1 4 1 2 1 4 1 8 12~~ 
12 hours (E9.0) yj 36 13 13 H 15 
— L  
To prepare embryos for whole mount in situ hybridization, embryos were 
dissected out in ice-cold DEPC-treated PBS. The yolk sac of each embryo was 
collected and the embryo proper was individually kept in separate tube. They were 
individually fixed and dehydrated until they were in 100% methanol as described in 
Section 2.8.1. The yolk sac of each embryo was used for DNA extraction and 
genotyping by PGR as described in Sections 2.5 and 2.6 respectively. After 
determining the genotype, embryos of the same genotype or +/+) under the 
same treatment (maternal diabetic/ non-diabetic; RA-treated/ untreated) were pooled 
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together for detection of PaxS by whole mount in situ hybridization according to 
Section 2.8. 
The cDNA plasmid of mouse PaxS was a gift from Dr. Martyn Goulding 
(Goulding et al” 1991). It contains 520 base pair of the 3’ coding region of the 
homeobox in PaxS (base pair 1071-1590) inserted into the Bluescript KS+ vector. To 
generate antisense RNA probe, the plasmid was linearized with Hindlll and 
transcribed by using T7 polymerase. To generate sense RNA probe, the plasmid was 
linearized with PstI and transcribed by using T3 polymerase. 
Three batches were carried out. Embryos in the same batch were developed in 
NBT/BCIP for the same duration and the expression levels of PaxS were compared 
between embryos in the same batch. 
4.2.2 Sample collection for studying the level of apoptosis in response 
to the interaction of maternal diabetes，Sp^^ mutation and RA 
by whole mount TUNEL staining 
To determine whether the amount of apoptosis in the neuroepithelium was 
dependent on the number of copies of Sp^^ alleles, comparison was made among 
Sp2Hl+ and +/+ embryos, which were obtained by mating between 
parents. Embryos were collected at E8.5, E9.0 and E9.5, during which active neural 
tube fusion was undergoing. The number of embryos studied was shown in Table 4.3. 
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Table 4.3 
No. of embryos employed in each genotype with different copies of Sp^" alleles 
for determination of apoptotic level 
… ’ �’ 人 、 • Genotype ； 
jEmbryohicstagP - ‘ � 一…‘• ^^ ；：•；' • 
V ‘ '；^  'V �- ‘ � � i^A^Hi^m V 2H,, ‘ “ I ' ‘““77. “ 
E8.5 5 " " “ ^ 12 1 
E ^ 4 9 4 
6 10 5 
To determine and compare the level of apoptosis in and +/+ embryos in 
response to maternal diabetes and/ or RA, embryos were obtained by mating between 
Sp^"/-^ male and diabetic or non-diabetic ICR (+/+) mice. At E8.5, diabetic or non-
diabetic pregnant mice were injected with 50mg/kg of RA or untreated. Embryos 
were collected at 0 hour (E8.5) or 12 hour (E9.0) or 24 hour (E9.5) after RA treatment. 
These time points were selected in order to study apoptotic levels at the optimum time 
since it has been shown that apoptosis could be detected in the neuroepithelium as 
soon as 12 hours after RA treatment (Alles and Sulik, 1990) and RA-induced 
apoptosis in the tail bud reached a maximal level at 24 hour after RA treatment and 
apoptotic cells were rapidly cleared away (Shum et al., 1999). The number of 
embryos studied was shown in Table 4.4. 
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Table 4.10 
No. of embryos employed in different treatment groups for whole mount TUNEL 
assay 
, � 2 《 ？ S P ， 、 < ? f h o « ��玲 i a b e % : f � " j ' - N o n - d i a b b t i ^ > 7 1 
效 难 i 御 a t m e n t : , 广 却 f ^ + V i：',,:、」> 处 ^ / ： : : :今丨七广k 
0 hours n 
(E8.5) 8 1 � 6 6 
12 hours 
0 mg/kg 7 9 8 9 
(E9.0) ^ 
24 hours 
(E9.5) 9 12 10 9 
12 hours ~~ 
(E9.0) 8 7 7 6 
50 mg/kg  
24 hours 
10 8 8 8 
(E9.5) 
To prepare embryos for whole mount TUNEL staining, embryos were 
dissected out in ice-cold PBS. The yolk sac was collected for DNA extraction and 
genotyping by PGR. The embryo proper of each embryo was separately fixed and 
dehydrated up to 100% methanol as described in Section 2.9. After determining the 
genotype, embryos of the same genotype under the same treatment were pooled 
together for detection of apoptotic cells by whole mount TUNEL staining according 
to Section 2.9. 
The level of apoptosis in three regions: (i) along the neural tube, (ii) in the 
cranial neuropore, and (iii) in the caudal neuropore were scored blindly according to a 
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grading system that ranged from Level 1 to Level 10, in increasing number of 
apoptotic bodies. A positive control of the TUNEL assay had been performed on E8.5, 
E9.0 and E9.5 ICR embryos in which all cells on the surface were nicked by DNase I 
and the level of apoptosis was regarded as Level 10. The procedures performed were 
similar to that as described in Section 2.9, except just prior to the labeling of DNA 
fragments by the TUNEL reaction mixtures, embryos were incubated in Img/ml of 
DNase I {Roche) (in 50mM Tris-HCl, pH 7.5; Img/ml BSA) for 10 minutes at 25�C in 
order to cut the DNA strands into fragments. Embryos were then washed with PBTL 
twice at room temperature for 20 minutes each before labeling, and subsequent 
processes were performed as described in Section 2.9. On the other hand, a negative 
control was performed by incubation without the terminal deoxynucleotidyl 
transferase enzyme and the level of apoptosis was regarded as Level 1. The 
intermediate levels were established in between these two extremes depending on the 
amount of apoptotic bodies found. 
This semi-quantitative grading system was adopted from Fine et al. (1999). 
Although theoretically, the number of apoptotic bodies can be quantified by an image 
analysis system, it has the limitation that apoptotic bodies within clumps cannot be 
accurately distinguished. Hence, the use of a semi-quantitative grading system was a 
more effective way to judge the density of apoptotic bodies. 
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4.3 Results 
4.3.1 Expression levels of Pax3 mRNA detected by whole mount in 
situ hybridization 
4.3.1.1 Expression oiPax3 in Sp^^l-^ and +/+ embryos 
+/+ embryos (non-diabetic) 
In +/+ embryos at E8.5 (Fig. 4.1 B)，E8.75 (Fig. 4.1 F) and E9.0 (Fig. 4.1 J), 
PaxS was expressed in the neural tube along the whole body axis (Fig. 4.1 B2, 4.1 F2 
and 4.1 J2; yellow arrow). In the cranial neuropore region where neural tube fusion has 
not yet occurred, PaxS expressed strongly in the dorsal neural plate/ neural fold of the 
entire open region, except at the otic level that corresponded to the future 
rhombencephalic region, PaxS expression level was much lower (Fig. 4.1 B3, 4.1 F3 
and 4.1 J3; orange arrowhead). In the caudal neuropore region, PaxS expression was 
initiated in the dorsal neural folds just before neural tube fusion occurred (Fig. 4.1 B4, 
4.1 F4, and 4.1 J4; red arrow). Besides expressing in the nervous system, PaxS also 
expressed in the segmental mesoderm (Fig. 4.1 B2; green arrowhead) and later in the 
dorsolateral portion of the somite (Fig. 4.1 F2 and 4.1 J2; green arrowhead), which 
would develop into the dermomyotome. 
embryos (non-diabetic) 
The expression pattern and level of PaxS mRNA transcripts in embryos 
(Fig. 4.1 A, 4.1 E and 4.1 I) were similar to that in +/+ embryos. This was due to the 
fact that although there was a 32 nucleotide deletion in the Sp^^ mRNA, which would 
translate into a truncated, non-functional PAXS protein, the mutated mRNA could still 
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be hybridized and detected by the antisense RNA probe employed in this study, which 
contained sequences complementary to region outside the mutated site. 
4.3.1.2 Effect of maternal diabetes on Pax3 expression in and +/+ embryos 
+/+ embryos (diabetic) 
Under maternal diabetic environment, at E8.5, there was an overall lower level 
of 尸 t r a n s c r i p t s in +/+ embryos (Fig. 4.1 D) when compared with embryos of the 
same genotype in a non-diabetic environment (Fig. 4.1 B). The reduced expression was 
observed in the closed neural tube (Fig. 4.1 D2), in the cranial neuropore region (Fig. 
4.1 D3), in the anterior margin of the caudal neuropore and also in the segmental 
mesoderm (Fig. 4.1 D4). As development progressed to E8.75, there was still a general 
lower level of PaxS expression in neural and somatic tissues in +/+ embryos of 
diabetic mice (Fig. 4.1 H) than those tissues in non-diabetic mice (Fig. 4.1 F). 
However, at E9.0, there was no longer any difference in expression levels of PaxS 
between +/+ embryos of diabetic (Fig. 4.1 L) and non-diabetic (Fig. 4.1 J) mice. 
(diabetic� 
At E8.5, the expression level of PaxS in embryos under maternal 
diabetic environment (Fig. 4.1 C) was very much lower than that in embryos 
under non-diabetic environment (Fig. 4.1 A). In the cranial region, PaxS transcripts 
were only slightly detectable in the neuroepithelium (Fig. 4.1 C3). In the caudal 
neuropore region, PaxS expression level in the anterior margin of the caudal neuropore 
region was very low (Fig. 4.1 C4). In comparing and +/+ embryos of non_ 
diabetic and diabetic mice, it was found that the effect of maternal diabetes in reducing 
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expression level was much greater on (Fig. 4.1 A and 4.1 C) than +/+ 
embryos (FigAlB and 4.1 D). 
As development progressed to E8.75, although the expression level of Pax3 in 
embryos of diabetic mice (Fig 4.1 G) was still lower than embryos of 
non-diabetic mice (Fig. 4.1 E), PaxS was clearly expressed in the neuroepithelium in 
the cranial neuropore region (Fig. 4.1 G3). Furthermore, the difference in expression 
levels of PaxS between 分 ( p i g 4 1 g) and +/+ embryos (Fig. 4.1 H) under 
maternal diabetes environment has narrowed in comparison to the difference between 
embryos of the two genotypes at E8.5 (Fig. 4.1 C and 4.1 D). 
At E9.0, there was no longer any difference in expression levels of Pax2 
between embryos of diabetic (Fig. 4.1 K) and non-diabetic (Fig. 4.1 I) mice, 
and also no difference between (Fig. 4.1 K) and +/+ embryos (Fig. 4.1 L) of 
diabetic mice. PaxS was highly expressed in the cranial neuropore region (Fig. 4.1 K3) 
and there was no longer any delay in onset of Pax3 expression in the anterior margin 
of the caudal neuropore (Fig. 4.1 K4). 
4.3.1.3 Effect of RA on Pax3 expression in Sp^^!-^ and +/+ embryos 
+/+ embryos (RA-treated) 
In examining +/+ embryos at 6 hour (E8.75) after in utero exposure to 50mg/kg 
of RA at E8.5 (Fig. 4.2 D), it was found that there was no difference in PaxS 
expression levels in all expression domains in comparison to control +/+ embryos that 
had not been exposed to RA (Fig. 4.2 B). At 12 hour after RA treatment (E9.0), there 
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was still no observable difference between RA-treated (Fig. 4.3 D) and untreated (Fig. 
4.3 B) embryos. 
To confirm that the lack of effect of RA on Pax3 expression was not due to the 
fact that the dose of 50mg/kg might not be sufficient to cause a difference, embryos 
were exposed to a higher dose of RA. At the dose of lOOmg/kg，preliminary data 
showed that almost all embryos developed neural tube defects. However, there was 
still no observable difference in PaxS expression levels in all regions between RA-
treated and untreated embryos at 6 hour (Fig. 4.2 F and 4.2 B) and 12 hour (Fig. 4.3 F 
and 4.3 B) after treatment. 
embryos (RA-treated) 
The result of the effect of RA on expression levels of Pax3 in embryos 
closely paralleled to that in +/+ embryos. At the dose of 50mg/kg and lOOmg/kg RA, 
RA did not cause any observable changes in the expression level ofPaxS in all regions 
of embryos at 6 hour (Fig. 4.2 C and 4.2 E) and 12 hour (Fig. 4.3 C and 4.3 E) 
after RA treatment in comparison to embryos of the corresponding stages that had not 
been treated with RA (Fig. 4.2 A and 4.3 A). 
4.3.2 Level of apoptosis detected by whole mount TUNEL 
As mentioned in Section 4.2, in order to semi-quantitatively assess the change 
in the level of apoptosis, a grading system consisting of 10 levels, from Level 1 to 
Level 10, was established by setting the positive control with the surface cells nicked 
by DNase I as Level 10, and the negative control with no terminal deoxynucleotidyl 
transferase as Level 1. Level 1 and Level 10 at different regions of the embryo at E8.5, 
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E9.0 and E9.5 were shown in Fig. 4.4 A-F. Scoring of apoptotic level of embryos 
under different conditions was made with reference to the corresponding region of the 
positive and negative control embryos at the same developmental stage (Fig. 4.4). 
The mean apoptotic level in the fused region of the neural tube and in the 
neuroepithelium of the cranial and caudal regions of and +/+ 
embryos at E8.5，E9.0 and E9.5 were shown in Table 4.5. The data were analyzed by 
Chi-square Fisher's exact test with the P value shown in Table 4.6. The mean 
apoptotic level in different regions of and +/+ embryos of diabetic and non-
diabetic mice before (E8.5) or at 12 hour (E9.0) and 24 hour (E9.5) after RA treatment 
or without treatment was shown in Table 4.7. The data were analyzed by Chi-square 
Fisher，s exact test with the P value shown in Table 4.8 (E8.5), Table 4.9 (E9.0) and 
Table 4.10 (E9.5). The data were regarded as statistically significant i f P < 0.05. 
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Table 4.10 
Apoptotic level in different regions ofSp^^ISp^ ,^ and +/+ embryos at 
different developmental stages 
EmbryonkT:, Genot^e o f ， � : V 二 .. Apoptosis Score (Mean 士 SE) - $ 
- / . ; ^ t a g e ; ‘ Embryos . f I^eumLTi^::I；：Cranial Region |:Caudal Region 
8.24 士0.65 9.35士0.92 9.02士 0.48 
E8.5 Sp2Hl+ 4.25±1.95 3.97士 1.24 3.42士 0.54 
+/+ 2.11 士0.98 3.02士 1.01 2.14 士 0.84 
Sp2HlSp2H 7.44 土0.24 9.40土 0.71 8.24 士 0.71 
E9.0 Sp2Hi+ 2.17 士0.33 4.04士 1.32 3.24士 0.48 
+/+ 1.86 士 0.41 3.15 士 1.01 2.03±0.44 
S p 2 H l S p 2 H 8 . 2 4 土 0 . 4 5 — 8 . 1 1 士0.37 8.27士 0 . 3 3 
E9.5 分，+ 2.00 士0.40 3.10土0.28 2.40士 0.16 
~ ~ +/+ 1.70±0.60 3.23士0.43 2.13士 0.51 
Apoptosis Score: Level 1 - Level 10 
Table 4.6 
Statistical analysis of apoptotic level in different regions of Sp^^/Sp^^, and 
+/+ embryos at different developmental stages 
S p 2 H / S p 2 H v s 0 . 0 0 3 2 * 0 . 0 0 3 1 * 0 . 0 0 2 8 * 
Neural Tube Sp^^/Sp^^ 0.0018* 0.0017* 0.0015* 
vs +/+ 0.0216* 0.5641 0.6215 
Sp2H/Sp�Sp2Hi+ ~Q.QQ88* 0.0075* 0.0125* 
Cranial Region 0.0047* ~~0.0054* 0.0100* 
vs +/+ 0.0903 0.1072 0.8817 
Sp2H/Sp2H v s Sp2Hl+ 0 . 0 0 4 9 * 0 . 0 1 2 7 * ^ ^ ^ 0 . 0 0 3 4 * 
Caudal Region vs +/+ 0.0036* 0.0025* 0.0034* 
vs +/+ 0.0395* 0.0326* 0.6681 
* Statistically significant (P < 0.05) 
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Table 4.10 
Apoptotic level in different regions of and +/+ embryos of diabetic and 
non-diabetic mice at different time points with or without RA treatment 
. 、： �々 入 站 4 \ Apoptosis Scbre 
^Vr^rrUir：'^� ^Matemal"' ；,Genotype Dose of- i^ , 玄 
浮n^ryo啊 t ic: : of ： ？ ‘ (Mean±SE) … 
, �S t a g e ….：、,“ - “ ‘ ”丄 ‘ �： , ^ •““r tt -^ 
� /、 : ， S t a t e .：：：： .Embryos (mg/kg) ” Neural Cranial Caudal 
警 机 , � ， 、 卜 紗 、, • 小 ； . . Tube炉，,.Region 一; ‘ Region 
Non-diabetic 分 Q 3.32士 1.03 一4.20士 1.25 3 . 0 2 ± 0 ^ 
E8.5 j ^ i 0 2.00士0.90 3.80士0.62 3.10士 0.43 
Diabetic Sp2H/+ 0 4.34士0.25 6.17士0.58 6.21士 0.62 
+/+ 0 3.83士0.67 4.57 士 1.12 3.79±1.15~ 
Non-diabetic 郎 ^ — 3.26±0.79 3.33±0.63 2.30士 O . f 
t!± 0 2.81 士0.38 2.83士0.54 1.90土 0.51 
E9.0 Diabetic 分 0 4.24士0.62 7.41土 0.51 5.21 士 0.40 
(12 hours 0 3.95士0.44 5.29士0.34 3.85±0.50 
2H ‘ 
treatment) Non-diabetic 却丨― ^ _ _ _ 2 ™ . 5 7 6.32士 1.2Q 4.40士0.79 
+/+ 50 2.68土 1.86 4.29士 1.11 2.82 士 0.86 
Diabetic 分，+ 50 6.47士 1.61 7.24 土 1.99 8.21士 1.77 
+/+ 30 5.91±1.24 6.03士2.37 2.82士 1.53 
郎'“丨七 0 2.00土 0.71 2.30 士 0.50 2.30土 0.47" 
t n 0 1.83+0.29 1.52 士0.68 2.14士 0.75 
E9.5 Diabetic • 6.49±1.53 4.41 士 1.12 7.32±0.93 
(24 hours ^ 0 5.44士0.85 5.25士0.23 5.83+0.65 
treatment) Non-diabetic 郎、  
t n 50 2.03±1.83 3.07士0.59 2.61±0.73 
Diabetic 50 6.41±0.29 8.22士0.47 8.4U1.34 
I +/+ 50 5.12士 1.63 5.76 士 0.76 8.35 士 
Apoptosis Score: Level 1 - Level 10 
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Table 4.10 
Statistical analysis of apoptotic level in different regions in comparison between 
different genotypes and different maternal environment in the embryos of E8.5 
ND vs +/+ 0.0922 0.6428 0.9258 
D 分 M/+VS+/+ 0.3143 0.0578 0.0322* 
分 DvsND 0.1857 — 0.0316* 0 .0285*“ 
+/+ DvsND 0.0301* 0.0917 0.0593 
* Statistically significant 
Table 4.9 
Statistical analysis of apoptotic level in different regions in comparison between 
different genotypes, different maternal environment and different dose of RA 
treatment in E9.0 embryos 
J.. \ ‘ ‘ . � � ‘ “ ： � �T ‘戶value" , • / • ” � ‘ 
ORAND vs +/+ 0.1998 0.0878 0.2592 
ORAD vs +/+ 0.3275 ~ 0.0453* 0.0668 
50RAND vs +/+ “ 0.4645 ~ ~ Q . 0 6 Q 5 _ _ Q i ) 5 8 ^ 
50RAD �+ V S + / + 0.3827 0.0857 0.0108* 
QRA DvsND 0.0724 0.0353* 0 m w 
Q 以 + / + DvsND 0.0582 0.0459* 0.0385* 
50RA DvsND 0.0402* 0.5621 0.0371* 
50RA +/+ DvsND 0.0425* 0.0911 “ 0.9072 
ND ~~ORA vs 50RA 0.6245 0.0328* 
ND +/+ QRA vs 50RA 0.8224 0.0724 0.0908 
D 分 Q R A vs 50RA 0.0420* 0.2726 
D+/+ I 0RAvs50RA 0.0416* 0.0892 0.9281 
* Statistically significant 
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Table 4.10 
Statistical analysis of apoptotic level in different regions in comparison between 
different genotypes, different maternal environment and different dose of RA 
treatment in E9.5 embryos 
_ O R A N D vs +/+ 0.8081 0.0725 0 . 5 7 3 1 ~ 
ORAD vs +/+ 0.0975 0.1148 0.0765 — 
_ 5 0 R A N D 分 , + vs+/+ 0.7653 一0.036^ _ _ 0 0 4 8 5 ^ 
50RAD vs +/+ 0.1276 0.0475* 0.8273 一 
ORA 分，+ DvsND 0.0152* 0.0721 0 .0098*~ 
Q 以 DvsND 0.0147* 0.0454* 0.0125* 
5 Q R A D v s N D 0.0477* 0.1346 0.0878 一 
50RA +/+ DvsND 0.0482* 0.0745 0.0301* 
ND QRA vs 5QRA 0.5244 0.0472*一 0.0486* 
ND+/+ ORA vs 5QRA 0.8278 一 Q . ( ) 7 2 8 _ _ _ ( I 5 0 2 ^ 
则p2H/+ QRA vs 5QRA 0.8073 0.0389* 0.4614 一 
_ _ D+/+ 0RAvs50RA 0.7232 | 0.1101 0.0788 
* Statistically significant 
4.3.2.1 Effect of allele on apoptosis 
In determining the dose effect of Sp^" allele on apoptosis, embryos that 
possessed two 分谢 alleles {Sp'"lSp'\ one Sp'H allele {Sp'"/+) and no allele 
(+/+) were compared (Table 4.5 and 4.6, Fig 4.5). Results showed that there was a 
general trend in which the higher the number of copies of Sp^" allele, the higher the 
apoptotic level in the neuroepithelium of the closed neural tube, and the cranial and 
caudal neuropores (Table 4.5). However, the level was not in direct proportion to the 
number of copies of Sp^" allele. In all three stages examined (E8.5, E9.0, E9.5), in the 
presence of two alleles there was extensive amount of apoptosis in 
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all three regions of the embryo (Fig. 4.5 A, 4.5 D and 4.5 G) with the mean apoptotic 
score ranging between Level 7 to Level 9. However, in Sp^"/^ embryos with one Sp^" 
allele，the level of apoptosis was significantly reduced to less than half of the amount 
of apoptosis in Sp^^/Sp^^ embryos, ranging from Level 2 to Level 4 (Fig. 4.5 B, 4.5 E 
and 4.5 H), and the level was only slightly higher than +/+ embryos without S p � " allele 
(Fig. 4.5 C, 4.5 F and 4.5 I). Note that at E9.5，the cranial neuropore of the Sp^^/Sp^" 
embryo was still widely opened (Fig. 4.5 G3) and the posterior neuropore was very 
large (Fig. 4.5 G4). This was in contrast to the and +/+ embryos in which the 
cranial neuropore had closed and apoptotic cells were mainly located in the dorsal 
midline region where fusion occurred (Fig. 4.5 H3 and 4.5 13), and the length of the 
posterior neuropore was much shorter (Fig. 4.5 H4 and 4.5 14). 
4.3.2.2 Effect of maternal diabetes on apoptosis in and +/+ embryos 
In comparing embryos under diabetic and non-diabetic environment, two 
general trends were observed (Table 4.7): Firstly，the level of apoptosis in embryos 
under diabetic environment was higher than embryos in non-diabetic environment. 
Secondly, the difference in apoptotic levels between and +/+ embryos became 
much greater when under a diabetic environment (Table 4.8, Table 4.9 and Table 
4.10). 
For example, at E8.5, there was only a slight increase in the apoptotic level in 
+/+ embryos under maternal diabetes (Fig. 4.6 D) in comparison to +/+ embryos under 
non-diabetic environment (Fig. 4.6 B) (Table 4.8). However, in comparing 
embryos in non-diabetic and diabetic environment, the apoptotic level increased 
significantly from Level 3 to Level 6 in the caudal neuropore region (Fig. 4.6 A4 and 
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4.6 C4) and from Level 4 to Level 6 in the cranial neuropore region (Fig. 4.6 A3 and 
4.6 C3)，whereas the difference in the closed spinal neural tube region was less 
obvious (Fig. 4.6 A2 and 4.6 C2). At E9.0，similar results as E8.5 were obtained (Table 
4.9). In comparing embryos of the same genotype under non-diabetic and diabetic 
environment, the increase in the level of apoptosis in the cranial and caudal neuropore 
regions of 分】付/+ embryos (from Level 3 to Level 7 in the cranial neuropore, and from 
Level 2 to Level 5 in the caudal neuropore; Fig. 4.7 A and 4.7 C) was much more 
significant than the increase in +/+ embryos (from Level 3 to Level 5 in the cranial 
neuropore, and from Level 2 to Level 4 in the caudal neuropore; Fig. 4.7 B and 4.7 D). 
At E9.5, the level of apoptosis in the neuroepithelium in all regions (closed neural tube 
along the spinal region, the closed neural tube in the cranial region and in the caudal 
neuropore region) was obviously much higher in both (around Level 4-7; Fig. 
4.8 C) and +/+ (around Level 5-6; Fig. 4.8 D) embryos in diabetic environment in 
comparison to embryos of the same genotype in non-diabetic environment (around 
Level 2 in all regions; Fig. 4.8 A，4.8 B) (Table 4.10). 
4.3.2.3 Effect of RA on apoptosis in and +/+ embryo 
In examining embryos at 12 and 24 hour after treatment with 50mg/kg of RA 
on E8.5, two general trends were observed (Table 4.7). Firstly, there was an increase in 
the level of apoptosis in the cranial and caudal neuropore regions in RA-treated 
embryos. Secondly, the effect of RA in increasing apoptosis was more significant on 
embryos than +/+ embryos (Table 4.9 and 4.10). 
For example, at 12 hour after RA treatment, while there was only a low level of 
increase in apoptosis from Level 3 to Level 4 in the cranial neuropore region (Fig. 4.7 
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B3 and 4.7 F3) and from Level 2 to Level 3 in the caudal neuropore region (Fig. 4.7 
B4 and 4.7 F4) in +/+ embryos, there was a significantly much greater extent of 
increase, from Level 3 to Level 6 in the cranial neuropore (Fig. 4.7 A3，4.7 E3), and 
from Level 2 to Level 4 in the caudal neuropore region (Fig. 4.7 A4, 4.7 E4) in 
embryos (Table 4.9). In contrast, RA did not appear to affect the closed region of the 
spinal neural tube in both Sp^"/^ and +/+ embryos (all around Level 3; Fig. 4.7 A2, 4.7 
B2, 4.7 E2 and 4.7 F2). 
At 24 hour after RA treatment, similar results as 12 hour after RA treatment 
were obtained (Table 4.10). The difference in apoptosis level in the closed neural tube 
of cranial region and the caudal neuropore region between RA-treated embryos 
(Fig. 4.8 E3 and 4.8 E4) and untreated 分�"/+ embryos (Fig. 4.8 A3 and 4.8 A4) was 
much higher than the difference between RA-treated +/+ embryos (Fig. 4.8 F3 and 4.8 
F4) and untreated +/+ embryos (Fig. 4.8 B3 and 4.8 B4). Again, there was no evidence 
of an increase in apoptosis along the closed spinal neural tube region after RA 
treatment in both (Fig. 4.8 A2 and 4.8 E2) and +/+ embryos (Fig. 4.8 B2 and 
4.8 F2). 
4.3.2.4 Effect of maternal diabetes and RA on apoptosis in and +/+ 
embryos 
In comparing the effect of RA on embryos of the same genotype under 
maternal diabetic and non-diabetic environment, there was a general trend that the 
level of apoptosis was higher in embryos of diabetic mice than embryos of non-
diabetic mice. However, a prominent difference in the effect of RA on embryos 
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and +/+ embryos under maternal diabetic environment was only observed in the caudal 
neuropore region (Table 4.7, 4.9 and 4.10). 
At 12 hour after RA treatment, embryos had a much higher level of 
apoptosis in the caudal neuropore region (Level 8; Fig. 4.7 G4) than +/+ embryos 
(Level 3; Fig. 4.7 H4) when under a maternal diabetic environment (Table 4.9). This 
difference was much greater than that between (Level 4; Fig. 4.7 E4) and +/+ 
embryos (Level 3; Fig. 4.7 F4) under non-diabetic environment after RA treatment, 
and also greater than that between (Level 5; Fig. 4.7 C4) and +/+ embryos 
(Level 4; Fig. 4.7 D4) of untreated diabetic mice. However, this differential effect of 
RA on Sp2Hl+ and +/+ embryos under diabetic condition was not observed in the 
cranial neuropore region. 
At 24 hour after RA treatment, while the level of apoptosis in the caudal 
neuropore region of embryos of diabetic mice remained high (Level 8; Fig. 4.8 
G4)，apoptosis in +/+ embryos has also reached a very high level (Level 8; Fig. 4.8 
H4). Hence, this has abolished the big difference in the level of apoptosis between 
分祝/+ (Level 8; Fig. 4.7 G4) and +/+ embryos (Level 3; Fig. 4.7 H4) of diabetic mice 
that was observed at 12 hour after RA treatment (Table 4.10). 
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4.4 Discussion 
The objective of this chapter was to determine whether the level of PaxS and 
apoptosis in the neuroepithelium of and wild-type embryos would show any 
corresponding changes under different conditions that could account for the 
interaction of maternal diabetes, RA and 放 mutation in increasing the susceptibility 
to neural tube defects, as found in Chapter 3. 
4.4.1 Underexpression of Pax3 and increases in apoptosis under 
maternal diabetes 
Results of the present study showed that under maternal diabetes, the 
expression level of PaxS in all expression domains of the embryo was lower than 
embryos in non-diabetic environment. However, this underexpression was only found 
in embryos at early stages (E8.5 and E8.75); by E9.0, there was no longer any 
differences. Since expression of Pax3 in the neural tissue of the embryo is initiated at 
E8.5 (Goulding et al., 1991), these results showed that maternal diabetes “delayed the 
onset of Paxr in the embryo, rather than causing down regulation of Pax3 that has 
already expressed. Reduced expression of Pax3 has also been reported in ICR 
embryos under maternal diabetes and hyperglycemic condition (Fine et al, 1999; 
Phelan et al., 1997). However, in those studies, it was found that expression of Pax3 
continued to remain at low levels, at least up to E9.5. This might be one of the reasons 
for the elevated incidences of neural tube defects in embryos of diabetic mice found in 
those studies (Phelan et al, 1997), whereas a transient delay in onset of Fax3, as 
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shown in the present study, might explain the findings in Chapter 3 that maternal 
diabetes alone was insufficient to cause manifestation of neural tube defects. 
Results of the present study showed that under maternal diabetes, besides 
exhibiting a reduction in PaxS expression level, there was also an increase in the level 
of apoptosis along the fused region of the neural tube and in the cranial and caudal 
neuropores in the embryo. It is recently shown that PaxS regulates neural tube closure 
by inhibiting p53-dependent apoptosis (Pani et al., 2002). Hence, it is most likely that 
there is a causal relationship between reduced expression of Pax3 and increased level 
of apoptosis associated with maternal diabetes. However, while reduction in PaxS 
level was only found at early stages (E8.5 and E8.75), and the difference between 
embryos of diabetic and non-diabetic mice has already restored by E9.0，the increased 
level of apoptosis in embryos of diabetic mice was more prominent in embryos at 
E9.5 than E8.5, showing that there was a time lapse between reduction in Pax3 level 
and the appearance of dead cells. Moreover, there is probably a threshold level of 
PAX3，at which apoptosis will only occur if PAX3 falls below this level. This was 
supported by the finding in the present study, which showed that in 
embryos that carried two non-functional PaxS alleles, extensive amount of apoptosis 
was observed in the neuroepithelium; however, in embryos that carried one 
non-flinctional Pax3 allele, there were very few apoptotic bodies, and the level of 
apoptosis was only slightly higher than that of wild-type embryos. Hence, showing 
that half of the normal level ofPAX3 is already sufficient to inhibit apoptosis in most 
of the neuroepithelial cells. Although in this study, the expression level of PaxS has 
not been quantified, the prominent increase in apoptosis in wild-type embryos under 
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maternal diabetes showed that PaxS level in the embryos must have been reduced by 
more than half of the original level. In fact, this was supported by a study, which 
showed that Pax3 expression level in the embryo of diabetic mice was at least 
threefold less than the normal level (Phelan et al , 1997). Furthermore, it is possible 
that maternal diabetes can induce apoptosis via genes other than Pax3. For example, 
as discussed in Section 1.3.4，maternal diabetes can up regulate TNF-a (Yelavarthi et 
al., 1991)，and its expression in the neural tube may play a role in regulating apoptosis 
(Wride and Sanders, 1993; Wride and Sanders, 1995). 
In this study, the RNA probe employed hybridized both the normal and 
mutated PaxS allele, therefore, the expression levels ofPax3 in wild-type and 
embryos, as detected by in situ hybridization using this probe, were the same under 
normal condition. However, it was found that under maternal diabetes, the expression 
level of PaxS in embryos was much lower than that in wild-type embryos 
during early stages of development (E8.5 and E8.75), showing that the effect of 
maternal diabetes in delaying the onset of PaxS was greater on embryos than 
on wild-type embryos. This was also reflected in the present finding that under 
diabetic environment, the level of apoptosis increased to a greater extent in 
embryos than +/+ embryos. This implied that there was indeed a synergistic 
interaction of maternal diabetes with the allele in exacerbating the reduction of 
P似3 and elevation of apoptosis. One of the possibilities is that maternal diabetes does 
not only reduce Pax3, but also directly acts on a downstream target of PaxS. 
Alteration of this target gene probably provides a feedback mechanism to further 
down regulate PaxS. Hence, this may explain why maternal diabetes will cause a 
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greater reduction in Pca3 levels in Sp川/— embryos than in wild-type embryos. 
Several PaxS downstream targets have been identified, which included N-cam 
(Edelman and Jones, 1998), a-2,8-polsialytransferase (Mayanil et al., 2001; Stuart 
and Gmss，1996), MyoD (Maroto et al., 1997)，c-MET (Epstein et al., 1996; Ginsberg 
et al.，1998), Dep-1 (Cai et al., 1998), cdc46 (Hill et al., 1998), myelin basic protein 
(Kioussi et al., 1995), MITF (Galibert et al.，1999; Watanabe et al., 1998), Tyrp-1 
(Galibert et al., \999\p53 (Pani et al., 2002) and Myx2 (Kwang et a l , 2002). Many of 
them are involved in modulating cell adhesion and migration, or involved in 
controlling the cell cycle or cell death. For instance, N-CAM, a cell adhesion 
molecule that expresses in the neural plate prior to neural tube closure, is abnormally 
glycosylated in the neural folds of splotch embryos (Moase and Trasler, 1991). 
Another cell adhesion molecule, N-CAD，which expresses in the apices of the cranial 
neural folds at the time of its elevation, is overexpressed in neural folds of splotch 
embryos (Bennett et al., 1998). The gene cdc46, which is important in the regulation 
of the cell cycle, is negatively regulated by Pax5-dependent pathway and is up 
regulated in embryos of diabetic mice and splotch embryos (Chen et al., 1992; Hill et 
al” 1998). Another candidate gene is Msx2, which is an immediate downstream 
effector, negatively regulated by PaxS (Kwang et al., 2002). Msx2 is a homeobox 
gene that acts as a regulator of BMP signaling (Liem et al., 1995). Increase in BMP4 
is associated with apoptosis in the neural crest (Graham et al., 1994). 
4.4.2 RA does not down regulate PaxS, but increases apoptosis 
In this study, it was found that there was no difference in the expression level 
in RA-treated and untreated embryos no matter whether or not they carried an 
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SP‘H allele. Even when embryos were exposed to a dose of RA which was high 
enough to induce neural tube defects, there was still no detectable changes in PaxS 
expression levels, showing that RA did not act directly on Pax3’ and RA-induced 
neural tube defects was not mediated via down regulation of Pax3 or affecting any 
genes upstream of Pax3. 
It is well documented that RA can induce apoptosis in a number of tissues, 
including the neuroepithelium (Alles and Sulik, 1989; Alles and Sulik, 1992; Osumi-
Yamashita et al., 1992). In this study, only a slight increase in apoptosis was found in 
the cranial and caudal neuropore regions of wild-type embryos at 12 and 24 hour after 
RA treatment. However, there was a much higher level of apoptosis in the cranial and 
caudal neuropores of embryos in response to RA, whereas no increase in 
apoptosis was observed in the fused region of the spinal neural tube. Since 
embryos did not exhibit any changes in PaxS level after RA treatment, but was more 
susceptible to RA-induced apoptosis than wild-type embryos, this showed that RA did 
not induce apoptosis via affecting genes upstream of Pax3, but rather, it is most likely 
that RA acts on a downstream target in the Pax5-dependent apoptotic pathway to 
increase apoptosis in embryos. 
In Chapter 3, it was shown that RA could induce neural tube defects in a small 
percentage of wild-type embryos. Nevertheless, there was only a minor increase in 
apoptosis in the cranial and caudal neuropores of wild-type embryos after RA 
treatment. Even in RA-treated embryos that exhibited significant increase in 
the incidence of spina bifida, the level of apoptosis in the caudal neuropore was still 
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lower than that of untreated 分 e m b r y o s under maternal diabetes, which did not 
develop neural tube defects. Hence, these results indicate that besides inducing 
apoptosis, RA can cause neural tube defects via other mechanisms. For instance, it is 
shown that RA will affect the nature of cytoskeletal elements of neuroepithelial cells, 
distorting the neural folds and increasing intercellular spaces (Tibbies and Wiley, 
1988; Yang and Trasler，1991; Yasuda et a l , 1987). Moreover, RA causes 
degeneration of neural crest cells in the neuroepithelium, and also up regulates N-
CAM expression in the cranial neural crest cells, which may result in non-
approximation of the neural folds (Alles and Sulik, 1992; Shankar et al., 1994; 
Yasuda et al. 1987). Furthermore, other than directly affecting the neuroepithelium, 
RA can also affect extrinsic factors that govern neural folds elevation and closure. For 
example, it is proposed that the pathogenetic mechanism of RA-induced spina bifida 
is mediated via excessive cell death in the mesenchyme and in the tail gut ventral to 
the neuroepithelium, which leads to disparity in growth between the ventral and 
dorsal regions of the tail, thereby preventing closure of the caudal neural tube (Alleles 
and Sulik, 1990). In addition, RA has also been shown to alter the expression of 
mesenchymal extracellular matrix molecules as soon as 3 hours after exposure, which 
might disrupt the mesenchyme and interfere with neural fold elevation (Morriss-Kay 
and Mahmood, 1992). 
4.4.3 Interaction of maternal diabetes and RA in increasing 
apoptosis 
As discussed in Section 4.4.1, although maternal diabetes increased apoptosis 
in the neuroepithelium, it was insufficient to cause neural tube defects. However, 
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when wild-type embryos of diabetic mice were treated with RA, there was a large 
extent of apoptosis in the caudal neuropore region, with the level of apoptosis higher 
than that of RA-treated wild-type embryos under non-diabetic condition or wild-type 
embryos of diabetic mice that had received no RA. The level of apoptosis was 
comparable to Sp^^/Sp^^ embryos that were prone to develop spina bifida. However, 
no such elevation of apoptosis in the cranial neuropore region was observed. These 
finding could thus correlate with the result in Chapter 3 that maternal diabetes 
interacted with RA to significantly increase spina bifida, but not exencephaly. 
Furthermore, in comparing the response embryos and wild-type embryos of 
diabetic mice to RA, it was found that elevation in apoptosis in the caudal neuropore 
region occurred much earlier in embryos (12 hours after RA treatment) than 
+/+ embryos (24 hours after RA treatment). This factor of the timing of appearance of 
apoptosis, together with the interactive effects of maternal diabetes and RA with the 
分纽 allele, which may be mediated via affecting downstream target genes of Pax3 as 
discussed earlier, may contribute to the significant increase in the frequency of spina 
bifida in RA-treated fetuses of diabetic mice (55%) in comparison to wild-type 
fetuses under the same conditions (12.5%). As for the cranial neuropore, maternal 
diabetes and RA could both on their own increase apoptosis to a high level in 
embryos, but there was no increase in exencephaly. On the other hand, combination of 
maternal diabetes and RA did not further increase the level of apoptosis in the cranial 
neuropore region; yet, there was a significant increase in the incidence of exencephaly 
in RA-treated fetuses of diabetic mice (21.7%) in comparison to RA-treated 
fetuses under non-diabetic environment (4.1%) or fetuses of diabetic 
mice that had received no RA (0%). Hence, showing that factors, other than apoptosis, 
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play an important role in the interaction of maternal diabetes, RA and the allele 
in increasing exencephaly. 
In this chapter, whole mount preparations were performed for in situ 
hybridization to detect Pax3 expression and TUNEL to detect apoptosis. The 
advantages of using whole mount preparations include the ease of analysis of Pax3 
and apoptotic levels in the fused and unfused region of the neuroepithelium along the 
whole body axis. Moreover, these methods are less time consuming as plenty of 
embryos can be processed simultaneously. 
However, the disadvantages of using whole mount in situ hybridization and 
TUNEL were the inability to accurately quantify the level of gene expression and 
apoptosis in comparison to the method of real time quantitative RT-PCR and the 
detection by TUNEL on sections in which the number of apoptotic bodies can be 
counted more easily. Furthermore, information on the spatial distribution of apoptotic 
bodies along the dorsoventral axis of the neural tube can be obtained on section. Since 
Pcix2 is expressed in the dorsal part of the neuroepithelium and it has been shown that 
Pcix3 acts cell autonomously in the neural tube (Mansouri et al., 2001), hence, the 
spatial distribution of apoptotic bodies and PaxS expression are more easily compared 
on sections to determine whether a downregulation of PaxS in the dorsal 
neuroepithelium show corresponding increase in apoptotic bodies. 
In conclusion, results of this chapter have provided insight that while maternal 
diabetes interacted with the Sp^" allele to further down regulate PaxS and increased 
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apoptosis, RA did not have a direct effect on Pax3, but could interact with the Sp�" 
allele to increase apoptosis. However, besides apoptosis, there were other mechanisms 
involved in the interaction of maternal diabetes, RA and the S p � " allele to increase the 
susceptibility to neural tube defects. 
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5.1 Introduction 
As mentioned in Chapter 1，genetic factors play an important role in the 
development of diabetes mellitus, especially type 1 diabetes. Although it is generally 
thought that diabetic embryopathy is the result of the teratogenic nature of the diabetic 
mdieu，it is possible that the increased susceptibility to congenital malformations in 
embryos of diabetic mothers may be due to the diabetogenic genes inherited from the 
parents. Hence, to study if there is any interaction between diabetogenic genes and 
maternal diabetic environment, mutants that are genetically predisposed to diabetes 
can be employed. As discussed in Chapter 1，NOD (non-obese diabetic) mice develop 
spontaneous diabetes that in many aspects simulates type 1 diabetes in humans. 
5.1.1 Diabetic embryopathy in NOD mice 
Although a lot of researches have been carried out on the NOD mice, with 
more than 3000 literatures, very few of them focused on studying congenital 
malformations of their embryos. 
NOD embryos are prone to congenital malformations (Otani et al., 1991). For 
example, homozygous NOD embryos of mothers with overt diabetes show increased 
susceptibility to left-right axis abnormalities, with the incidence rate being more than 
twofold higher than that of heterozygous NOD embryos (Morshima et al., 1996). The 
increased susceptibility may be due to sequence variations of HNF-3 P, which encodes 
a transcription factor important for left-right axis determination (Kaestner et al., 1994). 
These sequence variations include a three-base deletion in the putative promoter 
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region，as well as G to A nucleotide substitution within the exon 3 (Maeyama et al., 
2001). Furthermore, to distinguish whether maternal diabetic environment or genetic 
predisposition is the cause of congenital malformation in NOD embryos, a study has 
been carried out in which NOD/NOD embryos were transplanted to the uterus of 
wild-type mothers, and vice versa (Otani et al., 1991). It was found that both 
implantation and post-implantation development of wild-type embryos were greatly 
affected，with a significant increase in neural tube defects, when they were grown 
inside the uterus of NOD mothers with overt diabetes. Similarly, NOD/NOD embryos 
failed to develop normally even when they were grown within a normal maternal 
environment. These results provide the insight that apart from the maternal diabetic 
environment, the distinct genetic predisposition in NOD embryos also increases the 
susceptibility to congenital malformations. 
5.1.2 Experimental design of this chapter 
The objective of this chapter was to determine whether NOD mutation, which 
predisposes the embryo to diabetes, would interact with maternal diabetes and RA in 
increasing the susceptibility to neural tube defects. 
In NOD mice, islet (3-cell-reactive autoantibodies are produced as a result of 
accumulation of antigen presenting cells around the islets (Jansen et al., 1994). Hence, 
in NOD female mice with overt diabetes, the autoantibodies may transmit to the 
offspring that can trigger or exacerbate the onset of autoimmune diseases, as found in 
humans (Pirisi, 2002; Ziegler et al., 1999). Moreover, the reproductive organs of 
diabetic NOD mice may be another possible cause of developmental abnormalities 
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(Tatewaki et a l , 1989). For instance, structural alterations in the ovary may result in 
disorder in oocyte maturation, and structural changes in the uterus are suspected to be 
related to a decrease in the ratios of implantation and in the viability of embryos at 
post-implantation stage (Otani et al., 1991). Hence, to exclude these maternal effects 
of NOD mice that might influence the result of this study, NOD/+ fetuses were 
obtained from mating between homozygous NOD male mice and diabetic or non-
diabetic ICR (+/+) female mice. In other words, the NOD allele of NOD/+ fetuses 
was paternally inherited. As wild-type control, ICR male mice were used because the 
NOD mice were in ICR genetic background. Since PaxS is important for neural tube 
closure (Epstein et al., 1991), therefore, in this study, the expression levels of PaxS in 
embryos with different copies of NOD alleles under maternal diabetic or non-diabetic 
environment were studied by in situ hybridization in order to determine if NOD 
mutation would affect Pax3 levels that could account for the increased susceptibility 
of NOD embryos to neural tube defects. 
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5.2 Materials and Methods 
5.2.1 NOD mice 
The NOD mice used in this study were obtained from laconic, USA. The 
NOD mice were originally developed from non-inbred ICR mice and subsequently 
inbred for over 20 generations by Makino et al. (1980). Taconic's NOD mice were 
originated from a brother x sister mated colony. Five breeding pairs were obtained 
from Taconic in 2000 and the offspring were mated inter se to found a randomly-bred 
colony at The Chinese University of Hong Kong. 
5.2.2 Mating and RA injection protocol 
Four mating combinations were performed to obtain embryos from diabetic or 
non-diabetic ICR mothers, with or without the inheritance of the NOD allele from the 
father. 
To investigate the effect of maternal diabetes on neural tube development, the 
first group was obtained by mating of ICR male mice with streptozotocin-induced 
diabetic ICR female mice, or in the second group, with non-diabetic ICR female mice 
as control. To study the effect of NOD mutation on neural tube development, the third 
group was carried out by mating between homozygous NOD male mice and non-
diabetic ICR female mice to obtain NOD/+ fetuses. To investigate if there was any 
interaction between NOD mutation and maternal diabetes, in the fourth group, 
homozygous NOD male mice were mated with diabetic ICR female mice. Moreover, 
to compare the effect of RA treatment on fetuses of these four groups, pregnant mice 
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received an intraperitoneal injection of RA at a dose of 50mg/kg body weight on E8.5, 
while no treatment served as the control. Fetuses were dissected out on E13.5. The 
number of resorption sites and the number of live fetuses were recorded. The fetuses 
were examined for the presence or absence of exencephaly and spina bifida. 
5.2.3 Sample Collection for the Study of Pax3 Expression 
To investigate if Pax3 expression was affected by NOD mutation or by the 
interaction between maternal diabetes and NOD mutation, six types of mating were 
performed. The first four groups were obtained by mating between ICR or NOD male 
mice with diabetic or non-diabetic ICR female mice as described in Section 5.2.2. To 
confirm the effect of NOD mutation on Pax3 expression, two more groups of fetuses 
were obtained through mating between homozygous NOD male mice and 
homozygous NOD female mice. The NOD female mice were either non-diabetic or 
spontaneously-developed diabetic. Since it has been found in Chapter 4 that RA did 
not affect Pax3 expression, and the earlier part of the result in this Chapter (Section 
5.3.5) showed that RA did not have any positive interaction with a single NOD allele 
in increasing the susceptibility to neural tube defects, therefore, no study was 
performed to determine the effect of RA on PaxS expression in NOD/+ embryos. 
Embryos used for whole mount in situ hybridization to study PaxS expression 
were collected on E8.5 since results obtained in Chapter 4 showed that PaxS 
expression at E8.5 was affected under diabetic pregnancy. The procedures for probe 
preparation and in situ hybridization were as described in Sections 2.7 and 2.8 
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respectively. The number of embryos studied in each group was summarized in Table 
5.1. 
Table 5.1 
No. of embryos in each genotype employed for in situ hybridization to study 
P � 3 expression levels at E8.5 under maternal diabetic or non-diabetic 
environment 
：Maternal , � . ‘ Genotype 
di畔etic state NOD/NOD NOD/+ +/+ 
* Diabetic 5 20 W 
Non-diabetic 8 21 ^ 
* NOD/NOD: Spontaneously-developed diabetes 
NOD/+, +/+: Streptozotocin-induced diabetes 
Three batches were carried out. Embryos in the same batch were developed in 
NBT/BCIP for the same duration and the expression levels of PaxS were compared 
between embryos in the same batch. 
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5.3 Results 
Altogether eight groups of fetuses of either NOD/+ or +/+ genotype were 
obtained from the mating between diabetic or non-diabetic ICR female with 
homozygous NOD male or ICR male mice respectively, with or without RA treatment 
on E8.5. The number and percentage of live fetuses with exencephaly (with or 
without spina bifida; EX), spina bifida (with or without exencephaly; SB) and neural 
tube defects (including exencephaly and/ or spina bifida; NTD) in each group was 
shown in Table 5.2 to Table 5.13. The mean percentage of fetuses per litter with NTD, 
EX and SB was shown in Graph 5.1 A-C. The data were analyzed by Chi-square 
Fisher's exact test with the P value shown in Table 5.2 to Table 5.13. The number and 
percentage of resorption of each group was shown in Table 5.2 to Table 5.13. The 
mean percentage of resorption per litter was shown in Graph 5.2. The data were 
analyzed by Paired Student's t test. The data was regarded as statistically significant if 
P<0.05 . 
In this study, three factors: maternal diabetes, NOD mutation and RA, were 
tested. To facilitate the comparison of results, the effect of each individual factor on 
neural tube development was first discussed (Section 5.3.1 to 5.3.3)，followed by the 
interaction of two of the factors (Section 5.3.4 to 5.3.6), before the interaction of all 
three factors (Section 5.3.7) was analyzed. 
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5.3.1 Maternal diabetes alone 
Table 5.2 
Effect of maternal diabetes on ICR fetuses without RA treatment 
Maternal diabetic state - Diabetic Non-diabetic 
Genotype ^ +/+ 
Dose of RA (mg/kg) o o 
No. of litters 12 11 
No. of live fetuses n 5  
No. of resorption (%) 10 (7.3%) 10 (6.7%) 
value 0.969 
No. of fetuses with NTD (%) 4 (3.5%) | 1 (QJVq) 
P value 0.137 
No. of fetuses with EX (%) 4 (3.5%) | 1 (O.70/0) 
P value 0.137 
No. of fetuses with SB (%) Q (Q%) | Q (QQ/q) 
P value No measures of association were computed 
The percentage of fetuses that had developed NTD, EX and SB under non-
diabetic or diabetic maternal environment was summarized in Table 5.2 and Graph 
5.1. To determine the effect of maternal diabetes alone, fetuses used for comparison 
were all derived from ICR parents and without RA treatment. Under both diabetic and 
non-diabetic maternal environment, none of the fetuses had developed SB. However, 
a low incidence rate of EX was found in fetuses of both non-diabetic (0.7%) and 
diabetic (3.5%) mice. Although the incidence rate of EX found in fetuses of diabetic 
mothers was higher than that of non-diabetic mothers, the difference was not 
statistically significant and their resorption rates were similar (Table 5.2, Graph 5.2). 
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These results show that maternal diabetes alone cannot cause a significant 
increase in the incidence rate of NTD, including both incidence rates of EX and SB, 
in wild-type fetuses. 
5.3.2 NOD mutation alone 
Table 5.3 
Effect of NOD mutation on fetuses of non-diabetic mothers without RA 
treatment 
Maternal diabetic state Non-diabetic Non-diabetic 
Genotype 、二 ：： NOD/+ +/+ 
Dose of RA (mg/kg) 0 0 
No. of litters H 
No. of live fetuses \7A 136 
No. of resorption (%) 7(5.1%) 10(6.7%) 
P value 0.584 
No. of fetuses with NTD (%) Q (Q%) | i {0J%) 
P value 0.671 
No. of fetuses with EX (%) 0 (0%) | 1 (Ojo/。） 
P value 0.671 
No. of fetuses with SB (%) Q (Q%) | Q (qq/q) 
P value No measures of association were computed 
The percentage of fetuses obtained by mating of ICR mothers with ICR or 
NOD fathers that had developed NTD, EX and SB was summarized in Table 5.3 and 
Graph 5.1. To determine the effect of NOD mutation alone, fetuses were under non-
diabetic maternal environment and without RA treatment. Only one out of 136 wild-
type fetuses of ICR father developed EX, and none of the NOD/+ fetuses of NOD 
father developed any neural tube defects. Moreover, the resorption rates of both 
groups were quite similar (Table 5.3, Graph 5.2). 
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These results show that a single allele of NOD does not cause neural tube 
defects. 
5.3.3 RA alone 
Table 5.4 
Effect of RA treatment on ICR fetuses of non-diabetic mothers 
Maternal diabetic state Non-diabetic Non-diabetic 
Genotype jv^  
^ of RA (mg/kg) 、 ： 0 , 1 50 : 
No. of litters 11 
No. of live fetuses 121 
No. of resorption (%) 10(6.7%) 28 (25.1%) 
P value 0.058 
No. of fetuses with NTD (%) 1 (0.7%) | 4 (3.30/0) 
l va lue 0.181 
No. of fetuses with EX (%) 1 (0.7%) | 4 (3.30/0) 
P value 0.181 
No. of fetuses with SB (%) Q (Q%) | Q (QQ/q) 
P value No measures of association were computed 
The percentage of fetuses that had developed NTD, EX and SB under RA 
treatment or no treatment was summarized in Table 5.4 and Graph 5.1. To determine 
the effect of RA alone, fetuses were derived from ICR parents and under non-diabetic 
environment. Without RA treatment, only one out of 136 fetuses (0.7%) had 
developed EX. After treatment with 50mg/kg of RA on E8.5, there was a slight 
increase in the percentage of fetuses with EX (3.3%). In both groups, none of the 
fetuses had developed SB. The increase in the percentage of fetuses with EX after RA 
treatment was not statistically significant. The incidence of neural tube defects might 
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be underscored as RA caused a nearly significant increase of resorption rate with the 
P value at 0.058 (Table 5.4, Graph 5.2). 
These results show that at the dose of 50mg/kg, RA alone cannot cause a 
significant increase in the incidence rate of NTD, including both incidence rates of 
EX and SB, in wild-type fetuses. 
5.3.4 Maternal diabetes and RA interaction 
Table 5.5 
Effect of RA treatment on ICR fetuses of diabetic mothers 
Maternal diabetic state Diabetic Diabetic 
Genotype +/+ 
Dose of RA (mg/kg) , � , 0 , 50 . 
No. of litters \2 10 
No. of live fetuses 115 56 
No. of resorption (%) 10(7.3%) 61 (53.8%) 
P value 0.002* 
No. of fetuses with NTD (%) 4 (3.5%) | 15 (26.8%) 
P value < 0.0005* 
No. of fetuses with EX (%) 4 (3.5%) | 6 (10.7%) 
P value 0.065 
No. of fetuses with SB (%) 0 (0%) | 10(17.9o/o) 
P value J < 0.0005* 
* Statistically significant 
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Table 5.6 
Effect of maternal diabetes on ICR fetuses treated with RA 
M a t M l i a i a f e t i c state � ‘ “ Diabetic Non-diabetic ”e 
Genotype +/+ — +/+ 
Dose of RA (mg/kg) 50 — 50 
No. of litters 10 10 
No. of live fetuses 56 
No. of resorption (%) — 61 (53.8%) 28 (25.1%) 
-lvalue 0.027* 
No. of fetuses with NTD (%) 15 (26.8%) | 4 (3.3%) 
P value <0.0005* 
No. of fetuses with EX (%) 6 (10.7%) | 4 (3.3%) 
尸 value 0.071 
No. of fetuses with SB (%) 10(17.9%) | 0 (Qo/o) 
P value L < Q.Q0Q5*  
* Statistically significant 
The percentage of fetuses that had developed NTD, EX and SB under the 
effect of maternal diabetes and RA treatment was summarized in Table 5.5, Table 5.6 
and Graph 5.1. To exclude the effect of NOD mutation, fetuses considered were all 
derived from ICR parents. As shown in Table 5.5, the percentage of fetuses of 
diabetic mothers that had developed SB increased significantly after treatment with 
50mg/kg of RA on E8.5. As a result, the overall incidence rate of NTD also increased 
significantly. There was also an increase in the percentage of fetuses with EX, 
although the increase was not high enough to be statistically significant. 
Comparison of results in Table 5.5 with Table 5.4 showed that RA only 
caused a significant effect in increasing the incidence rate of SB, and hence the 
incidence rate of NTD, when under diabetic condition. Hence, there was a statistically 
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significant difference between fetuses of diabetic and non-diabetic mice in response to 
RA-induced SB, and thus the overall incidence rate of NTD (Table 5.6, Graph 5.1). 
Moreover, while maternal diabetes alone did not result in any increase in the 
resorption rate (7.3% Table 5.2, Graph 5.2), addition of RA increased the resorption 
rate to 53.8% (Table 5.5), which was statistically higher than the resorption rate in 
non-diabetic pregnancy in response to RA (25.1%; Table 5.6, Graph 5.2). 
Hence, taken into account the results in Table 5.4, Table 5.5 and Table 5.6, it 
is concluded that maternal diabetes can exacerbate the incidence rate of RA-induced 
SB, and therefore the overall incidence rate of NTD. 
5.3.5 NOD mutation and RA interaction 
Table 5.7 
Effect of RA treatment on NOD/+ fetuses of non-diabetic mothers 
Maternal diabetic state Non-diabetic Non-diabetic 
Genotype NOD/+ NOD/+ 
Dose of RA (mg/kg) 0 ^  
No. of litters 10 
No. of live fetuses UA 91 
No. of resorption (%) 7(5.1%) 33 (25.3%) 
P value 0.022* 
No. of fetuses with NTD (%) 0 (0%) | 3 (3.3%) 一 
P value 0.078 
No. of fetuses with EX (%) 0 (0%) | l (1.1%) 
P value 0.429 
No. of fetuses with SB (%) 0 (0%) | 2 (2.2%) 
P value 0.183 
* Statistically significant 
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Table 5.8 
Effect of NOD mutation on fetuses of non-diabetic mothers treated with RA 
Maternal diabetic state Non-diabetic Non-diabetic 
Genotype . : . 巻 HiV::�,NOD/+. “~~“ +/+ 
Dose of R A (mg/kg) 50 一 50 
No. of litters 10 10 
No. of live fetuses 91 121 
No. of resorption (%) 33 (25.3%) 28 (25.1%) 
value 0.984 
No. of fetuses with NTD (%) 3 (3.3%) | 4 (3.3%) 
尸 value 0.654 
No. of fetuses with EX (%) 1 ( 1 . 1 % ) | 4 (3.30/0) 
P value 0.315 
No. of fetuses with SB (%) 2 (2.2%) | 0 (Qo/o) 
P value I 0.246 
The percentage of NOD/+ and wild-type I C R fetuses that had developed NTD, 
EX and SB after RA treatment or no treatment was summarized in Table 5.7, Table 
5.8 and Graph 5.1. To exclude maternal effect, all fetuses were obtained from non-
diabetic mothers. As shown in Table 5.7, there was a low incidence rate of EX and SB 
in NOD/+ fetuses after treatment with 50mg/kg of RA on E8.5. However, comparison 
with results in Table 5.4 showed that RA also caused a low incidence rate of EX in 
wild-type fetuses, but there was no significant difference in the response of NOD/+ 
and wild-type fetuses to RA (Table 5.8, Graph 5.1). Similarly, although there was a 
significant increase in the resorption rate of NOD/+ fetuses after RA treatment (Table 
5.7, Graph 5.2), this increase was not due t o the effect of the NOD mutation (Table 
5.8, Graph 5.2). 
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Hence, taken into account the results in Table 5.4, Table 5.7 and Table 5.8, it 
is concluded that a single NOD allele does not increase the susceptibility of the fetus 
to RA-induced neural tube defects, including both exencephaly and spina bifida. 
5.3.6 NOD mutation and maternal diabetes interaction 
Table 5.9 
Effect of maternal diabetes on NOD/+ fetuses without RA treatment 
Maternal diabetic state : Diabetic 1： Non-diabetic , 
Genotype NQD/+ NOD/+ 
Dose of RA (mg/kg) 0 o 
No. of litters 10 10 
No. of live fetuses ^  
No. of resorption (%) 12(11.7%) 7(5.1%) 
P value 0.193 
No. of fetuses with NTD (%) 9 (10.5%) | Q (qq/q) 
P value < 0.0005* 
No. of fetuses with EX (%) 6 (7.0%) | Q (QQ/Q) 
P value 0.005* 
No. of fetuses with SB (%) 4 (4.7%) | Q (QQ/q) 
P value 0.029* 
* Statistically significant 
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Table 5.10 
Effect of NOD mutation on fetuses of diabetic mothers without RA treatment 
Maternal diabetic state D iabe^ Diabetic 
� G e r 5 ^ r ^ t : j : � r� T ‘ N 舰 … , +/+ 
Dose of RA (mg/kg) o 0 
No. of litters 10 
No. of live fetuses 86 U5 
No. of resorption (%) — 12(11.7%) 10 (7.3%) 
lva lue 0.208 
No. of fetuses with NTD (%) 9 (10.5%) | 4 (3.5%) 
P value 0.045* 
No. of fetuses with EX (%) 6 (7.0%) | 4 (3.50/0) 
P value 0.211 
No. of fetuses with SB (%) 4 (4.7%) | Q (qq/q) 
P value 0.032* 
* Statistically significant 
The percentage of NOD/+ and wild-type ICR fetuses that had developed NTD, 
EX and SB under diabetic or non-diabetic environment was summarized in Table 5.9, 
Table 5.10 and Graph 5.1. To exclude the effect of RA, all fetuses were untreated. As 
shown in Table 5.9, there was a significantly higher incidence rate of SB, EX and 
NTD in NOD/+ fetuses of diabetic mice in comparison with NOD/+ fetuses under 
non-diabetic environment. As the result in Table 5.2 showed that maternal diabetes 
alone could not cause a significant increase in the incidence rate of NTD in wild-type 
fetuses, this implied that a single NOD allele would increase the susceptibility of the 
fetus to SB and the overall incidence rate of NTD when under a diabetic environment 
(Table 5.10, Graph 5.1). NOD/+ fetuses of diabetic mice also had a higher incidence 
rate of EX (7%) than wild-type fetuses of diabetic mice (3.5%), although the 
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difference between them was not large enough to be statistically significant (Table 
5.10, Graph 5.1). 
Taken into account the results in Table 5.2, Table 5.9 and Table 5.10, it is 
concluded that a single NOD allele can interact with maternal diabetes to significantly 
increase the incidence rate of SB and hence the overall incidence rate of NTD. 
5.3.7 Maternal diabetes, NOD mutation and RA interaction 
Table 5.11 
Effect of maternal diabetes on NOD/+ fetuses treated with RA 
Maternal diabetic state Diabetic Non-diabetic 
Genotype NQD/+ NOD/+ 
Dose of RA (mg/k^) 50 ^  
No. of litters IQ 10 
No. of live fetuses 70 91 
No. of resorption (%) 38 (42.4%) 33 (25.3%) 
P value 0.169 
No. of fetuses with NTD (%) 32 (45.7%) | 3 (3.3%) 
P value < 0.0005* 
No. of fetuses with EX (%) 9 (12.9%) | 1 (lAVo) 
P value 0.0003* 
No. of fetuses with SB (%) 30 (42.9%) | 2 (2.2%) 
P value < 0.0005* 
* Statistically significant 
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Table 5.12 
Effect of NOD mutation on fetuses of diabetic mothers treated with RA 
^ m a l diabetic state Diabetic Diabetic 一 
:^enotype ‘ “ \ N6D/+ / ’ +/+ , 
Dose of RA (mg/kg) 50 50 二 
No. of litters 10 10 
No. of live fetuses 70 ^ 
No. of resorption (%) 38 (42.4%) 61 (53.8%) 
l v a l u e 0.465 
No. of fetuses with NTD (%) 一 32 (45.7%) 15 (26.8%) 
户 value 0.022* 
No. of fetuses with EX (%) 9 (12.9%) | 6 (10 J % ) 
l v a l u e 0.467 
No. of fetuses with SB (%) 30 (42.9%) ！ 10 (17.9%) 
P value 0.002* 
* Statistically significant 
Table 5.13 
Effect of RA treatment on NOD/+ fetuses of diabetic mothers 
Maternal diabetic state Diabetic Diabetic 
Genotype NOD/+ NOD/+ 
" , 一 * t 广字 , • ^ 办 、 ： ：•"“：— — 
-Dose of R A (mg/kg) 0 50 
No. of litters 10 
No. of live fetuses ^ 70 
No. of resorption (%) 12(11.7%) 38 (42.4%) 
P value 0.004* 
No. of fetuses with NTD (%) 9 (10.5%) | 32 (45.7%) 
P value < 0.0005* 
No. of fetuses with EX (%) 6 (7.0%) | 9 (12.9%) 
P value 0.167 
No. of fetuses with SB (%) 4 (4.7%) | 30 (42.9%) 
P value < 0.0005* 
* Statistically significant 
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The percentage of NOD/+ and wild-type ICR fetuses of diabetic and non-
diabetic mice that had developed NTD, EX and SB under RA treatment or no 
treatment was summarized in Table 5.11，Table 5.12，Table 5.13 and Graph 5.1. As 
shown in Table 5.11, when NOD/+ fetuses were exposed to 50mg/kg of RA on E8.5, 
there was only a low incidence rate of SB and EX if the fetus was in a non-diabetic 
environment. However, under a maternal diabetic environment, there was more than 
tenfold increase in the overall incidence rate of NTD (from 3.3% to 45.7%), which 
was due to a significant increase in both incidence rates of SB (from 2.2% to 42.9%) 
and EX (from 1.1% to 12.9%). This maternal diabetic effect in increasing the 
susceptibility of NOD/+ fetuses to NTD when treated with RA was due to its 
interaction with NOD mutation, since NOD/+ fetuses of diabetic mice had a 
significantly higher incidence rate of NTD, which was mainly attributed by an 
increase in the incidence rate of SB, in comparison to wild-type fetuses of diabetic 
mice under RA treatment (Table 5.12). Although a single NOD allele could interact 
with maternal diabetes to significantly increase the incidence rate of SB and hence the 
overall incidence rate of NTD (Table 5.9, Table 5.10), this interactive effect was 
greatly exacerbated in combination with RA treatment (Table 5.13). 
To summarize, maternal diabetes alone can only cause a low and insignificant 
incidence rate of NTD. However, it can interact with a single NOD allele or RA to 
significantly increase the incidence rate of SB, and hence the overall incidence rate of 
NTD. Moreover, maternal diabetes can interact with a single NOD allele and RA 
together to greatly exacerbate the susceptibility of the fetus to both SB and EX. 
-127-
Chapter 5: Maternal Diabetes, NOD and RA Interaction 
5.3.8 Expression of PaxS in embryos with different copies of NOD 
alleles 
Since PaxS plays an important role in neural tube closure, and embryos of 
diabetic NOD mice have a high incidence of neural tube defects (Otani et al., 1991), 
therefore, in situ hybridization was carried out on E8.5 embryos to determine whether 
NOD mutation on its own, or when interacted with maternal diabetes, would cause 
any changes in Pax3 expression levels that could account for the significant increase 
in the incidence rate of neural tube defects in NOD/+ embryos under a diabetic 
environment, as shown in Section 5.3.6. 
In the wild-type ICR embryos, Pax3 was expressed in the neural tube along 
the whole body axis (Fig. 5.1 A2) and in the neuroepithelium along the cranial 
neuropore and caudal neuropore (Fig. 5.1 A3 and A4) PaxS was also expressed in the 
segmental mesoderm (Fig. 5.1 A2). This expression pattern was similar to that 
obtained in Section 4.3.1.1. In heterozygous NOD embryos with a single NOD allele, 
there was no change in the expression level of PaxS in all regions examined (Fig. 5.1 
B). Even in homozygous NOD embryos with two NOD alleles, there was still no 
observable difference in PaxS expression levels (Fig. 5.1 C) in comparison to wild-
type ICR embryos without any NOD allele. These results indicate that NOD mutation 
does not affect PaxS expression. 
To determine if NOD mutation would interact with maternal diabetes to alter 
the expression level of PaxS, embryos of diabetic mice that possessed different copies 
of NOD alleles were examined. Under maternal diabetic environment, there was a 
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general lower level of Pax3 expression in all regions of the wild-type ICR embryos 
(Fig. 5.2 B) in comparison to wild-type ICR embryos under non-diabetic environment 
(Fig. 5.2 A). In heterozygous NOD embryos that inherited one NOD allele from the 
father, under maternal diabetes, their Pax3 expression levels (Fig. 5.2 C) were similar 
to wild-type ICR embryos of diabetic mice without the NOD allele (Fig. 5.2 B). Even 
for homozygous NOD embryos, which developed inside the NOD female mice that 
had spontaneously developed diabetes, and hence, most likely would develop neural 
tube defects, they still did not exhibit any observable differences in PaxS expression 
levels (Fig. 5.2 D) in comparison to wild-type ICR embryos under diabetic 
environment (Fig. 5.2 B). Hence, these results indicate that NOD mutation does not 
interact with maternal diabetes in reducing PaxS expression to increase the 
susceptibility to neural tube defects. 
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5.4 Discussion 
The objective of this chapter was to determine whether there were any 
interactions of maternal diabetes with genetic susceptibility factor alone, or in 
combination with exposure to a teratogen, such as RA, in increasing the susceptibility 
to neural tube defects. The genetic susceptibility factor studied was NOD, which was 
diabetogenic and paternally in inherited. 
5.4.1 Maternal diabetes interacts with NOD mutation to increase 
susceptibility to neural tube defects 
In the present finding, it was found that maternal diabetes alone would cause a 
small，but insignificant increase in neural tube defects in wild-type ICR fetuses. In 
contrast, results in Chapter 3 (Section 3.3.1) showed that fetuses did not exhibit any 
neural tube defects under diabetic environment. This difference in susceptibility to 
maternal diabetes might be attributed by the fact that the genetic background of the 
fetus was not the same in the two studies. In this chapter, the wild-type fetuses were 
obtained by mating between ICR parents, whereas in Chapter 3，the wild-type fetuses 
were obtained by mating between (C3H/101/CBA) and ICR mice. As 
discussed in Section 3.4.4，it is known that the genetic background will affect the 
susceptibility of the embryos to the teratogenic effect of maternal diabetes or other 
teratogens (Machado et al., 2001; Phelan et al., 1997; Tom et al., 1991). 
Before development of diabetes, NOD female mice will give birth to normal 
offspring. However, once the NOD female mice become overt diabetic, the pregnancy 
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rate will be much reduced, and a high percentage of malformations, including neural 
tube defects, are found among the fetus (Phelan et al” 1997). However, the increased 
susceptibility to malformations may not be caused simply by the NOD mutation and 
the maternal diabetes status, but it can also be attributed by the immunological 
responses and structural changes in the reproductive tract of NOD female mice (Otani 
et al., 1991; Tatewaki et al., 1989). In the present study, this complicated factor was 
excluded by employing wild-type ICR female mice rendered diabetic using 
streptozotocin, and the NOD mutation was introduced via the father. Results clearly 
showed that a single NOD allele could interact with maternal diabetes to significantly 
increase the susceptibility to spina bifida, and also, to a lesser extent, increased 
exencephaly. 
5.4.2 Interaction of maternal diabetes with NOD mutation is greatly 
exacerbated when exposed to RA 
In the present study, it was found that a dose of 50mg/kg of RA injected on 
E8.5 was insufficient to induce spina bifida in wild-type fetuses of non-diabetic mice. 
Maternal diabetes alone was also unable to induce spina bifida in wild-type fetuses. 
However, when these two factors (maternal diabetes and RA) interacted together, they 
could significantly increase the susceptibility of the fetus to spina bifida, and hence a 
significant rise in the overall incidence rate of NTD. There was also an increase in the 
incidence rate of exencephaly, although the increase has not yet reached a statistically 
significant level. These results agreed with those obtained in Chapter 3, and the 
possible mechanisms have been discussed in Section 3.4.3. 
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In examining NOD/+ fetuses of diabetic mice, it was found that they exhibited 
a significant increase in susceptibility to neural tube defects, mainly attributed by an 
almost tenfold increase in the incidence rate of SB, when they were exposed to RA 
(NTD: increased from 10.5% to 45.7%; SB: increased from 4.7% to 42.9%). However, 
this increase was not simply due to the interaction of RA with the maternal diabetic 
environment. It was because in comparing with wild-type fetuses of diabetic mice 
under RA treatment, the incidence rates of NTD and SB were only 26.8% and 17.9% 
respectively, which were significantly lower than the response of NOD/+ fetuses of 
diabetic mice to RA. In contrast, no difference between these two genotypes in 
response to RA was observed if the mother was non-diabetic. Although this might 
give the impression that there was no interaction between NOD and RA in increasing 
the incidence of SB, however, the fact that the incidence rate of SB in RA-treated 
NOD/+ fetuses of diabetic mice (42.9%) was significantly much higher than NOD/+ 
fetuses of diabetic mice without RA treatment (4.7%) or RA-treated +/+ fetuses of 
diabetic mice (17.9%) indicated that the large increase in the incidence rate of SB in 
NOD/+ fetuses of diabetic mice after RA treatment was not merely an additive effect 
of maternal diabetes-RA interaction with maternal diabetes-NOD interaction, but also 
involved interaction of NOD with RA, which on its own was insufficient to result in 
the manifestation of neural tube defects, but nevertheless could exacerbate the effect 
of maternal diabetes. 
Taken together all these results, it is concluded that the interaction of maternal 
diabetes and NOD mutation will be greatly exacerbated when exposed to RA. 
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5.4.3 PaxS is not involved in the interaction 
Regarding the mechanism of interaction between maternal diabetes and NOD 
mutation in increasing the incidence of neural tube defects, results from in situ 
hybridization studies showed that there was no difference in Pax3 expression levels 
among NOD/NOD, NOD/+ and wild-type embryos. Moreover, although the 
expression level of PaxS in the neuroepithelium of the embryo at E8.5 was reduced 
under maternal diabetes, the extent of reduction was the same regardless of whether 
the embryo carried any NOD mutation. Even in NOD/NOD embryos of diabetic 
mothers, which have been shown to exhibit a high risk of neural tube defects (Phelan 
et al., 1997), there was still no observable difference in Pax2 levels when compared 
with wild-type embryos of diabetic mice. Hence, these results showed that the effect 
of NOD mutation, and its interaction with maternal diabetes to increase the 
susceptibility to neural tube defects, was not mediated via a direct effect on PaxS or 
any genes upstream of Pax3. However, the possibility that NOD mutation might 
affect downstream targets of Pax3 could not be excluded. Furthermore, since it has 
been shown in Chapter 4 that RA did not affect Pax3 gene, therefore, the interaction 
of NOD and RA under maternal diabetes was unlikely to be mediated via any direct 






Chapter 6: Conclusion and Future Perspectives 
The aim of this thesis was to test the hypothesis that genetic and/ or 
environmental factors could interact with maternal diabetes to increase the 
susceptibility to congenital malformation. The effect of RA, Sp^" and NOD mutations 
in inducing neural tube defects under maternal diabetes was used as an example to test 
the hypothesis. 
In Chapter 3 and Chapter 5, it was shown that maternal diabetes could 
exacerbate the teratogenic effect of RA in inducing neural tube defects. This result 
may have some important implications for human pregnancy. RA is the most active 
metabolite of vitamin A. Both RA and vitamin A are well-known human teratogens 
(Lammer et al” 1985; Martinez-Frias and Rodriguez-Pinilla, 1999; Rosa et aL, 1986; 
Rothman et al.，1995). The teratogenic effect of vitamin A is similar to RA (Morriss 
and Steele, 1977), and its action on embryonic development is most likely mediated 
via its conversion to RA, which then acts on target genes containing the RA response 
element (Petkovich, 1992). Vitamin A is a common component of multivitamin 
supplements, whereas isotretinoin (l3-cis retinoic acid) and tretinoin (alUrans 
retinoic acid) are prescribed as dermatological medication for severe cystic acne and 
other chronic skin lesions, and for the treatment of acute promyelocytic leukemia 
(Lipson et al., 1993; Tallman, 1994). Despite the fact that exposure to high doses of 
vitamin A or retinoic acid prior to or during early pregnancy is a well-known cause of 
congenital malformation, vitamin A can still be obtained in exceedingly high doses as 
over-the-counter preparations. Moreover, there is an increasing propensity for self-
medication with megadoses of vitamins and there is alarming report, which shows 
that 4% of vitamin A users take doses at five times of RDA (Recommended Daily 
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Allowance) (Canadian Paediatric Society, 1971; Food Chemical News, 1983; Shepard 
et al., 1986). If humans are more susceptible to vitamin A/ RA teratogenicity as found 
in mice in this study, it may have the implication that the recommended safety dose of 
vitamin A for diabetic pregnant women will need to be lower than that for non-
diabetic women. At the moment, it is difficult to directly extrapolate the dose and the 
extent of increased sensitivity found in mice in the present study to humans because 
how much vitamin A consumed by humans is converted into dXUrans RA is unknown 
and there are also species differences in response to a teratogen. Nevertheless, results 
of this study have provided the evidence that maternal diabetes could interact with 
environmental factors, such as RA, in increasing the susceptibility to neural tube 
defects. Further study should be carried out to determine if interaction is limited to 
RA, and the nature and type of environmental factors that can interact with maternal 
diabetes. 
Besides determining the effect of environmental factor, the interaction of 
maternal diabetes with genetic susceptibility factors were also examined in this thesis. 
In Chapter 3，it was found that a single Sp^" allele, although on its own was unable to 
cause neural tube defects, could greatly exacerbate the interaction of maternal 
diabetes and RA teratogenicity. Since the human homologue of splotch has been 
identified (Foy et al., 1990), it may be worth to carry out genetic screening on 
prospective parents, especially women who are diabetic, to determine whether this 
genetic susceptibility factor is present, and hence counseling and preventive measure 
can be carried out to reduce the risk of having malformed infants. Further study 
should also be carried out to identify other susceptible loci. 
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Besides studying the 分谢 locus that is non-diabetogenic, this thesis has also 
examined whether the diabetogenic gene inherited from the parent would affect 
embryonic development. Results in Chapter 5 showed that a single diabetogenic NOD 
allele would significantly increase the susceptibility of the fetus to neural tube defects 
under a maternal diabetic environment. Hence, this may imply that the increased risk 
of congenital malformation in offspring of diabetic mothers, especially those with 
type 1 diabetes, may not be solely attributed by the teratogenic effect of the maternal 
diabetic milieu, but also because of its interaction with the diabetogenic gene in the 
fetus that is inherited from the mother or the father. Moreover, results of Chapter 5 
also showed that the presence of the diabetogenic gene in the fetus might increase its 
susceptibility to teratogens, such as RA, if their mothers are diabetic. These results 
may shed the light that, while using chemically-induced diabetic animal models to 
study the effect of maternal diabetes on embryo development is useflil for dissection 
of the role play by individual factor, the fact that the genetic make-up of the fetus will 
affect its response to the maternal diabetic environment should also be considered. 
Regarding the mechanism of interaction, results in Chapter 4 and Chapter 5 
showed that the interaction of maternal diabetes with RA or NOD mutation was not 
mediated via a direct effect on PaxS or genes upstream of PaxS. Other than PaxS, 
many genes critical for neural tube closure have been identified (Juriloff and Harris, 
2000). For example, HNF-Sfi, which expresses in the notochord and floor plate, is 
essential for proper development of the neural tube (Ang and Rossant, 1994), and 
sequence variation in HNF-Sp has been found in NOD embryos (Maeyama et al, 
2001). Moreover, HNF-3p and Shh regulate each other's expression (Chiang et al., 
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1996; Weinstein et al” 1994), and Shh can interact with RA (Ogura et al., 1996; 
Tsukui et al., 1999). Hence, it will be interesting to study the effect of maternal 
diabetes, NOD mutation and RA on their own or in combination, on the expression of 
HNF-315 and Shh to determine if these genes may play a role in the interaction of 
NOD mutation, RA and maternal diabetes in increasing the susceptibility to neural 
tube defects. 
In conclusion, results of this thesis have provided evidences for an interaction 
of environmental and /or genetic factors with maternal diabetes in increasing the 
susceptibility to neural tube defects. At a time when there is a worldwide tendency 
towards earlier onset of diabetes (Bingley and Gale, 1992), an increasing number of 
people is expected to be diabetic during childbearing years, hence, there is an urgent 
need to understand the cause and pathogenetic mechanisms of diabetic embryopathy. 
This thesis provides the insight that the increased risk of congenital malformation in 
infants of diabetic pregnancy may not be solely attributed by the teratogenic effect of 
the maternal diabetic milieu, but can be greatly exacerbated by its interaction with 
environmental factors, such as RA, and is also influenced by diabetogenic or non-
diabetogenic susceptibility factors in the embryo. Hence, it is of paramount 
importance to investigate the environmental and genetic risk factors that can interact 
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Figure 3.1 Fetuses at E13.5 that exhibit different types of neural tube defects 
A; Normal fetuses 
B: Fetuses with exencephaly and spina bifida 
C: Fetuses with exencephaly only 
D: Fetuses with spina bifida only 
Figure legend 
Blue arrow: exencephaly 
Yellow arrow: spina bifida 
Scale bar 
A, B, C and D: 1.00mm 
Normal Exencephaly and   
spina bifida 
圔國 
Exencephaly Spina bifida 
ii 
Figure 4.1 Pax3 expression in different regions of and +/+ embryos at 
different deve lopmenta l stages under non-diabetic or diabetic 
maternal environment 
A: E8.5 heterozygous Sp^^ embryos of non-diabetic mothers 
B: E8.5 wild-type (+/+) embryos of non-diabetic mothers 
C: E8.5 heterozygous Sp^" {Sp^^Iembryos of diabetic mothers 
D: E8.5 wild-type (+/+) embryos of diabetic mothers 
1 ： Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
Figure legend 
Yellow arrow: neural tube 
Red arrow: anterior limit of caudal neuropore 
Orange arrowhead: neuroepithelium at otic level 
Green arrowhead: segmental mesoderm 
Scale bar 
A1，B1,C1 and Dl: 0.50mm 
A2, A3, A4, B2, B3, B4, C2, C3, C4, D2, D3 and D4: 1.50mm 
E8.5 
Whole Spinal Cranial Caudal 
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Figure 4.1 PaxS expression in different regions of Sp'"!^ and +/+ embryos at 
d i f ferent deve lopmental stages under non-diabetic or diabetic 
materna l environment 
E: E8.75 heterozygous Sp:H {SfT^i-) embryos of non-diabetic mothers 
F: E8.75 wild-type (丄/—) embryos of non-diabetic mothers 
G: E8.75 heterozygous Sp'" (5/?'^/+) embryos of diabetic mothers 
H: E8.75 wild-type (+/+) embryos of diabetic mothers 
1: Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
Figure legend 
Yellow arrow: neural tube 
Red arrow: anterior limit of caudal neuropore 
Orange arrowhead: neuroepithelium at otic level 
Green arrowhead: somite 
Scale bar 
E1，F1,G1 and H I : 0.50mm 
E2, E3, E4, F2, F3, F4, G2, G3, G4, H2, H3 and H4: 1.08mm 
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Figure 4.1 Pax3 expression in different regions of and +/+ embryos at 
different deve lopmental stages under non-diabetic or diabetic 
maternal environment 
I: E9.0 heterozygous Sp^^ embryos of non-diabetic mothers 
J； E9.0 wild-type (+/+) embryos of non-diabetic mothers 
K: E9.0 heterozygous Sp'^ embryos of diabetic mothers 
L： E9.0 wild-type (+/+) embryos of diabetic mothers 
1 ： Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
Figure legend 
Yellow arrow: neural tube 
Red arrow: anterior limit of caudal neuropore 
Orange arrowhead: neuroepithelium at otic level 
Green arrowhead: somite 
Scale bar 
II, J1,K1 and LI: 0.50mm 
12,13，14, J2, J3, J4, K2, K3, K4, L2, L3 and L4: 1.20mm 
E9.0 
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Figure 4.2 Pax3 expression in different regions of Sp讯hr and +/+ embryos of 
non-diabetic mice at 6 hour after treatment with different dosages 
o f R A o n E8.5 
A: Heterozygous S p � " embryos of non-diabetic mothers at E8.75 without 
RA treatment 
B: Wild-type (+/+) embryos of non-diabetic mothers at E8.75 without RA 
treatment 
C: Heterozygous Sp^" embryos of non-diabetic mothers at 6 hour after 
treatment with 50mg/kg of RA 
D: Wild-type (+/+) embryos of non-diabetic mothers at 6 hour after treatment 
with 50mg/kg of RA 
E: Heterozygous Sp^^ embryos of non-diabetic mothers at 6 hour after 
treatment with lOOmg/kg of RA 
F: Wild-type (+/+) embryos of non-diabetic mothers at 6 hour after treatment 
with lOOmg/kg of RA 
1: Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
Scale bar 
Al, Bl , CI, Dl，El and Fl : 0.50mm 
A2, A3, A4, B2, B3, B4，C2, C3, C4, D2, D3, D4, E2, E3, E4, F2, F3 and F4: 1.08mm 
E 8.75 (6 hours after RA treatment) 
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Figure 4.3 Pax3 expression in different regions of and +/+ embryos of 
non-diabetic mice at 12 hour after treatment with different 
dosages of RA on E8.5 
A: Heterozygous Sp'^ embryos of non-diabetic mothers at E9.0 without 
RA treatment 
B: Wild-type (+/+) embryos of non-diabetic mothers at E9.0 without RA 
treatment 
C: Heterozygous Sp^^ embryos of non-diabetic mothers at 12 hour after 
treatment with 50mg/kg of RA 
D: Wild-type (+/+) embryos of non-diabetic mothers at 12 hour after treatment 
with 50mg/kg of RA 
E: Heterozygous Sp^^ (Sp�" 1+) embryos of non-diabetic mothers at 12 hour after 
treatment with lOOmg/kg of RA 
F: Wild-type (+/+) embryos of non-diabetic mothers at 12 hour after treatment 
with lOOmg/kg of RA 
1: Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
Scale bar 
Al , Bl, CI, Dl , El and Fl : 0.50mm 
A2, A3, A4, B2, B3, B4, C2, C3, C4, D2, D3, D4, E2, E3, E4，F2, F3 and F4: 1.20mm 
E 9.0 (12 hours after RA treatment) 
Whole Spinal Cranial Caudal 
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Figure 4.4 Apoptotic cells in different regions of positive control and negative 
control embrvos at different developmental stages 
A: E8.5 positive control embryo (Level 10) 
B: E8.5 negative control embryo (Level 1) 
1: Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
A l a n d B l : 0.50mm 
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Figure 4.4 Apoptotic cells in different regions of positive control and negative 
control embrvos at different developmental stages 
C: E9.0 positive control embryo (Level 10) 
D: E9.0 negative control embryo (Level 1) 
1 ： Whole embryo 
2： Closed neural tube along spinal region 
3 ： Cranial neuropore region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
CI andDl: 0.50mm 
C2, C3, C4, D2, D3 and D4: 1.19mm 
E9.0 
Whole Spinal Cranial Caudal 
Embryo Region Region Region 
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Figure 4.4 Apoptotic cells in different regions of positive control and negative 
control embrvos at different developmental stages 
E: E9.5 positive control embryo (Level 10) 
F: E9.5 negative control embryo (Level 1) 
1: Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
E l a n d F l : 0.50mm 
E2, E3, E4, F2, F3 and F4: 1.56mm 
E9.5 
Whole Spinal Cranial Caudal 
Embryo Region Region Region 
Figure 4.5 Apoptotic cells in different regions of S/丑AS/丑，丑/+ and +/+ 
embryos at different developmental stages 
A: E8.5 homozygous Sp ' " embryos 
B: E8.5 heterozygous Sp"(分embryos 
C: E8.5 wild-type (+/+) embryos 
1 ： Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
A 1 , B 1 and CI : 0.50mm 
A2, A3, A4, B2, B3, B4, C2, C3 and C4: 1.50mm 
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Figure 4.5 Apoptotic cells in different regions of S/丑AS/丑，丑/+ and +/+ 
embryos at different developmental stages 
D: E9.0 homozygous S p � " embryos 
E: E9.0 heterozygous Sp'" embryos 
F: E9.0 wild-type (+/+) embryos 
1 ： Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
D1,E1 andFl : 0.50mm 
D2, D3, D4, E2, E3, E4, F2, F3 and F4: 1.19mm 
E9.0 
她 ole Spinal Cranial Caudal 
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Figure 4.5 Apoptotic cells in different regions of S/丑AS/丑，丑/+ and +/+ 
embryos at different developmental stages 
G: E9.5 homozygous Sp'^ embryos 
H: E9.5 heterozygous (分’+) embryos 
I: E9.5 wild-type (+/+) embryos 
1 ： Whole embryo 
2： Closed neural tube along spinal region 
3: Cranial neuropore/ neural tube region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
G1,H1 and II: 0.50mm 
G2, G3, G4, H2, H3, H4,12,13 and 14: 1.56mm 
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Figure 4 6 Apoptotic cells in different regions of E8.5 冲进/+ and +/+ embryos 
under non-diabetic and diabetic maternal environment 
A: Heterozygous Sp:"你-识/+) embryos of non-diabetic mothers 
B: Wild-type (+/+) embryos of non-diabetic mothers 
C: Heterozygous Sp'"(分谢/+) embryos of diabetic mothers 
D: Wild-type (+/+) embryos of diabetic mothers 
1 ： Whole embryo 
2： Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
A1,B1,C1 andDl : 0.50mm 
A2, A3, A4, B2, B3, B4, C2, C3, C4, D2, D3 and D4: 1.50mm 

Figure 4.7 Apoptotic cells in different regions of Sp- /+ and +/+ embryos 
under non-diabetic and diabetic maternal environment at E9.0 or 
12 hour after treatment with 50mg/kg of RA on E8.5 
A- Heterozygous Sp'^ (5/7"^/+) embryos of non-diabetic mothers at E9.0 without 
RA treatment 
B. Wild-type (+/+) embryos of non-diabetic mothers at E9.0 without RA 
treatment 
C. Heterozygous embryos of diabetic mothers at E9.0 without RA 
treatment 
D: Wild-type (+/+) embryos of diabetic mothers at E9.0 without RA treatment 
1 ： Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
A1，B1,C1 and Dl: 0.50mm 
A2, A3, A4, B2, B3, B4, C2, C3，C4, D2, D3 and D4: 1.19mm 
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Figure 4.7 Apoptotic cells in different regions of S /力 + and +/+ embryos 
under non-diabetic and diabetic maternal environment at E9.0 or 
12 hour after treatment with 50mg/kg of RA on E8.5 
Heterozygous embryos of non-diabetic mothers at 12 hour after 
RA treatment at E8.5 
F: Wild-type (+/+) embryos of non-diabetic mothers at 12 hour after RA 
treatment at E8.5 
G: Heterozygous Sp^^ embryos of diabetic mothers at 12 hour after RA 
treatment at E8.5 
H： Wild-type (+/+) embryos of diabetic mothers at 12 hour after RA treatment at 
E8.5 
1: Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
E1,F1,G1 and HI: 0.50mm 
E2, E3，E4，F2, F3, F4, G2, G3，G4, H2, H3 and H4: 1.19mm 
E 9.0 (12 hours after RA treatment) 
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Figure 4.8 Apoptotic cells in different regions of 5^，+ and +/+ embryos at 
E9.5 or 24 hour after treatment with 50mg/kg of RA on E8.5 
A. Heterozygous Sp^" (Sp�"1+) embryos of non-diabetic mothers at E9.5 without 
RA treatment 
B- Wild-type (+/+) embryos of non-diabetic mothers at E9.5 without RA 
treatment 
Q. Heterozygous Sp'" embryos of diabetic mothers at E9.5 without RA 
treatment 
D: Wild-type (+/+) embryos of diabetic mothers at E9.5 without RA treatment 
1 ： Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore/ neural tube region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
A1,B1,C1,D1: 0.50mm 
A2, A3, A4，B2, B3, B4, C2, C3, C4，D2, D3, D4: 1.56mm 
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Figure 4.8 A p o p t o t i c cells in different regions of and +/+ embryos at 
E9.5 or 24 hour after treatment with 50mg/kg of RA on E8.5 
E. Heterozvsous S p ' " iSp'"!^) embryos of non-diabetic mothers at 24 hour after 
RA treatment at E8.5 
F. Wild-type (+/+) embryos of non-diabetic mothers at 24 hour after RA 
treatment at E8.5 
G: Heterozygous Sp'" embryos of diabetic mothers at 24 hour after RA 
treatment at E8.5 
H: Wild-type (+/+) embryos of diabetic mothers at 24 hour after RA treatment at 
E8.5 
1 ： Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore/ neural tube region 
4: Caudal neuropore region 
N.B. Apoptotic cells stained brown in colour 
Scale bar 
E 1 , F 1 , G 1 and H I : 0.50mm 
E2, E3，E4, F2 , F 3 , F 4 , G 2 , G 3 , G4，H2, H 3 and H 4 : 1 . 1 9 m m 
E 9.5 (24 hours after RA treatment) 
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Figure 5.1 PaxS expression in different regions o f+ /+ , NOD/+ and NOD/NOD 
embryos at E8.5 under non-diabetic materna l environment 
A: Wild-type ICR (+/+)embryos of non-diabetic mothers 
B: Heterozygous NOD (NOD/+) embryos of non-diabetic mothers 
C: Homozygous NOD (NOD/NOD) embryos of non-diabetic mothers 
1: Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
Scale bar 
A1，B1 and CI : 0.50mm 
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Figure 5.2 Pcix3 expression in different regions of + / + ， N O D / + and NOD/NOD 
embryos at E8.5 under non-diabetic and/ or diabetic maternal 
environment 
A: Wild-type ICR (+/+) embryos of non-diabetic mothers 
B: Wild-type ICR (+/+) embryos of diabetic mothers 
C: Heterozygous NOD (NOD/+) embryos of diabetic mothers 
D: Homozygous NOD (NOD/NOD) embryos of diabetic mothers 
1: Whole embryo 
2: Closed neural tube along spinal region 
3: Cranial neuropore region 
4: Caudal neuropore region 
Scale bar 
A1，B1,C1 and Dl: 0.50mm 
A2, A3, A4, B2, B3，B4，C2, C3, C4, D2, D3 and D4: 1.50mm 
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卞 /^<0.0005 compared with 妨好/+ fetuses of non-diabetic mice without RA treatment 
t P<0.0005 compared with fetuses of diabetic mice without RA treatment 
• P<0.0005 compared with fetuses of non-diabetic mice treated with RA 
• P<0.0005 compared with fetuses of diabetic mice treated with RA 
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Effect of RA on resorption rate of fetuses of diabetic and non-diabetic mothers 
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Effect of RA on resorption rate of NOD/+ and +/+ fetuses of diabetic and non-
diabetic mothers 
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